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ABSTRACT 
 
Human immune deficiency virus (HIV) currently affects around 34 million people 
worldwide, but due to recent advancements in antiretroviral treatments the morbidity and 
mortality of HIV has greatly improved (UNIAIDS, 2009). Tenofovir (TFV) is a nucleoside 
reverse transcriptase inhibitor (NRTI) that is currently widely used in most HIV regimens due 
to its favourable pharmacokinetic and pharmacodynamic properties, which allows for once 
daily dose (Gallent et al., 2004). TFV is used to treat HIV in both treatment experienced and 
treatment naive patients; it is also used as a treatment for hepatitis B and has recently been 
approved for use as a pre-exposure prophylaxis treatment. The preclinical trials for TFV 
showed that it had a good safety profile, however there has been an increasing number of 
patients presenting with TFV induced renal damage specifically proximal tubule dysfunction 
(Cooper et al., 2010). It was hypothesised that TFV was inducing this tubule damage via 
mitochondrial dysfunction, as this has been widely reported as an adverse reaction associated 
with NRTI’s (Kontorinis et al., 2003). Within these studies in vitro cell models were 
modified via culturing them in galactose media in order to probe for mitotoxins (Marroquin et 
al., 2007). The cytotoxicity and mechanisms of cell death induced via TFV were elucidated 
within these modified cell lines. Work presented has shown that TFV causes delayed 
mitochondrial cytotoxicity, which causes a cell cycle arrest within the G2/M phase leading to 
an accumulation of cell within the S phase. It was shown that the cell cycle arrest is likely 
due to the inhibition of mitochondrial polymerase γ leading to decreased mitochondrial DNA 
and ultimately cell death firstly via apoptosis (caused by release of caspase 3/ 7), and then 
necrosis when cellular ATP levels become too low to sustain apoptosis. Work presented also 
showed that autophagy induced by TFV, may play a protective role within cells at lower time 
period. A study within this thesis using patient urine samples was presented to look for a 
possible biomarker of TFV proximal tubule dysfunction. Kidney injury molecule-1 (KIM-1) 
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was selected as previous studies have shown that it is specific to proximal tubule cells 
(Ichimura et al., 2008). Results demonstrated that TFV did not significantly alter the KIM-1 / 
creatinine ratio within patient urine samples. However the data from this pilot study are novel 
and should be used for future research into the possible use of KIM-1 as a biomarker for TFV 
induced proximal tubule dysfunction. The biomarker work presented within this thesis should 
be carried forward to power a future study using a larger and adequate patient cohort. The 
work presented within this thesis has now opened doors for further study into this subject 
area especially with regards to the study of KIM-1 as a biomarker, which is a pressing matter 
as TFV is now widely available for use as a PrEP treatment. 
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ABBREVIATIONS 
 
 ABC                    Abacavir 
 ADEF                  Adefovir 
 ADRs                   Adverse Drug Reactions 
 AIDs                    Autoimmune deficiency virus 
 Apaf-1                 Apoptotic protease activating factor 1 
 ATP                     Adenosine TriPhosphate (ATP) 
 ATV                     Atazanavir 
 AZT                     Zidovudine 
 BAF                     Bio-Analytical Facility 
 BUN                    Blood Urea Nitrogen 
 CAR                    Cellular Accumulation Ratio 
 CARD                 Caspase Activation and Recruitment Domain 
 CKD                    Chronic Kidney Disease 
 Cmax                   maximum Concentration 
 CNS                     Central Nervous System 
 C-path                  Critical path Institute 
 CYP450                human Cytochrome P450 
 d4T                       Stavudine 
 ddC                       Zalcitabine 
 ddI                        Dianosine 
 DED                      Death Effector Domain 
 DHE                      DiHydroEthidium 
 DISC                     Death-Inducing Signal Complex 
 DMF                      n-DiMethylFormamide 
 DMSO                   DiMethylSulphOxide 
 DNA                     Deoxyribonucleic acid 
 EFV                       Efavirenz 
 eGFR                     estimated Glomerular Filtration Rate 
 ELISA                   Enzyme-Linked Immuno-Sorbant Assay 
 EMA                     European Medicines Agency 
 ETC                      Electron Transport Chain (ETC) 
 EU                        European Union 
 FACs                    Flow Cytometry 
 FADD                  Fas- Associated Death Domain 
 FBS                      Foetal Bovine Serum 
 FDA                     Food and Drug Administartion 
 FS                         Forward Scatter 
 FTC                      Emtricitabine 
 GFR                      Glomerular Filtration Rate 
 GUM                    GenitoUrinary Medicine 
 HAART                Highly Active Antiretroviral Therapy 
 HAVCR-1            Hepatitis A Virus Cellular Receptor 1 
 HBSS                   Hanks Balanced Salt Solution 
 HEK293                a human renal cell line 
 hENT-1                human Equilibrative Nucleoside Transporter 1 
 Hep B                  Hepatitis B 
 HEPES                N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) 
 HepG2 cells         a human hepatic cell line 
 hOAT                   human Organic Anion Transporter's 
 II                           Integrase Inhibitors 
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 KIM-1                  Kidney Injury Molecule -1 
 KO                       KnockOut 
 LPV                      Lopinavir 
 MI                        Maturation Inhibitors 
 MRP                     Multi Drug resistant transporters 
 MSD                     Meso Scale Discovery 
 mtDNA                 mitochondrial DNA 
 mtDNA pol γ        mitochondrial DNA polymerase γ 
 MTT                     3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltrazolium bromide 
 NAG                     N-Acetyl-β-D-Glucosaminidase 
 NIAID                  National Institute of Allergy and Infectious Diseases 
 NKC                     Natural Killer Cells 
 NNRTIs                Non-Nucleoside Reverse Transcriptase Inhibitors 
 NR                        Neutral Red 
 NRTI                    Nucleoside Reverse Transcription Inhibitors 
 OXPHOS             mitochondrial Oxidative Phosphorylation 
 PBMCs                Peripheral Blood Mononuclear Cells 
 PI                         Propidium Iodide 
 PI’s                      Protease Inhibitors 
 PI3K                    Phosphyatidylinositol-3-Kinase 
 PMOM                Permeabilisation of the Mitochondrial Outer Membrane 
 PNS                     Peripheral Nervous System 
 PrEP                   Pre-Exposure Prophylaxis 
 PS                        PhosphatidylSerine 
 RIs                      Reverse transcriptase Inhibitors 
 RNA                   Ribonucleic acid 
 ROS                    Reactive Oxygen Species 
 RTV                    Ritonavir 
 SCr                      Serum Creatinine 
 SD                       Standard Deviation of the mean 
 SDS                     Sodium Dodecyl Sulfate 
 SIVcpz                Simian immunodeficiency virus 
 SNPs                   Single Nucleotide Polymorphisms 
 SS                        Side Scatter 
 TDF                    Tenofovir Disoproxil Fumarate 
 TFV                    Tenofovir 
 TIM-1                 T cell Immunoglobulin Mucin domains-1 
 TMRE                 TetraMethylRhodamine Ethyl ester 
 TNF                    Tumour Necrosis Factor 
 UNAIDS             United Nations programme on HIV/AIDS 
 US                       United States 
 WHO                  World health organisation 
 [
3
H]                     tritiated 
 3MA                    3-MethylAdenine 
 3TC                     Lamivudine 
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1.1 Introduction  
The World Health Organisation (WHO) recommends the use of Tenofovir (TFV) in all 
regimens for the treatment of human immunodeficiency virus (HIV), both for HIV treatment-
naive and treatment-experienced patients due to its good efficacy and tolerability properties 
[1]. TFV acts through the inhibition of the viral reverse transcriptase enzyme and thus 
prevents further viral replication [2]. Although TFV has a relatively good safety profile, there 
have recently been clinical reports of patients developing chronic kidney disease (CKD). This 
renal specificity has been linked to its accumulation in the proximal tubules of the kidney [3]. 
1.2 Tenofovir as a pharmacological agent 
1.2.1 The problem of HIV  
The HIV infection was first defined in 1981 when autoimmune deficiency virus (AIDs) was 
first recognised as a disease [4]. The virus is thought to have originated from Simian 
immunodeficiency virus (SIVcpz) which infects chimpanzees [5]. The SIVcpz virus is known 
to infect chimpanzees in central Africa but the origins of this virus itself is still unknown [6]. 
More than 20 species of African primates have been identified to have species-specific strains 
of the SIVcpz virus [7]. Recent evidence suggests that the SIVcpz virus in chimpanzees arose 
from a recombination of two different simian immunodeficiency viruses, SIV rem (from red -
capped mangabeys) and SIVgsn (from greater spot -nose monkeys) [8-9]. These primate 
species are both preyed upon by chimpanzees which are where cross contamination and the 
production of SIVcpz occurred [6]. 
Evidence suggests that cross contamination of humans occurred during butchering of infected 
primates for food in sub-Saharan Africa [7]. Whilst butchering the animals the humans came 
into contact with the contaminated blood which passed into humans via open wounds [10]. 
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This cross contamination between primates and humans went unnoticed for a long period of 
time [11]. The African continent at that time provided optimal conditions for the viral spread 
of HIV, such as mass migration from urban to rural areas leading to the breakup of family 
units and conditions that meant commercial sex was favoured. Once the virus was deeply 
spread in Africa the development of increased sexual freedoms and the increase in global 
travel, led to the spread of the HIV virus to more developed countries and eventually global 
contamination occurred [11]. 
 If left untreated then HIV becomes the more serious form of AIDs which ultimately leads to 
death of the patient. HIV currently affects more than 34 million people worldwide [12]. It can 
be spread through contact with other infected patients via sexual transmission, sharing of 
infected needles or through contact with infected bodily fluids [13]. According to the United 
Nations programme on HIV/AIDS (UNAIDS) the spread of HIV in richer countries has 
decrease dramatically by a third over the last few years. This is largely due to better 
education and increased access to contraception that prevents the spread of the virus. 
However, there are still an estimated 6000 new cases of HIV reported in the United Kingdom 
(UK), alone each year. In the poorer areas of the world there has been an increase in the 
access to treatment, however more education about how the virus spreads is needed in order 
to prevent further cases of HIV infection. Since the early 1990’s the impact of AIDs has 
decreased life expectancy of African people by at least 25 years. Recent development in HIV 
drug regimens has led to an increase in the number of people who have HIV and survive 
leading to the figures for the total global amount of people with HIV has increased. This can 
be seen when comparing the number of AIDS related deaths in 1998 (2.8 million) to the 
amount of AIDS related deaths in 2008 (2 million), and when comparing the number of 
people living with HIV in 1998 (33 million) to the number of people living with HIV in 2008 
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(34 million). HIV treatment has led to a better quality and quantity of life for HIV patients 
and has dramatically decreased the number of HIV patients that develop AIDs [14-15]. 
1.2.2 The different phases of HIV-1 infection. 
Once HIV enters the body and infects the CD4 cells, it can become dormant by hiding within 
the cytoplasm of the cell or by incorporation into the cellular genetic material. Once hidden, 
the HIV virus can evade immune response and lay dormant for months or even years [16]. 
These cells are known as latent reservoirs of the virus [17].  Even though HIV can be treated 
with antiretrovirals, which suppresses the viral load to undetectable within blood, the virus 
cannot be eliminated completely due to these reservoirs [17].  
There are three main phases of HIV infection. The first phase, known as acute infection, 
covers the period from first patient contact with the infection [12]. After 2-4 weeks from 
contracting the virus the patients usually experience an acute illness called acute retroviral 
syndrome [12]. During the acute period the virus undergoes rapid replication within the CD4 
cells; this leads to a rapid decline in patient CD4 count [12]. The risk of viral transmission is 
higher during this acute phase, as viraemia is at its peak. After the rapid replication period, 
viral replication becomes stable (known as a viral set point). This stability results in an 
increase in patient CD4 count, however the patients CD4 count will still remain lower than 
before they contracted the virus [18]. 
The second phase of HIV infection is the asymptomatic phase. It is during this stage that the 
virus undergoes low levels of replication and patients will have no symptoms and feel 
generally well. Their CD4 counts will be at healthy levels and viral load will be undetectable. 
This phase can last up to 8 years, creating the problem of further viral spread throughout the 
general population [19]. 
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Later on during this second phase the CD4 count of patients will begin to decline as viral load 
steadily increases; it is at this point that patients are usually diagnosed with HIV. The final 
phase is the development of AIDS [14]. AIDS can be prevented by the regular use of an 
antiretroviral regimen. AIDS is defined as a CD4 cell count that is below 200 cells/mm
3 
(a 
healthy person has a CD4 cell count of between 500- 1600 cells/mm
3
) [12]. When a patient 
develops AIDS they have an extremely weakened immune system and are vulnerable to 
opportunistic infections. Without treatment life expectancy of a patient with AIDS is three 
years, which shortens to one year if they develop an opportunistic infection [19]. 
1.2.3 How HIV replicates in the human body and the role of the 
immune cells 
When outside the host system viruses are termed virions. They are very small (20-30nm) 
infective agents that cannot function without a host as they contain no metabolic systems of 
their own. Virions consist of a nucleic acid core that is encapsulated in a protein coat 
(capsid). The nucleic acid core and the capsid coat together are termed the nucleocapsid and 
are contained inside a lipoprotein envelope. The difference between other virions and that of 
HIV-1 is the presence of viral enzymes unique to HIV-1, such as reverse transcriptase 
(Figure 1.1). The HIV-1 virion contains the docking glycoprotein gp120 and the 
transmenbrane glycoprotein gp41 [20]. 
  
11 
 
  
         Figure 1.1: A schematic image of the contents of a HIV-1 virion 
Once the HIV-1 virus enters the blood stream, its docking glycoprotein gp120 recognises 
CD4+   cells and their co-receptors CCR5 or CXCR4 [21]. Once recognised, the HIV-1 virus 
will bind to the surface of the host CD4
+
 T-cells via its gp120 glycoprotein [22-23]. The 
binding to the surface receptor activates other surface proteins and allows the virus to fuse to 
the outside of the cell (Figure 1.2) [24]. 
The first site of viral replication is within the lymph nodes closest to the site of viral entry 
(e.g. viral contraction through sharing of needles, the viral entry site will be the arm and the 
regional lymph node will be the draining lymph nodes) [25]. This primary replication site has 
only a few viral variants and is the point that modest viral amplification takes place [12]. 
Within this primary replication site the HIV-1 virus targets specific white blood cells (the 
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white blood cells that the HIV-1 virus infects are the CD8
+   
T cells, macrophages and the 
CD4
+
 cells (main target)) and ultimately leads to their destruction [26]. 
The main function of CD8
+ 
T cells is to directly kill virally-infected cells and to release 
cytokines that are antiviral (e.g. interferon-γ). Macrophages are involved in cellular 
phagocytosis either to engulf and destroy bacteria or to clean up cellular debris and dead 
cells. The main function of CD4
+
 cells is to release cytokines (e.g. interleukin-2 / interleukin 
4) and stimulate the B cells and natural killer cells (NKC) [25]. B cells are involved in the 
production of antibodies to fight off foreign bodies and NKC eliminate infected cells [25]. 
When HIV-1 infects these white blood cells it leads to the depletion of these cells and causes 
the immune system to become immunocompromised leading to a decreased defence against 
the disease or against other invading pathogens [12]. Thus HIV-1-infected patients are at risk 
of contracting opportunistic infections. Secondary replication takes place within the spleen, 
bone marrow and gastrointestinal tract due to migration of infected T lymphocytes [26].  
Following binding the viral capsid is released into the host cell; the viral enzyme reverse 
transcriptase is released from the capsid and converts the two viral Ribonucleic acid (RNA) 
strands into double stranded Deoxyribonucleic acid (DNA) which can then be incorporated 
into the host genome allowing further viral replication (Figure 1.2) [24]. 
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Figure 1.2: A schematic image showing HIV-1 binding to CD4
+
 surface receptors 
Once transcribed, the HIV-1 DNA locates to the host cell’s nucleus. Another viral enzyme, 
integrase, is responsible for inserting the proviral DNA into the host’s DNA [27-28]. This 
integration step also masks the viral DNA’s location, making removal impossible. When the 
host cell replicates to produce new proteins, it will simultaneously produce new HIV-1 
virions [27-28]. Upon integration, HIV-1 directs the cell to produce new proteins. The strands 
of viral DNA produced in the nucleus separate and undergo translation where a 
complementary strand of genetic material is produced [24]. The result of the translation step 
is many long protein strands which are then processed into smaller strands by the viral 
enzyme protease [29-30]. Some of these smaller proteins become structural parts of new 
HIV-1 virions and others become the vital viral enzymes [29-30]. Once the viral particles are 
assembled they bud off from the host cell to create a new virus. This new virus then 
undergoes maturation which involves viral protein processing [12, 31]. This processing is the 
cleavage of the gag-pol polyprotein via the viral enzyme protease [12, 31].  Maturation of the 
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virus enables the new virus to become infectious [29-30]. After all the stages of viral 
production are complete the newly matured virus can proceed to infect more cells [29-30]. 
1.2.4 Current HIV treatments 
There are many different classes of drugs which act upon separate targets within the HIV 
cycle (Figure 1.3) currently approved for the treatment of HIV-1. 
 
 
 Figure 1.3: A schematic diagram showing the replication stages of HIV-1 and where current 
treatments target this process. 
 
Entry/ fusion of HIV-1 can be prevented by the use of entry/ fusion inhibitors (act at 
labelled number 1 in Figure 1.3). This class of drugs interfere with the binding of the HIV-1 
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gp120 glycoprotein with the CD4 cell surface and therefore prevent fusion and entry into the 
host cell [32]. Examples include Pfizer’s drug selzentry (generic name Maraviroc) which was 
first approved in august 2007 [33]. Selzentry works by binding to CCR5 and prevents 
interaction with HIV-1 gp120 glycoprotein therefore inhibiting HIV-1 from binding to CD4 
surface [34]. Also Roche’s drug fuzeon (generic name Enfuvirtide first approved in March 
2007) which acts by inhibiting gp140 glycoprotein on the HIV virion’s surface preventing 
binding and entry of HIV into the host’s cell [33].  There are currently a few novel drugs in 
this class that are still in experimental stage of drug discovery [35]. They include Progenics 
drug PRO 140 which is a monoclonal antibody that blocks the action of CD4 cells co-
receptor CCR5. In 2008 PRO 140 entered into phase 2 clinical trials and is still currently 
within this phase [36]. Also Tanox’s drug TNX-355 which acts by targeting and binding to 
the CD4 protein on CD4 cells preventing HIV binding [35]. 
 
Reverse transcriptase inhibitors (RIs) (act at labelled number 2 in Figure 1.3). These drugs 
inhibit the action of the viral enzyme reverse transcriptase [37]. Reverse transcriptase is 
responsible for converting the two viral single RNA strands into double stranded viral DNA, 
so that it can then be incorporated into the host’s genome [37].  Inhibiting this step means 
new HIV virions cannot be produced. There are two types of RIs and they are: 
 
     1) Nucleoside / nucleotide reverse transcriptase inhibitors (NRTIs) which act as analogues 
and mimic the naturally occurring deoxynucleotides which make up the viral DNA chain. 
NRTIs compete with the naturally occurring deoxynucleotides for incorporation into the viral 
DNA chain. Once incorporated, DNA synthesis is blocked as the NRTIs lack a 3’ hydroxyl 
group that is essential for the formation of a 5’ to 3’ phosphodiester bond between the 
growing DNA chain and a new nucleotide base. This results in termination of DNA synthesis. 
As NRTIs compete with naturally occurring nucleotides they are known as competitive 
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substrate inhibitors [37].  All Food and Drug Administration (FDA) approved NRTI's are 
pro-drugs lacking the 3'hydroxyl group which forces chain termination in the viral RT 
enzyme [38]. Examples of NRTI’s include Abacavir (ABC) which is a guanosine analogue 
produced by ViiV healthcare and Lamivudine (3TC) produced by GalxoSmithKline [33]. 
TFV is an example of a nucleotide reverse transcriptase inhibitor it is produced by Gilead and 
its trade name is Trvuda [33]. An example of a discontinued NRTI is Adefovir (ADEF) [33]. 
ADEF was manufactured by Gilead Sciences under the trade name of Preveon for the 
treatment of HIV. However, in 1999 its use for HIV treatment was not granted by the FDA 
and the development of this drug was discontinued due to its severe renal impairment [39]. 
ADEF was later granted FDA approval under the drug name Herpsera, when used at lower 
doses for the treatment of hepatitis B (Hep B) [39]. 
 
    2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have a different mechanism 
of action and are not incorporated into the HIV virus due to their structure. They bind at a 
different active site on the viral reverse transcriptase enzyme compared to the NRTIs [40]. 
NNRTIs do not compete with naturally occurring nucleotides for incorporation into DNA 
during DNA synthesis, instead they bind at their active site [40]. Binding of NNRTIs to the 
active site causes a conformational change to the structure of reverse transcriptase that limits 
the movement of protein domains needed to carry out DNA synthesis [40]. NNRTIs are 
classified as non-competitive inhibitors [38]. Examples of NNRTIs include Efavirenz (EFV) 
which is produced by the company Bristol-Myers Squibb under the trade name sustiva [33]. 
Despite NRTI's and NNRTI's being highly effective at inhibiting the actions of the viral 
reverse transcriptase and decreasing viral load, the problem patients encounter is resistance 
[41]. The viral reverse transcriptase enzyme can undergo mutations as it does not have any 
proof reading activity [42]. This is especially prominent whilst a patient is on NRTI/ NNRTI 
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treatments due to the selective pressure placed upon reverse transcriptase [42]. Patients who 
experience resistance whilst taking the antiretroviral drugs within the classes NRTI’s, 
NNRTI’s or PI, can benefit from using entry/ fusion inhibitors as they have a different mode 
of action and therefore a decreased chance of experiencing the same resistance problems [42]. 
Integrase inhibitors (II) (act at labelled number 3, Figure 1.3), act to inhibit the action of 
the viral enzyme integrase, therefore they prevent the incorporation of the viral genetic 
material into the host cells genome [43]. Examples include Raltegravir [3]. 
 
Protease inhibitors (PI’s) are an alternative class of antiretroviral drugs (act at labelled 
number 4 in Figure 1.3) that target the viral protease enzyme. Protease is responsible for 
cutting up the newly made viral proteins. Without this step no new functional HIV virions 
can be produced, preventing the further spread of HIV [44].  It is currently recommended that 
this drug class is taken alongside at least two other HIV approved drugs in order to treat the 
HIV treatment effectively (e.g. 1 PI + 2 NRTI’s is a usual combination) [44]. Examples of 
PIs include Genetech's invirase (generic name is Saquinavir) and Bristol-Myers Squibb's 
reyataz (generic name is Atazanavir) [33]. 
 
There is another class of drugs termed maturation inhibitors (MI) (act at point labelled 5 in 
Figure 1.3), which are currently in development. MIs act by inhibiting the final step in the 
gag processing. The inhibition of this step results in the production of non-infectious virions, 
which prevents further spread of the virus in the host’s body [45].  At present there are no 
approved MIs, but there is a few that are in development such as Bevirimat [33]. This drug 
class would be useful for those patients who have experienced resistance to the other 
antiretroviral drugs [45].   
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The WHO recommends that patients be treated using the highly active antiretroviral therapy 
(HAART) approach [33]. This method was developed by the National Institute of Allergy 
and Infectious Diseases (NIAID) and involves using two or more classes of antiretrovirals at 
the same time in order to increase the CD4 count and to decrease the risk of the patient 
developing resistance [46]. HAART can be achieved by either giving the patient a single drug 
that contains more than one agent (a multidrug combination product) such as Truvada, which 
is a combination of Tenofovir and Emtricitabine. Alternatively, the patient can be given more 
than one drug to be taken alongside each other for example 2 NRTI’s alongside a PI [46].  
 
1.3 Tenofovir as a toxicological agent 
1.3.1 Tenofovir current indications 
Tenofovir (TFV) belongs to the NRTI class of drugs. It was approved for use against HIV by 
the FDA on October 28
th
 2001 and for use against hepatitis B on August 11
th
 2008. It is given 
to patients as tenofovir disoproxil fumarate (TDF) which is the pro-drug form of TFV, to 
increase its oral bio-availability (Figure 1.4) [47]. TDF is phosphorylated to form TFV inside 
cells via cellular enzymes [13]. 
 
Figure 1.4: The structure of the pro-drug TDF and its active form TFV 
TFV is currently indicated to treat both HIV and hepatitis B infections in patients (both 
treated with 300mg daily of Viread in adults). TFV is indicated to treat HIV in adults and 
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paediatric patients as young as two and to treat hepatitis B (Hep B) in adults and paediatric 
patients as young as 12 [48]. 
Hep B is an infectious inflammatory virus that affects the liver; it is epidemic in Asia and 
Africa and is endemic in China [49]. Hep B is spread in a similar way as HIV. Recent studies 
showed to be 180,000 people within the UK currently infected with Hep B [50]. Hep B can 
be treated with TFV, Viread and a low dose of Adefovir, Hepsera [49]. 
 
TFV is also currently used to prevent mother to baby transfer of HIV through the placenta 
[13].  Usually a typical regimen to prevent mother to baby transmission of HIV consists of 
TDF + 3TC + EFV [13]. 
TDF was the first of the NRTI class approved for the treatment of HIV [51]. It is widely used 
in many, if not all, HIV regimens due to its excellent properties, which include good potency, 
good tolerability and its convenience (one pill daily) [51]. TDF possesses good 
pharmacokinetic and pharmacodynamic properties, such as long serum (17 hours) and 
intracellular (> 60 hours) half-lives, allowing a one daily dose regimen [1]. The convenience 
of TDF regimens being one pill daily via oral administration allows for better patient 
compliance [1]. This is essential for HIV patients as they must keep their plasma HIV RNA 
levels consistently low to prevent further viral growth [51]. TFV regimens can be 
administered as TDF alone (Viread) or TDF co formulated with either emtricitabin (Truvada) 
or emtricitabin and efavirenz (Atripla) [33]. 
TFV is not a substrate, inducer or inhibitor of human cytochrome P450 (CYP450) enzymes in 
vitro or in vivo and its oral bioavailability can be enhanced through its administration with a 
high-fat meal [51]. TFV can be used in both treatment-naive and treatment-experienced 
patients, as the pharmacokinetics is dose-proportional and similar in healthy volunteers and 
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HIV-infected individuals [1]. In patients with renal and/ or hepatic impairment TFV can still 
be used as long as TFV levels are monitored via plasma liquid chromatography [51]. 
Drug-drug interactions may result in increased or inadequate drug concentrations. If drug 
concentrations are increased, the risk of the patient developing adverse drug reactions (e.g. 
renal dysfunction) (ADRs) also increases [52]. If the drug levels become inadequate, in the 
case for HIV-1 patients, this leads to poor management of viral load. For this reason doctors 
and clinicians devote great attention to the potential drug-drug interactions of each 
antiretroviral [52]. This is essential as many HIV-1 patients take a HARRT regimen that 
usually involves the use of 2 NRTI’s and one PI alongside each other.  
The known drug-drug interactions associated with TFV treatment are similar to those with 
the NRTI diadanosine (ddI), the PI atazanavir (ATZ) and lopinavir (LPV) / ritonavir (RTV) 
[33]. When the coadministration of TFV with DDI takes place patients must be monitored for 
ddI associated ADRs (pancreatitis and neuropathy), as clinical monitoring has shown TFV to 
significantly increase the maximum concentration (Cmax) and the area under the curve 
(AUC) of ddI [53]. The mechanism of this interaction is unknown, however; research has 
demonstrated that the monophosphate and diphosphate forms of TFV are inhibitors of the 
purine nucleoside phophorylase enzyme, which is essential for ddI clearance and breakdown, 
thus increasing the circulating levels of ddI within patients [53]. Coadministration of TFV 
with ATV has shown to increase circulating TFV concentrations within patients [54]. The 
mechanism of this interaction is still unknown. Patients taking both drugs should be 
monitored for TFV associated ADRs, such as renal dysfunction and Fanconi syndrome [54]. 
LPV and RTV are taken in combination in a fixed dose regimen [55]. RTV is a known 
inhibitor of the CYP450 enzymes for this reason it is used as a PI booster as it increases 
circulating PI concentrations [55]. Studies have shown that coadministration of TFV with 
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LPV/ RTV increases circulating TFV concentrations [54-55], but the mechanisms of this 
interaction are unknown [55]. Patients who are taking TFV and LPV/ RTV should be 
monitored for TFV associated ADRs [55]. 
Coadministration of drugs that affect renal function alongside TFV, will affect circulating 
TFV concentrations as TFV is metabolised primarily via the kidneys [56]. Certain drugs (e.g. 
cyclovir, ganciclovir cidofovir, and valganciclovir), may reduce renal function or compete for 
active tubular secretion thus increasing serum concentrations of TFV and/or increase the 
concentrations of other drugs eliminated renally [56].  
Although TFV has a relatively good safety profile, it has been linked to a number of renal 
dysfunctional problems especially when patients have been on TFV regimens long term 
which is usually the case for HIV patients [57]. 
1.3.2 Tenofovir pharmacodynamics 
TFV can be taken as a once daily tablet for oral administration (300mg Viread). As TFV is 
polar and ionised, it has low oral bioavailability and so it must be administered as a pro-drug 
(TDF). TDF (Figure 1.4) was designed to mask the two main ionic regions of TFV to 
enhance its penetration thorough the gut wall and increase bioavailability [13]. Upon 
absorption into the intestinal wall, TDF is converted to a monoester by the carboxylesterase 
enzyme. This monoester is then converted into TFV upon first pass metabolism through the 
liver making TFV the main circulating species [13]. 
 
After first pass metabolism within the liver circulating TFV reaches the kidneys. TFV is 
excreted unchanged into the urine via a combination of glomerular filtration and proximal 
tubule secretion [58]. TFV enters the proximal tubule cells via active transport through the 
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basolateral membrane. This active transport is mediated by the human organic anion 
transporter's (hOAT) 1 and to a lesser extent 3 (hOAT-1, hOAT-3). OAT transporters are part 
of a superfamily that facilitates the transmenbrane transport of endogenous and exogenous 
compounds (Figure 1.5) [58]. 
 
Figure 1.5 A schematic image of the uptake and elimination of TFV. 
 
TFV is excreted from proximal tubule cells into the urine via the apical membrane multi drug 
resistant transporters 2 and 4 (MRP2, MRP4), which are highly expressed within the apical 
membranes of renal proximal tubule cells [58].  
1.3.3 The anatomy of the kidneys 
The kidneys are key organs that help to regulate volume, electrolyte content and pH of 
extracellular fluid. Several hundred litres of plasma enter the kidneys daily, 120 litres of this 
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plasma is filtered [59]. Water is filtered through the kidneys and 99% is reabsorbed along 
with reabsorbtion of most of the sodium ions. The average adult human kidneys produce 1.5 
litres of urine in an average 24 hour period. 
The kidney is made up of an outer cortex, an inner medulla and a hollow pelvis which 
empties into the urethra [59]. The main functional component of the kidneys is the nephrons. 
Each average adult kidney contains approximately 1.4x10
6
 nephrons (this number declines 
with age). Each of these nephrons are made up of 5 main sections including the glomerulus, 
proximal tubule, loop of Henle, distal convoluted tubule and the collecting ducts (Figure 1.6) 
[59]. 
 
Figure 1.6 A schematic diagram of the anatomy of the kidneys 
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The glomerulus is made up of a bundle of blood capillaries that enter the renal tubule at the 
dilated end. Fluid enters the Bowmans capsule (Figure 1.6) through the capillaries under 
hydrodynamic pressure [59]. The first set of cells that the filtrate encounters are the proximal 
tubule cells. At this meeting point the filtrate is at its most concentrated, therefore these cells 
are at greater risk of toxicity caused by the components of the filtrate [59]. The proximal 
tubule cells are permeable to ions and water and permit passive flow in either direction. 
Around 60-70% of sodium reabsorption occurs in the proximal tubule cells [59]. Sodium ions 
enter the proximal tubule cells via sodium/ hydrogen exchange. The enzyme carbonic 
anhydrase is an intracellular enzyme and is essential for the production of hydrogen ions that 
are exchanged for sodium ions [59]. The main active transport of the proximal tubule cells 
happens via the sodium potassium ATPase pump (sodium pump). This pump is located in the 
basolateral membrane of the proximal tubules and is responsible for expelling the excess 
sodium ions that have built up inside the proximal tubule cells into the blood [59]. The excess 
bicarbonate that is produced intracellularly and exchanged for the sodium ions is broken 
down in the extracellular fluid by the carbonic anhydrase enzyme into water and carbon 
dioxide. This reaction occurs at the brush border of the proximal tubules [59]. As the 
proximal tubule cells are responsible for the active transport of many ions, they are highly 
abundant in mitochondria needed for the production of cellular ATP. This makes the 
proximal tubule cells more susceptible to mitochondrial toxicity induced by mitotoxins [60]. 
Upon leaving the proximal tubule the filtrate is only 30-40% of its original volume and 
passes to the loop of Henle (Figure 1 .6), where further reabsorption of ions and water takes 
place [59]. After filtrate from the loop of Henle enters the distal tubule, further reabsorbtion 
of ions occurs, regulated via the hormones paratharmore and calcitrol [59]. The filtrate leaves 
the distal tubule and enters the collecting ducts via the collecting tubules [59]. Within this 
section movement of ions and water are controlled only by the hormones aldosterone 
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(reabsorption of sodium chloride) and the anti-diuretic hormone (reabsorption of water) [59]. 
The kidneys control the pH of the urine and favour an acidic pH to facilitate the removal of 
phosphoric/ sulphuric acids and sulphur containing amino acids from the diet [59]. After 
leaving the collecting ducts the filtrate leaves the kidneys as urine via the urethra [59]. 
 
1.3.4 Tenofovir induces toxicity via kidney injury 
1.3.4.1 Tenofovir induces renal dysfunction 
Current antiretroviral therapies that contain NRTI's are plagued with toxicity and RT 
resistance [61]. Although TFV is known to be less toxic than other nucleoside analogues such 
as adefovir and cidofovir it is still well reported as a nephrotoxin [58-61]. Specifically 
clinical cases of TFV induced renal toxicity include Fanconi's Syndrome, acute renal failure, 
nephrogenic diabetes insipides and chronic kidney disease (CKD) [58-61] 
Initial pre-clinical trials and the post clinical studies reported that TFV is safe due to low 
incidence of renal impairment (1-3%), which was characterised by elevated serum creatinine 
clearance [58]. However recent case reports and data from cohort studies show a clear 
association between prolonged TFV use and the development of nephrotoxicity; this was 
recently reported as a 20% incidence rate within HIV-1 infected patients [58]. 
The first report of kidney disease induced via TFV use was published in 2002. The patient 
presented with normal baseline renal function, however further investigations confirmed that 
the patient had developed TFV induced Fanconi syndrome (Verhelst et al., 2002). Fanconi 
syndrome is a disease that affects the renal proximal tubules and leads to excessive loss of 
glucose, uric acid, phosphates, bicarbonate and amino acids within the urine. The onset of 
Fanconi syndrome can lead to further complications such as renal tubular acidosis due to loss 
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of bicarbonate ions and bone diseases e.g. rickets due to loss of phosphates. Since 2002, the 
onset of renal disease induced via TFV use has been reported both in numerous singular cases 
or cases within a small subset of patients. The symptoms that the patients presented with 
varied, some develop acute renal failure [63-73], whilst most patients had developed 
tubulopathy, occasionally with overt Fanconi syndrome [61,74-80]. The signs and symptoms 
associated with kidney tubulopathy (including glucosuria in cases when patients had normal 
serum glucose levels), include hypokalemia (with or without acute renal failure), phosphate 
wasting (with hypophosphateamia), acidosis and proteinuria (usually mild); these were 
among the most frequent renal dysfunctions in patients experiencing TFV induced 
nephrotoxicity. There was also a small subset of patients with nephrogenic diabetes insipidus 
[63, 81-82].  
The risk factors for the development of TFV-induced nephrotoxicity include baseline renal 
dysfunction (this has also been linked to the age of a patient, as renal function declines as a 
person ages), low CD4 counts and low body weight [83, 84]. Patients are at higher risk if they 
have pre-existing systemic conditions or are taking a regimen that involves the use of 
potential nephrotoxins [70-71, 81, 85]. The antiretroviral medications that were associated 
with a higher onset of TFV-induced renal dysfunction were; LPV [63, 67-68, 70-71, 74-75, 
78, 82, 86-87] or ddI [66, 76, 81]. A review of the cases reported to the FDA on the onset of 
TFV induced renal dysfunction within patients from 2001 through to 2006, showed that of 
those cases, 164 met the definition for Fanconi syndrome [88]. Of those 164 cases, 83% of the 
patients were coadministered TFV and a PI as part of their HIV-1 HAART regimen, 34% of 
these patients were also taking ddI [58]. 
Patient data that was obtained from patients  not involved in clinical trials reported significant 
increase in the serum creatinine levels as well as a reduction in the estimated glomerular 
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filtration rate (eGFR) in patients on TFV compared to those taking other nucleoside regimens 
[89]. 
Kidney damage is usually seen in patients on TFV containing antiretroviral treatment after 6 
months post treatment; however a recent study reported cases where renal dysfunction did not 
develop until 18 months after initiation of treatment and suggest that patients should be 
monitored for this period post initiation [77]. Renal dysfunction usually presents as acute 
renal failure with decreased glomerular function [61]. The renal damage is usually seen as 
tubular dysfunction which is specific to the proximal tubules and has an incidence rate of 20% 
within HIV-1 infected patients who may already be renally compromised due to the HIV-1 
infection [58].  
Although data from clinical trials suggest that TFV toxicity affects 2% of the population this 
may be an under estimation due to the use of only healthy volunteers vs. the target population 
[90], who are immunocompromised. Therefore the patient cohort data that shows a 20% 
incidence rate of TFV associated renal dysfunction may provide a more reliable figure [58]. 
1.3.4.2 Tenofovir induced chronic kidney disease 
Upon discontinuation of TFV treatment the acute kidney damage is shown to reverse in 
cohort studies. However, once the kidney damage has developed into chronic kidney disease 
(CKD) the effects of TFV induced renal toxicity cannot be reversed. Therefore, it is 
important to detect damage earlier in TFV treatment in order to prevent long lasting renal 
dysfunction [58]. As a gold standard, the clinical marker of kidney function is serum 
creatinine that is determined via the estimated Glomerular Filtration Rate (eGFR).  When a 
person has an eGFR of 90 ml /min/ 1.73
2
 or above is considered normal. A patient is 
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diagnosed with CKD if their eGFR falls below 60 ml /min/ 1.73
2
 for a period longer than 3 
months [91]. 
Patients with CKD are at increased risk of suffering a stroke or of having a heart attack. A 
decline in eGFR to 30-59 ml /min/ 1.73
2
 is considered as moderate CKD [91]. At this stage 
hormones and mineral levels within patients become unbalanced; this can lead to anaemia 
and weakened bones [91]. Sever reduction in eGFR is classified as an eGFR in the range 15-
29 ml /min/ 1.73
2
 [91]. At this stage the kidneys are damaged and patients must undergo 
invasive treatment including haemodialysis, peritoneal dialysis and in some cases patients 
undergo kidney transplant (a healthy kidney donated from a family member or a matched 
donor) [91]. Kidney failure will occur when patient’s eGFR is below 15 ml /min/ 1.732; it is 
at this point that a patient will need to undergo either dialysis or a transplant to sustain life. 
CKD is irreversible and cannot be cured, but if identified early stages patients will be able to 
maintain kidney function if the perpetrator of the kidney damage is inhibited [91]. Upon 
discontinuation of TFV in patients on TFV, kidney function will remain at a steady stage; 
CKD effects will not be reversed, but further damage will be prevented [58-61]. This is why 
early identification if TFV induced renal damage is essential; development of a new 
biomarker is needed [58]. 
 
1.3.5 Mechanisms of Tenofovir induced renal toxicity 
As TFV has only been approved as a HIV drug since late October 2001 the current in vitro 
and in vivo experiments to determine TFV’s mechanistic pathways and associated toxicities 
are not well established. A summary of the main in vitro and in vivo experiments used to 
study TFV-induced toxicity can be seen in Table 1.1. This table highlights that there needs to 
be further investigations into the molecular pathways of TFV in vitro and in vivo to elucidate 
its toxicological pathways. 
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Table 1.1: Summary of the in vitro and in vivo research into TFV 
Authors 
Drugs being 
tested 
ex  vitro /in vivo 
model/s used 
Experimental Aims Results 
Birkus et 
al., 2001 
TFV toxicity  vs. 
other NRTI's 
HepG2 cells, 
skeletal muscle cells 
and proximal tubule 
epithelial cells 
3 weeks treatment with 
concentrations from 3 - 
300 µM of NRTI drugs. 
The mtDNA levels and 
COX II / COX IV mRNA 
levels were assessed and 
lactate levels were 
determined. 
TFV did not induce any significant effects on 
mtDNA levels in all cell types. TFV did not 
affect COX II or COX IV . Lactate production 
was decreased by < 20% at 300 µM TFV. No 
toxicities were associated with TFV dosing. 
Cihlar et 
al .,2001 
TFV in 
comparison to 
other NRTI's 
(ZDV, ddC, ddI, 
d4T, abacavir 
(ABC) and 3TC) 
HepG2 cells, 
skeletal muscle 
cells, erythroid 
progenitor cells, 
renal proximal 
tubule epithelial 
cells  and  myeloid 
cell lineage  
to examine the cytotoxic 
effects of TFV in 
comparison to other 
NRTI's 
TFV inhibited proliferation of HepG2 cells 
and normal skeletal muscle cells with CC50 
values of 398 and 870 µM. This > CC50 
values for the other NRTI's. TFV was less 
cytotoxic within erythroid progenitor cells 
than ZDV, d4T, and ddC. the inhibitory 
activity of NRTIs in myeloid cell lineage, was 
(highest severity to lowest) 
ddC>ZZDV>D4t>TFV>3TC. TFV showed 
weaker effects on proliferation and viability of 
renal proximal tubule epithelial cells than 
cidofovir 
Rompay 
et al., 
2004 
TFV rhesus macaque in 
vivo and using 
isolated rhesus 
macaque PBMC 
cells 
determining affect of TFV 
on  interleukin-12 (IL-12) 
expression 
TFV caused a small increase in vivo and in 
vitro of IL-12. IL-12 has been shown to  
mediate anti-apoptotic responses 
Ray et 
al., 2006 
TFV CaCO transfected 
with human MRP2 
and MDCKII 
to determine which 
transporters are 
responsible for TFV 
uptake and efflux  
OAT1 / 3 are responsible for TFV uptake and 
MRP4 is responsible for TFV efflux. It was 
found that TFV was not a substrate for MRP2 
Vidal et 
al., 2006 
TFV alone and in 
combination with 
AZT 
(zidovudine), 
ddI, RTV and 
LPV 
renal proximal 
tubule epithelial 
cells  
cytotoxicity was 
determined after a 22 day 
period, mtDNA levels and 
cytochrome oxidase II 
(COX II) mRNA levels 
were assessed 
TFV alone and in combination showed no 
associations with toxicity therefore taking 
TFV in combinations will not increase toxicity 
Tong et 
al., 2007 
TFV + PIs 
(DRV/RTV, 
LPV/RTV, 
ATV/RTV) 
human ovarian 
carcinoma cell line 
(CaCo-2) and 
Mandin-Derby 
canine kidney cell 
line (MDCKII) 
To determine the effect of 
PIs on TFV intestinal 
absorption 
It was demonstrated that TFV 
permeabilisation was decreased due to ester 
cleavage, this is possible reason for increased 
circulating TFV when coadministered with 
PI'S 
Venhoff 
et al., 
2007 
TFV alone and in 
combination with 
FTC, ABC 
HepG2 cells evaluation of the 
mitochondrial toxicity of 
the drugs via assessment 
of cell growth, lactate 
production, intracellular 
lipids, mtDNA and COX 
II / COX IV 
TFV showed no or minimal toxicity . FTC + 
TFV slightly reduced proliferation without 
affecting mitochondrial parameters. TFV 
attenuated ddI related cytotoxicity but 
worsened the cytotoxic effects of CBV and 
AZT 
Cihlar et 
al .,2007 
TFV and ADEF Isolated human 
proximal tubule 
cells 
to determine if transporter 
expression of hOAT -1 is 
responsible for TFV /  
ADEF induced 
nephrotoxicity 
There was no associated TFV cytotoxicity 
within the proximal tubule cells. TFV was 
transported via hOAT1 
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Cihlar et 
al .,2007 
TFV + PIs 
(DRV/RTV, 
LPV/RTV, 
ATV/RTV) 
Isolated human 
proximal tubule 
cells 
to determine how PI 
affects TFV transport 
(human OAT 1 / 3 and 
MRP4 assessed ) 
The PI's did not affect cytotoxicity of TFV.  It 
was shown that PI’s caused < 20 % inhibition 
of TFV transport via the hOAT1. hOAT3 saw 
a 62% decline in TFV transport with RTV and 
a 37 % decline with LPV. Outcome: low 
potential of PI's to interfere with active 
secretion of TFV 
Bousquet 
et al., 
2008 
TFV + EFV + 
FTC 
(emtricitabine) 
peripheral blood 
mononuclear cells 
(PBMC)- obtained 
from healthy 
volunteers 
transporter expression in 
response to drugs (p-
glycoprotein and MRP 1- 
6) 
TFV significantly reduced MRP1, MRP5 and 
MRP6 MRNA expression 
The conclusion from previous work [92-100], is that TFV causes nephrotoxicity due to its 
accumulation within the proximal tubules. The exact molecular mechanisms of TFV toxicity 
are not fully understood however there are two main hypotheses. 
1.3.5.1 Tenofovir toxicity is linked to cellular transporters  
The first hypothesis is an increase in the activity of OAT 1/3 transporters, or a decrease in the 
activity of the MRP2/4 transporters will lead to increased accumulation of TFV in the 
proximal tubules [101]. (Figure 1.7)  
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Figure 1.7 A schematic diagram of renal dysfunction induced by TFV when the transport 
of TFV is changed 
 
This increased accumulation of TFV leads to greater exposure of the mitochondria to TFV 
and increases any mitochondrial toxicity that TFV may induce (Figure 1.7). This hypothesis 
states that a person’s pharmacogenetics could predispose them to TFV induced renal 
dysfunction. For example an increased expression of OAT1 within an individual will lead to 
increased TFV accumulation within the proximal tubules, therefore increasing their risk of 
developing TFV induced proximal tubule toxicity [53]. 
Transporter levels may also alter due to taking multi-drug therapies such as the HIV regimens 
[53]. These therapies can lead to a change in the activity of the transporters key to TFV 
uptake and/ or elimination. An example is a patient taking TFV alongside a protease inhibitor 
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(e.g. ritonavir), ritonavir is eliminated from proximal tubule cells via the MRP2 transporters. 
This will lead to increased circulating TFV concentrations as both drugs compete for the 
same MRP2 transporter [53]. 
In vivo studies have utilised MRP4 -/- knockout (KO) mice to study TFV. It was reported that 
the KO mice became more susceptible to TFV induced nephrotoxicity. This was reportedly 
due to a decreased elimination of TFV into the urine. This supports the hypothesis that 
patients may have polymorphisms in specific transporter genes which may lead to up/ down 
regulation of transporters responsible for TFV influx and efflux, making some patients more 
susceptible to TFV induced toxicity [60]. It has also been suggested in the literature that TFV 
itself can cause the up/down regulation of these key transporter's leading to increased 
accumulation of TFV within the proximal tubule cells and a higher incidence of renal 
dysfunction [60].  
Other studies showed that there are differences in the activity or expression in genes coding 
for the key transporters involved in TFV efflux according to race [13]. Studies showed single 
nucleotide polymorphisms (SNPs) in the MRP2 genes (c-24T and G1249A) and MRP4 genes 
(A3463G and T4131G) have been shown to be linked to differences in expression due to race 
[13]. 
Smaller cohort studies have shown associations between gender (males have a higher 
metabolic rate than females, this may lead to an increased rate of TFV accumulation),  or  
race (different races have variations in the expression of transporters needed for TFV influx 
and  efflux), of patients and the increased risk factors for TFV induced renal toxicity [102]. 
Studies have shown females to have a higher incidence rate of developing renal dysfunction 
when taking TFV regimens [102]. These findings may be essential for developing relevant 
PrEP treatments for different patient populations [103]. 
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1.3.5.1 Tenofovir toxicity is linked to mitochondrial damage 
The second hypothesis is based on the interaction of TFV with mitochondria. Once TFV is 
transported into the proximal tubule cells they gain access to the mitochondria which are 
present in abundance in these cells to help facilitate active transport. It is hypothesised that 
TFV can non-specifically inhibit mitochondrial DNA (mtDNA) polymerase γ, causing 
mitochondrial dysfunction [38, 93]. This hypothesis is based on the known mechanistic 
pathway of ADEF-induced proximal tubule dysfunction [38, 93]. Mitochondrial dysfunction 
can lead to anaerobic respiration, oxidative damage, lactic acid production and renal damage 
leading eventually to CKD. MtDNA damage may lead to the disruption of the electron 
transport chain which is essential for cellular energy production. This damage and disruption 
of mitochondrial function may also cause the activation of apoptosis via the many intrinsic 
cell death pathways that mitochondria are essential for [93]. NRTI’s can inhibit mtDNA in a 
similar fashion as how they inhibit the viral reverse transcriptase. 
Pre-clinical trials, in vitro studies and enzymatic assays of TFV toxicity have demonstrated 
that TFV is not as effective in inhibiting mtDNA pol γ as other NRTI’s [13]. However, recent 
clinical data has linked TFV to mitochondrial toxicity which was observed as a decrease in 
the reabsorbtion of glucose, uric acid, phosphates or amino acids. These data also reported 
TFV effects on bone density [53, 58, 62]. Patients on long term TFV treatment have 
presented with significantly reduced bone density, which could be due to the alteration in 
phosphate metabolism within the proximal tubule cells caused via mitochondrial dysfunction. 
This impacts on bone mineral density [94].  
Many in vitro and in vivo studies support the hypothesis that NRTI exposure leads to 
mitochondrial impairment [46, 53, 58, 62, 104]. Studies have demonstrated that NRTI’s, such 
as ADEF, induce renal toxicity primarily by mitochondrial toxicity via the inhibitation of 
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mitochondrial pol γ [53, 58, 93]. As ADEF and TFV have similar structures with only the 
addition of a methyl group on TFV compared to ADEF (Figure 1.8), the adverse affects of 
ADEF and the other NRTI’s may be mechanistically shared by TFV. Therefore the effect of 
TFV on cellular mitochondria needs to be investigated within an adequate cell model. 
 
Figure 1.8: The structure of ADEF and TFV (only an additional methyl group compared to 
ADEF) 
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1.4 Thesis Aims 
TFV is the backbone of most HIV regimens due to its good pharmacodynamic and 
pharmacokinetic properties [1]. Many pre-clinical studies showed that TFV was a safe drug 
in comparison to previous HIV-1 treatments; however recent data from cohort studies have 
reported a significant number of patients that develop TFV induced renal dysfunction [46, 53, 
58, 62, 104]. For this reason it was the aim of this Ph.D. to elucidate the mechanistic pathway 
of TFV induced toxicity in order to develop safer HIV treatments in future, either via the 
identification of potential biomarkers to monitor TFV induced renal dysfunction, or by 
identifying those patients who are more susceptible to TFV induced renal dysfunction.  
The cytotoxicity induced by TFV will be investigated by developing in vitro models with 
which to probe the mechanistic pathway and to understand TFV induced cytotoxicity. Within 
these in vitro models the mechanisms of cell death induced by TFV will be elucidated via the 
assessment of apoptosis, and necrosis determined by different markers including caspase 
activity, mitochondrial membrane depolarisation, reactive oxygen species (ROS) production 
and DNA content. Finally the possible use of kidney injury molecule-1 as a biomarker for 
TFV induced proximal tubule dysfunction will be assessed using the urine from a cohort of 
HIV-1 patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Two 
 
GENERATION AND VALIDATION OF METABOLICALLY 
MODIFIED CELL LINES TO PROBE MITOCHONDRIAL 
TOXICITY 
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1.1 Introduction 
In this chapter the methodology and results from the work to generate and validate 
metabolically modified cell lines will be presented. These studies were essential in order to 
generate an in vitro model that could be used as a mechanistic tool for the elucidation of TFV 
induced cytotoxicity. Previous work has shown that TFV does not cause any cellular injury 
during in vitro studies [1-4]. 
Clinical toxicity caused by therapeutic drugs is referred to as an adverse drug reaction (ADR) 
[5].  ADRs are a major health problem worldwide; there are two main types of ADRs which 
are called on target and off target responses. On target ADRs are always predictable from the 
known pharmacology of the drug and are dose-dependent. Off target ADRs are also referred 
to as idiosyncratic or immune-mediated responses. These idiosyncratic responses are not 
predictable from the known pharmacology of the drug and the mechanisms behind them are 
not understood [5]. In order to predict these ADRs both during drug development in order to 
prevent toxicity before the drug is licensed, and to monitor ADRs after drug licensing via the 
use of biomarkers, the mechanistic pathways of toxicity must be elucidated and understood 
[5]. 
TFV toxicity is usually a time-delayed event clinically, that accumulates when a patient is on 
TFV long term [6]. This delayed accumulative toxicity means previous attempts at studying 
TFV toxicity in vitro have not been successful as discussed in Chapter 1 [1-4]. Therefore, 
careful consideration had to be taken in order to define the most relevant cell model for the 
study of TFV-induced cytotoxicity. As previously discussed in Chapter 1, the use of NRTIs 
including TFV, have been associated with the induction of mitochondrial dysfunction. 
Human cells rely heavily on mitochondria for their energy production, however the in vitro 
models previously used to study TFV cytotoxicity were immortalised cell lines, which 
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produce their energy mainly via glycolysis. To elucidate the effect of TFV on mitochondrial 
function and viability, cell lines would need to be modified to produce a cellular system that 
closely represents the aerobic conditions of human cells. 
 The most ideal cell model would have been to use primary human proximal tubule cells as 
these are the target cell of TFV-induced toxicity clinically [7]. Primary cells have the 
advantage that they are not glycolytic and are abundant in mitochondria, therefore are a better 
representation phenotypically to in vivo cells.  However, practically the use of primary cells 
has distinct disadvantages. The main disadvantage is the problem of isolation of the primary 
cells which can be technically challenging and can lead to contamination of the cells with 
other cell types thus altering the results gained. Another problem with using primary cell 
lines is their survival rate which is short (2- 4 passages),  making long term study difficult; 
the use of these cells is limited as their phenotype  begins to change the longer they are left in 
culture, which may make results unreliable. When using primary cells they have to be 
replaced after a maximum of 4 passages making their usage expensive. The kidney biopsy 
used to obtain these cells is a high risk procedure as the kidney is highly vascular; also there 
will be patient variation in the health of their mitochondria. All these disadvantages mean that 
for in vitro studies, primary cell lines whilst representing more closely the patient cellular 
conditions, are rarely used [8].  As the study of TFV induced cytotoxicity was to be studied, 
primary cells would not have a viable option due to the time delayed toxicity that has been 
associated with TFV use clinically [9]. Therefore we considered other in vitro options that 
will have a high survival rate, allowing longer culturing, whilst still retaining enough 
resemblance phenotypically to human proximal tubule cells in order to gain reliable results. 
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1.1.1 The importance of the mitochondria for cellular energy 
production 
The mitochondria are considered the powerhouse of the cell. The mitochondria are essential 
for many functions within the cell; the main functions being the production of energy in the 
form of adenosine triphosphate (ATP) via mitochondrial oxidative phosphorylation 
(OXPHOS) [10] 
Figure 2.1: A schematic diagram of the production of ATP via the mitochondrial OXPHOS 
pathway (modified from a picture in White et al., 2010)    
The mitochondrial respiratory chain (Figure 2.1) is responsible for catalysing the transfer of 
electrons from reduction donors (NADH and FADH2) to molecular oxygen (O2),  producing 
water (H2O). Acetyl CoA which is generated either by glycolysis (in the cytosol) or by the 
oxidation of fatty acids (inside the mitochondria), is passed through the tricarboxylic acid 
cycle. This cycle leads to the generation of the reduction donors NADH and FADH2 which 
are essential for the electron transport chain (ETC). There is a large redox potential difference 
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between the electron donors and the final electron acceptor within the ETC. The electron 
flow along the respiratory chain is accompanied by a decrease in the Gibbs potential (which 
results in the release of free energy). This energy is used to pump protons across the inner 
mitochondrial membrane. This leads to production of an electrochemical gradient, allowing 
protons to return to the mitochondria via specific channels. As the protons pass through these 
channels the synthesis of ATP is catalysed. ATP is then exchanged for cytosolic ADP via the 
ADP/ATP translocator. Another key function of the mitochondria is their involvement in the 
intrinsic apoptotic pathway (discussed in detail in Chapter 4), showing mitochondria are 
essential regulators of cellular survival [10] 
Tumour-derived immortalised cell lines have become the most widely used type of cellular 
systems used for in vitro work. These cell lines have the advantage of rapid growth and long 
survival periods under culture conditions. However, they produce their energy mainly via 
glycolysis instead of mitochondrial oxidative phosphorylation (OXPHOS); this is known as 
the Crabtree effect [8].  Immortalised cell lines derive their energy in this way despite the fact 
that they contain fully functional mitochondria. It has been shown that this Crabtree effect is 
due to the allosteric modulation of glycolytic enzymes [8], and the binding of the enzyme 
hexosekinosine to the mitochondrial porin [11].  As these immortalised cell lines generate 
their energy mainly via glycolysis, they are not reliant on mitochondria for ATP production. 
Therefore, in these cell lines mitochondrial toxicity is virtually non-existent, due to the fact 
that mitochondrial toxins have little or no effect on cell viability or cell growth [8].  
Studies have shown that when HepG2 cells are grown in glucose-free media supplemented 
with galactose, the glycolysis pathway becomes inhibited.  Therefore, cells become more 
reliant on mitochondrial OXPHOS, thus making them more susceptible to mitochondrial 
toxins [8]. This study showed that when HepG2 wild type (HepG2 WT) cells are incubated 
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with the classical mitochondrial toxin rotenone, no cytotoxicity is seen, however when the 
HepG2 cells were grown in galactose media cytotoxicity induced by rotenone was clear 
showing that rotenone is causing mitochondrial specific toxicity [8].   These galactose grown 
cells more closely represent human cells, as human cells use 95 % OXPHOS to generate 
cellular ATP [12]. Other studies showed that when grown in galactose media HepG2 cells 
increase their respiration rate to maintain the cellular ATP levels, this is known as the 
Warburg effect  as can be seen in Figure 2.2 below [13]. 
 
Figure 2.1 A schematic diagram showing how growing cells in galactose media makes them 
more susceptible to mitochondrial toxins 
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2.1.2 Aims of Chapter 
The aim of this chapter was to aerobically modify cell lines in order to elucidate the effect of 
TFV on cellular mitochondria. The cell lines that were chosen for generation and validation 
were HepG2 cells (a human hepatic cell line) and HEK293 (a human renal cell line). The 
HepG2 cells were chosen as they had previously been grown in galactose media; results 
showed they became susceptible to mitochondrial toxicity induced by rotenone these cells 
were used alongside HEK293 cells that have not been aerobically modified before. The 
HEK293 cells used were transfected with human kidney injury molecule-1 (KIM-1) so that 
further studies into using KIM-1 as a possible biomarker for TFV induced proximal tubule 
dysfunction could be carried out (Chapter 5).  All work carried out in the HEK293 KIM-1 
cells was also carried out within HEK293 PcDNA cells which are HEK293 cells transfected 
with an empty vector so that any effects of the transfection could be identified. The 
progression of this metabolic switch was monitored using rotenone, a classical mitotoxin. 
Rotenone is used in solution as a pesticide and is known to cause mitochondrial toxicity via a 
specific inhibition of Complex I (NADH –dehydrogenase, inhibiting this enzyme inhibits 
mitochondrial respiration) [14]. Rotenone toxicity is observed when glycolysis pathways are 
inhibited, thus cells must rely on mitochondrial OXPHOS [8]. The following states the aims 
of this chapter: 
1) In order to validate when the glucose grown cells were dependent solely on the 
mitochondrial OXPHOS pathway, 24 hr rotenone MTT assays were carried out at each 
passage point until the point when rotenone cytotoxicity was prominent after only 24hrs 
[8].    
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2) In order to verify the use of the cells in a TFV study, the presence of transporters needed 
for TFV accumulation were examined. The levels of the transporters MRP2, MRP4, 
MRP7, OAT1 and OAT3 were determined within both cells lines when grown in glucose 
and galactose, via PCR methods.  
3) Finally the accumulation of TFV within the HepG2 cells grown in glucose (HepG2 WT) 
and galactose (HepG2 galactose) was determined using radiolabelled TFV to determine 
the profile of TFV accumulation in these cells. 
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2.2 Materials and Methods 
2.2.1 Materials 
Basal culture media (DMEM high glucose and DMEM no glucose) were ordered from life 
technologies, Invitrogen (Paisley, UK) Hanks balanced salt solution (HBSS), 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltrazolium bromide (MTT), Sodium dodecyl sulfate (SDS), 
N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), sodium pyruvate, trypan 
blue (0.4%) solution, dimethylsulphoxide (DMSO), ethanol, acetic acid,   Neutral Red, 
Adefovir,  Lamivudine,  n-dimethylformamide (DMF), chloroform, isopropanol, nuclease 
free water,  Foetal bovine serum (FBS) and D-(+)-Galactose were all purchased from Sigma 
(Poole, UK). Primers and probes, master mix, and kit containing all components of the PCR 
reaction mix were purchased from Applied Biosystems, (Warrington, UK). Tenofovir was 
ordered from Toronto Research Chemicals (Toronto, Canada) 
2.2.2 Cell Culture and Experimental Preparation 
HepG2 and HEK293 cell lines were maintained in either DMEM high glucose or DMEM no 
glucose. Under both conditions, the media was supplemented with 10% v/v FBS, 1% v/v 
sodium pyruvate and 5 % v/v HEPES. To the cells grown in DMEM no glucose, galactose 
was added to a final concentration of 10 mM. Once cells were confluent, 1 x 10
6
 cells were 
then seeded in 30 ml of freshly supplemented media in a new 75 cm
2
 flask. The cells were 
incubated in a humidified incubator with 5% CO2 and were maintained at of 37
o
C.  
The viability of the cells was based upon a trypan blue exclusion from the cells that was 
carried out using haemocytometer and a light microscope (x 10; Axioskop, Welwyn Garden 
City, UK). 20µl of trypan blue 4% solution was added to a 100µl aliquot of cells, this was 
then counted. Cell viability was above 95% for all experiments carried out. During 
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experiments cells were exposed to drug stock solutions which were made up in DMSO the 
final concentration of the DMSO was below 1 % v/v in each incubation. Experimental 
conditions were carried out in quadruplicate on at least 3 separate occasions. 
2.2.3 The assessment of cytotoxicity using MTT assays 
The MTT assay is a colorimetric assay that is based upon the reduction of the soluble 
tetrazolium MTT dye to its insoluble formazan salt via the dehydrogenase enzymes found 
within viable cells [15]. This assay produces a colour change from the original yellow MTT 
to purple when incubated with viable cells. The quantity of formazan present is directly 
proportional to cell viability [15],   
All cell lines were plated at a density 0.4 x 10
6
 cells/ml. Cells were plated, in triplicate, in 
flat-bottom 96-well plates and were exposed to a range from 0 µM to 100 µM of each 
compound for 24 hours. Following incubation of the cells with the compound 20 µl of MTT 
solution (5 mg / ml in HBSS) was added to each well. After 2 hour incubation at 37 
0
C, 100 
µl of lysis buffer (20 %  w / v SDS; 50 %  v / v DMF) was added to each well. The lysis step 
was to dissolve the formazan crystals, after this step the plate was again incubated for 4 
hours. The absorbance of the wells was read using a test wavelength of 570 nm and a 
reference wavelength of 590 nm using a plate reader (MRX, Dynatech Laboratories). The 
results were expressed as a percentage of the non-treated vehicle only cells. The EC50 values 
were estimated from the inhabitation curves that were plotted using the GraFit software. 
2.2.4 The assessment of cytotoxicity using Neutral Red Assays 
The Neutral Red (NR) assay is based upon the cell’s ability to bind the NR dye within its 
lysosomes.  The quantity of retained dye is directly proportional to the number of viable cells 
[16]. 
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All cell lines were plated at a density 0.4 x 10
6
 cells / ml. Cells were plated, in triplicate, in 
flat-bottom 96-well plates and were exposed to a range from 0 µM to 100 µM of each 
compound for 24 hours. On the day before carrying out the NR assay, the NR solution (40 
mg/ml in appropriate media) was prepared and left in the incubator overnight. Following 
incubation of the cells with the compound, the NR solution was centrifuged for 10 min at 600 
g to remove any precipitated dye crystals. The cell media was decanted from all wells and 
100 µl of NR solution was added to each well. After 2 hour incubation at 37
0
C, the NR 
solution was decanted from all wells and the plate was washed with HBSS. After the wash 
step 150 µl of NR destain solution (50 %  v / v of  96 % ethanol, 49 % v / v distilled water 
and 1 %  v / v acetic acid).  The plate was then shaken on a microtilter (300 g) for at least 10 
minutes. The plate was then read using spectrophotometer at a wavelength of 540 nm this 
measures the optical density of the NR in each well. The EC50 values were estimated from the 
inhibitation curves that were plotted using the GraFit from Erithacus software. 
2.2.5 The determination of cellular Tenofovir accumulation 
1 x 10
6 
cells/ml were incubated in their usual media that contained tritiated ([
3
H])-TVF. The 
cells were incubated at 37 
o
C, with 5 % CO2 with the antiretroviral drug TFV (1 µM). The 
cells were incubated with the radiolabelled drugs for 1 hour (37 
o
C ) then they were removed 
from the incubator and spun at 9000g for 1 min. 100µl of supernatant was put into a 
scintillation vial and the rest of the supernatant was discarded. The pellet from each sample 
was kept and underwent 3 wash steps with ice-cold HBSS (after each step the samples were 
spun at 9000 g for 1 min). The pellet samples were then resuspended in 100 µl of water and 
were added to scintillation vials. Scintillation fluid (4 mls) was added to all scintillation vials. 
All samples were then counted on a scintillation counter (assuming a cell volume of 1 pl for 
each cell) and the cellular accumulation ratio (CAR, which is a ratio of pellet [
3
H]-TVF 
association compared to extracellular media [
3
H]-TFV) was estimated.  
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2.2.6 PCR Analysis of transporter mRNA levels in cell lines 
The levels of mRNA expression of MRP2, MRP4, MRP7, OAT1 and OAT3 were assessed in 
each cell line. Total RNA extraction was extracted using phenol-chloroform extraction and 
Tri reagent. Cells (1 x 10
6
 cells / ml) were incubated at room temperature for 5 minutes, then 
centrifuged for 10 minutes at 12,000 g (4 
0
C). After centrifuging 200µl of chloroform was 
added to all cells, they were mixed vigorously and incubated at room temperature for 15 
minutes this incubation step was repeated 2 times. The aqueous phase was removed, 500µl of 
isopropanol was added and the cells were vortexed for 10 seconds. The cells were incubated 
at room temperature for 10 minutes and then centrifuged for 8 minutes at 12,000 g (4 
0
C). 
The supernatant was discarded and to the resultant pellet, 1ml of 75 % ethanol was added. 
The cells were spun (7,500 g, 5 minutes), the ethanol was removed and the RNA pellet was 
dissolved in 15 µl Nuclease-free water. 
After RNA extraction spectrophotometric analysis was carried out on all samples to 
determine the amount of RNA in each sample (ng / µl). All samples were made up to a 
volume of 20 µl, in nuclease free water to a final concentration of 2 ng / µl of RNA.  All 
samples (20 µl) were added to a white PCR plate and 31.5 µl of reverse transcription reaction 
mix was added to each well (reaction mix for each well consist of  5µl reverse transcriptase 
buffer, 11 µl magnesium chloride, 10 µl DNTP’s, 2.5 µl random Heks, 1 µl RNAse inhibitor, 
1.75 µl reverse transcriptase). The plate was loaded into a PCR machine (Bio-Rad / MJ 
Research Opticon 2 Real-Time PCR) and reverse transcription was carried out.  
The final step was to carry out PCR using the separate probes for each transporter. To each 
well of a white PCR plate, 12.5 µl master mix, 1.25 µl probe (specific to the transporter of 
interest or to the housekeeper gene), 1.5 µl DNA sample (from the reverse transcription PCR 
plate or from human kidney cDNA samples- used to test if probes are working correctly), 
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9.75 µl nuclease-free water was added. Samples were run in triplicate. The plate was then 
read on a PCR machine (Bio-Rad / MJ Research Opticon 2 Real-Time PCR) and the levels of 
transporter of interest were estimated using Opticon 2 software. 
2.2.7 Statistical Analysis 
Data are expressed as a mean + standard deviation. A Shapiro-Wilk test was first carried out 
to assess the distribution of the data.  A Student’s t-test was used for all normally distributed 
data and a Mann-Whitney U test was carried out on non-normally distributed data. All 
calculations were carried out using the StatsDirect software. Significance is indicated as 
follows * P < 0.05, ** P < 0.01, *** P < 0.001. 
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2.3 Results 
2.3.1 Metabolic modification of glucose dependent cells into 
galactose dependent cells 
Cells were grown in galactose media over a period of 8 passages, as previously reported [8]. 
In order to assess the progression of metabolic modification, cytotoxicity assays were carried 
out using the classic mitochondrial toxin rotenone. The cytotoxicity assays carried out were 
MTT and NR assays after 24 hr incubations with rotenone.  
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2.3.1.1 The assessment of cytotoxicity using MTT assays in the 
presence of rotenone for 24 hours. 
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Figure 2.3-Dose-response curves of HepG2 cells grown in galactose media 
treated with rotenone 24hr. A =MTT of HepG2 WT and HepG2 at passages 1 and 
2 with galactose media. B = HepG2 WT and HepG2 at passages 4 and 5 with 
galactose media. C = HepG2 WT and HepG2 at passages 6 and 7 with galactose 
media. D = HepG2 WT and HepG2 cultured in galactose for > 8 passages. Results 
are the mean +S.D of three or more independent experiments. 
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Figure 2.4 -Dose-response curves of HEK293 KIM-1 cells grown in galactose 
media treated with rotenone 24hr. A =MTT of HEK293 KIM-1 WT and HEK293 
KIM-1 at passages 1 and 2 with galactose media. B = HEK293 KIM-1WT and 
HEK293 KIM-1 at passages 3, 4 and 5 with galactose media. C = HEK293 KIM-
1WT and HEK293 KIM-1 at passages 6 and 7 with galactose media. D = HEK293 
KIM-1 WT and HEK293 KIM-1 cultured in galactose for > 8 passages. Results are 
the mean +S.D of three or more independent experiments.  
 
Table 2.1 A and 2.1 B. Table 2.1 A- EC50 values for 24hr MTT for the HEK 293 KIM-1 
cells.B- EC50 values for 24hr MTT for the HepG2 cells. The IC50 values are shown  ± 
standard error, n was > 3. 
 
 
Passage 
number 
HEK293 KIM-1 
EC50 values 
± standard 
deviation 
(µM) 
 
Passage number 
HepG2 
EC50 values ± 
standard 
deviation 
(µM) 
WT 0 > 100 
 
WT 0 > 100 
Galactose 1 > 100 
 
Galactose 1 > 100 
Galactose 2 > 100 
 
Galactose 2 > 100 
Galactose 3 > 100 
 
Galactose 3 > 100 
Galactose 4 > 100 
 
Galactose 4 > 100 
Galactose 5 29.0  ± 3.5 
 
Galactose 5 12.4  ± 3.1 
 Galactose 6 24.9  ± 2.1 
 
Galactose 6  9.3  ±  1.6 
 Galactose 7 7.16 ±  2.8 
 
Galactose 7  2.8 ± 1.7 
>8 passages in 
galactose 
2.6 ± 1.3 
 
>8 passages in 
galactose 
2.2 ± 2.2 
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Table 2.2A and B. 2.2A – Shows the results for the statistical analysis performed on the 
HepG2 MTT data. 2.2B - Shows the results for the statistical analysis performed on the 
HEK293 KIM-1 MTT data. Significance is indicated as follows * P < 0.05, ** P < 0.01, *** 
P < 0.001. 
 
 
 
 
Concentration of rotenone (µM) 
 Passage 
number 
(HepG2) 
0.1 1 5 10 50 100 
WT vs 
Galactose 
WT - - - - - - - 
Galactose 1 - - - - * * * 
Galactose 2 - - - - ** ** ** 
Galactose 3 - - - - * ** ** 
Galactose 4 - - - * ** ** ** 
Galactose 5 - - - * ** *** ** 
Galactose 6 - - - * ** *** *** 
Galactose 7 - - * ** *** *** *** 
> 8  - - * *** *** *** *** 
 
 
Concentration of rotenone (µM) 
 Passage 
number 
(HEK293 
KIM-1) 
0.1 1 5 10 50 100 
WT vs 
Galactose 
WT - - - - - - - 
Galactose 1 - - - - - - - 
Galactose 2 - - - * * - - 
Galactose 3 - - - * * * * 
Galactose 4 - - * * * * * 
Galactose 5 - - * * * ** * 
Galactose 6     * ** ** ** ** 
Galactose 7 - - * ** *** *** *** 
> 8 - - *** *** *** *** *** 
 
As time in galactose media increased the susceptibility to rotenone induced cytotoxicity also 
increases (Figures 2.3 and 2.4). This is demonstrated when comparing the EC50 value for 
HepG2 WT cells (EC 50 was > 100), to the EC50 for HepG2 cells passaged in galactose 7 
times (EC50 was 2.8 µM).  This increase in susceptibility to rotenone induced cytotoxicity as 
passaging in galactose increases is also seen in the HEK293 KIM-1 cells, for example 
A 
B 
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rotenone is 14 times more toxic in HEK293 KIM-1  cells at passage 7 (EC50 was 7.1 µM) 
compared to HEK293 KIM-1 WT (EC50 was > 100 µM). Interestingly the EC50 values 
remains at > 100 µM up until passage 5 in both cell lines where it falls to 12.4 µM in the 
HepG2 cells and 29µM in the HEK293 KIM-1 cells (Tables 2.1A and 2.1B). Figures 2.3D 
and 2.4D illustrate that when the cell are considered fully modified they are susceptible to 
rotenone  induced cytotoxicity when compared to glucose grown cells (WT). The EC50 values 
decrease from >100 µM for both WT cell lines to 2.2 µM for the HEK293 KIM-1 galactose 
cells and to 2.6 µM for the HepG2 galactose cells (Tables 2.1A and 2.1B) 
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2.3.1.2 The assessment of cytotoxicity using NR assays in the 
presence of rotenone for 24 hrs. 
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Figure 2.5-Dose-response curves of HepG2 cells grown in galactose media 
treated with rotenone 24hr. A =MTT of HepG2 WT and HepG2 at passages 1 and 
2 with galactose media. B = HepG2 WT and HepG2 at passages 3, 4 and 5 with 
galactose media. C = HepG2 WT and HepG2 at passages 6 and 7 with galactose 
media. D = HepG2 WT and HepG2 cultured in galactose for > 8 passages. Results 
are the mean +S.D of three or more independent experiments. 
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Figure 2.6 -Dose-response curves of HEK293 KIM-1 cells grown in galactose 
media treated with rotenone 24hr. A =MTT of HEK293 KIM-1 WT and HEK293 
KIM-1 at passages 1 and 2 with galactose media. B = HEK293 KIM-1WT and 
HEK293 KIM-1 at passages 3, 4 and 5 with galactose media. C = HEK293 KIM-
1WT and HEK293 KIM-1 at passages 6 and 7 with galactose media. Results are the 
mean +S.D of three or more independent experiments. D = HEK293 KIM-1 WT and 
HEK293 KIM-1 cultured in galactose for > 8 passages. Results are the mean +S.D of 
three or more independent experiments. 
 
Table 2.3A and 2.3 B. Table 2.2 A- IC50 values for 24hr NR for the HepG2 cells. Table 2.2 
B- EC50 values for 24hr NR for the HEK 293 KIM-1 cells. The EC50 values are shown +/- 
standard error, n was > 3. 
 
Passage number  
HepG2 
EC50 values ± 
standard 
deviation 
(µM) 
 
Passage number 
HEK293 KIM-1 
EC50 values ± 
standard 
deviation 
(µM) 
WT 0 > 100 
 
WT 0 > 100 
Galactose 1 > 100 
 
Galactose 1 > 100 
Galactose 2 > 100 
 
 Galactose 2 > 100 
Galactose 3 > 100 
 
Galactose 3 > 100 
Galactose 4 > 100 
 
Galactose 4 > 100 
Galactose 5 > 100 
 
Galactose 5 > 100 
Galactose 6 4.4 ±  3.9 
 
Galactose 6 9.4  ±  4.0 
Galactose 7 2.2 ±  4.4 
 
Galactose 7 7.0 ± 3.6 
>8 passages in 
galactose 
2.9 ± 1.7 
 
>8 passages in 
galactose 
5.8 ± 1.8 
Table 2.4A and B. 2.4A – Shows the results for the statistical analysis performed on the 
HepG2 NR data. 2.4B - Shows the results for the statistical analysis performed on the 
HEK293 KIM-1 NR data. Significance is indicated as follows * P < 0.05, ** P < 0.01, *** P 
< 0.001. 
B 
A 
D 
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Concentration of rotenone (µM) 
 Passage 
number 
(HepG2) 
0.1 1 5 10 50 100 
WT vs 
Galactose 
WT - - - - - - - 
Galactose 1 - - - - - - - 
Galactose 2 - - - - - - - 
Galactose 3 - - - - - - - 
Galactose 4 - - - - - - - 
Galactose 5 - - - - - - - 
Galactose 6 - - * ** ** *** *** 
Galactose 7 - - * ** ** *** *** 
> 8  - - ** ** *** *** *** 
   
 
Concentration of rotenone (µM) 
 Passage 
number 
(HEK293 
KIM-1) 
0.1 1 5 10 50 100 
WT vs 
Galactose 
WT - - - - - - - 
Galactose 1 - - - - - - - 
Galactose 2 - - - - - - - 
Galactose 3 - - - - - - - 
Galactose 4 - - - - - *   
Galactose 5 - - - - - * * 
Galactose 6 - - - ** ** *** *** 
Galactose 7 - - - ** ** *** *** 
> 8  - - - ** ** *** *** 
 
With increased galactose passage the susceptibility to rotenone induced cytotoxicity also 
increases (Figures 2.5 and 2.6). This is shown when comparing the EC50 value for HepG2 
WT cells (EC 50 was > 100 µM), to the EC50 for HepG2 cells at passage 7 (EC50 was 2.2 
µM). This increase in susceptibility to rotenone induced cytotoxicity as time spent in 
galactose increases is also observed in the HEK293 KIM-1 cells. In the HEK293 KIM-1 cells 
at passage 7, the EC50 was 7 µM compared to HEK293 KIM-1 WT EC50 was > 100 µM. 
Interestingly the EC50 values remains at > 100 µM up until passage 6 in both cell lines where 
it falls to 4.4 µM in the HepG2 cells and 9.4 µM in the HEK293 KIM-1 cells (Table 2.3A 
and 2.2B). Figures 2.5D and 2.6 D show that at the point that the cells are considered fully 
A 
B 
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modified (> 8 passages) they are susceptible to rotenone induced cytotoxicity when compared 
to glucose grown cells (WT). The EC50 values decrease from > 100µM for both WT cell lines 
to 5.8 µM  for the HEK293 KIM-1 galactose cells and to 2.9 µM  for the HepG2 galactose 
cells (Table 2.3A and B). 
 
2.3.2 Accumulation of Tenofovir in HepG2 cells 
Accumulation studies using the cell lines HepG2 and HEK293 KIM-1 (both grown in glucose 
and galactose-containing media) of the antiretroviral drug TFV were carried out. The aim of 
this study was to show, with the use of radioactively labelled TFV [
3
H], that it accumulates in 
the cell lines used in this study. An additional aim of this study was to demonstrate if the 
metabolic switch affects the rate of TFV [
3
H], accumulation.  
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Figure 2.7 A and 2.7 B. A = accumulation of TFV [
3
H], in HepG2 WT and HepG2 
galactose passage 1. B = accumulation of TFV [
3
H], in HepG2 WT and HepG2 galactose 
passage 8. Results are the mean + S.D of three or more independent experiments. KEY ** 
P < 0.01 * P < 0.05. S.D. is shown as significance between HepG2 WT compared to the 
HepG2 galactose cells. 
 
At passage point 1 there is a significant difference between the HepG2 WT (at 1 µM TFV the 
CAR was 6.4 ± ) and the HepG2 galactose passage 1 cells (at 1 µM TFV the CAR was 2.1±) 
(Figure 2.7A). At galactose passage point 8 there is no significant difference in the TFV 
accumulation between the HepG2 WT (at 1 µM TFV the CAR was 3.8 ±) and the HepG2 
Galactose cells (at 1 µM TFV the CAR was 3.0 ±) (Figure 2.7B). 
A 
B 
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2.3.3 The determination of cellular transporter levels via PCR 
methods 
PCR analysis of drug transporters was carried out and determined by calculating the relative 
ΔΔCT values which were normalised to a housekeeping gene. The aim of this study was 
firstly to show that these cell lines contained the key transporters for TFV transport (MRP2, 
MRP4, MRP7, OAT1 and OAT3) [17]. Secondly this study would show how / if galactose 
culturing affects the cellular physiology or transporter expression within each cell line. 
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2.3.3.1The determination of cellular transporter levels within 
HEK293 KIM-1 cells and HepG2 cells via PCR methods. 
 
 
 
 
 
 
A 
B 
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Figure 2.8 A, B, C, D and E Transporter analysis in HepG2, HEK293 KIM-1(KIM-1) 
and HEK293 PcDNA cells grown in glucose and galactose media. A= MRP2 analysis. B= 
MRP4 analysis. C= OAT1 analysis. D =MRP7. E= OAT 3 analysis. Results are the mean + 
D 
C 
E 
OA
T3 
Lev
els 
(ΔΔ
CT) 
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S.D of three or more independent experiments.  KEY: * P< 0.05. S.D. is shown as 
significance between those data sets as indicated by the arrow bars. 
 
These studies have  determined transporter levels (ΔΔ CT) within HepG2 WT/ galactose cells 
and HEK293 KIM-1 cells WT/ galactose cells (Figure 2.8 A, B, C and D) demonstrated that 
all cell lines expressed MRP2, MRP4, MRP7 and OAT1 however OAT3 was not detected in 
these cell lines. The MRP2 levels in the HepG2 WT were 0.46 and for the HepG2 galactose 
cells it was 0.47(Figure 2.8 A). There was no significant difference in the levels of 
transporters between the cell lines when cultured in glucose (WT) compared to when cultured 
in galactose for example;  MRP4 levels detected for HepG2 galactose cells was 0.36 and for 
HepG2 WT it was 0.41(Figure 2.8 B). The OAT 1 levels detected for the HEK293 KIM-1 
WT was 0.41 and for the HEK293 KIM-1 galactose OAT1 levels were 0.50 (Figure 2.8 C). 
The MRP2 levels in the HepG2 WT were 0.46 and for the HepG2 galactose cells it was 
0.47(Figure 2.8 A). The MRP7 transporter values for the HEK293 KIM-1 WT was 0.54 and 
for the HEK293 KIM-1 galactose cells it was 0.50 (Figure 2.8 D). As a positive control 
human kidney DNA was tested using the OAT 3 probe to verify that the OAT3 probe was 
working correctly. This confirmed that the cells did not have OAT 3 (Figure 2.8 E).  There 
was no significant difference between transporter levels detected in the HepG2 cells 
compared to the HEK 293 KIM-1 cells except for MRP7 (Figure 2.8 D). 
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2.3.3.2 The determination of transporter levels within HepG2 cells 
throughout the modification into galactose cultured cells using PCR 
methods. 
 
 
 
 
 
Figure 2.9 A, B, C and D Transporter analysis in HepG2 WT and HepG2 Galactose 
cells. 2.9 A= MRP2 analysis. 2.9 B= MRP4 analysis. 2.9 C= MRP7 analysis. 2.9 D = OAT 1 
analysis. Results are the mean + S.D of three or more independent experiments.   
 
The graphs  showing the determined transporter levels (ΔΔCT)  throughout the modification 
of WT cells to galactose grown cells (Figure 2.9 A, B, C and D)  showed that there was no 
significant difference in the levels of transporters between the HepG2 WT and HepG2 cells 
A 
B 
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grown in galactose for 8 passages. However, there seemed to be a general trend of an increase 
in transporters levels when HepG2 cells were cultured with galactose over 2 passages the 
transporter levels for MRP2 in HepG2 WT was 0.67 and when cultured in galactose 2 times 
this increased to 1.45 (Figure 2.9 A). After this increase the transporter levels within the 
HepG2 galactose cells lowered to be the same as HepG2 for MRP2 after culturing in 
galactose for 8 passages the transporter levels were 0.69 (Figure 2.9 A). For MRP4 the 
transporter levels where higher until passage 8 (The HepG2 WT MRP4 levels were 0.25 and 
after 8 passages the HepG2 WT MRP4 level was 1.17) (Figure 2.9 B). There was variable 
transporter expression for MRP7, levels initially increased after 2 passages within galactose 
media to 1.4, this level then decreased at each passage point to 0.2 at passage 8within 
galactose media (Figure 2.9C). and then  Finally for OAT1 the HepG2 WT transporter levels 
increased from 0.25 to 0.73 at passage 4, there was a decrease to 0.30 at passage 6 and finally 
the transporter levels increase at passage 8 to 1.09 (Figure 2.9 D). 
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2.4 Discussion 
Work presented within this chapter has focussed on the generation and validation of a cell 
model that could be used to study the mechanistic pathway of TFV-induced cytotoxicity. 
These studies were essential as the mechanistic pathway of TFV-induced cytotoxicity has 
previously not been reported due to lack of a suitable cell model [1-5]. Cells (HepG2 / 
HEK293 KIM-1) were cultured in galactose containing media in order to modify them to rely 
on mitochondrial OXPHOS for cellular ATP production which has been shown in other 
studies [8]. These modified cells better represent the physiological aerobic conditions; this 
study has shown that human cells rely on 95 % OXPHOS for the generation of cellular ATP 
[12]. When the cells become reliant on the mitochondrial OXPHOS they become more 
susceptible to mitotoxins because they are reliant solely on mitochondria for the production 
of cellular ATP [8].  
To determine when the cells had become fully modified galactose passaging cells were 
incubated with the known classical mitotoxin rotenone for a period of 24 hours and 
cytotoxicity was determined either by MTT or NR assays [8]. NR assays were used to ensure 
that galactose culturing was not interfering with the cytotoxicity determined via MTT assays, 
as the NR assay is not influenced by mitochondrial enzymes [16].  MTT assays were chosen 
as they measure mitochondrial cytotoxicity and it has been hypothesised that TFV induces its 
cytotoxic effects via inhibitation of mitochondrial polymerase γ which leads to mitochondrial 
specific toxicity [6]. The MTT/NR results (Figures 2.3 to 2.6), showed that cells became 
fully reliant on the mitochondrial OXPHOS by passage 7 seen by the increase to in 
susceptibility to rotenone induced cytotoxicity. It was decided that cells would be used after 8 
passages within galactose media which supports previous studies [8] (MTT and NR results 
showing fully modified galactose cells can be seen in Figures 2.7 and 2.8). The kinetics of 
the transition towards relying solely on mitochondrial OXPHOS for cellular energy 
  
71 
 
production can be clearly seen within the dose response curves. For the MTT assays the 
transition can be seen after 5 passages in galactose containing media for both the HepG2 and 
HEK293 KIM-1 cells which is shown by the sharp decrease in EC50 values at this passage 
point (Figure 2.3 C and 2.4 C). For the NR assays the transition is seen later after 6 passages 
cultured in galactose media (for both HepG2 and HEK293 KIM-1 cells), shown again by a 
sharp decrease in EC50 values at this passage point (Figure 2.5 C and 2.6 C). The difference 
between the two assays shows that the cytotoxicity being induced is mitochondrial specific as 
the MTT assay shows cytotoxicity at an earlier passage point. The delay seen in the 
determined cytotoxicity via the NR assay, could be due to previously established observation 
that the cell has an abundance of mitochondria, a certain threshold point in the percentage of 
dysfunctional mitochondria must be reached before any cellular cytotoxicity is seen [10]. A 
recent study has shown that this transition toward relying on mitochondrial OXPHOS for 
cellular energy production can be induced after only 2 hours when culturing cells in serum 
free media containing galactose [18]. The switch over can be achieved within 2 hours due to 
the use of serum-free media. Serum contains a small amount of glucose therefore these cells 
have no option but to convert to mitochondrial OXPHOS for cellular ATP production. Whilst 
this method would benefit the study of mitochondrial cytotoxicity within immortalised cells 
induced by most drugs, TFV toxicity is reported clinically to be delayed toxicity only induced 
after long term-exposure, and cells could not be cultured for long in serum-free media as they 
would not survive. Also these cells may become stressed due to these extreme conditions and 
may produce less reliable results [18]. 
Accumulation studies were carried out to determine if TFV accumulated within the HepG2 
cells and to show if culturing the cells in galactose-containing media alters the accumulation 
rate of TFV. The accumulation results (Figure 2.9) showed that TFV was able to accumulate 
within the HepG2 cells and that there was no significant difference in accumulation n the 
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HepG2 WT compared to the fully modified HepG2 cells grown in galactose-containing 
media. However, there was a significant difference in accumulation between HepG2 WT and 
HepG2 cultured with galactose for one passage; this could be due to a decrease in cellular 
ATP levels which has been shown to happen initially after culturing cells in galactose-
containing media, as transport is active and reliant upon cellular ATP levels [18]. However, 
as cells were only used in further experiments following 8 passages this finding is unlikely to 
affect the experiments. 
The mRNA levels of MRP2, MRP4, MRP7, OAT1 and OAT3 were determined via PCR 
analysis as these transporters are essential for the uptake and efflux of TFV within human 
proximal tubule cells [19]. The transporter results (Figures 2.10 and 2.11) showed that all 
transporters except for OAT3 were expressed in both HepG2 and Hek293 cells grown in 
glucose and galactose media. As OAT3 was absent from both cell lines and because it has 
been shown that TFV uptake is dependent mainly on OAT1 which is present within all cell 
lines [19], it was decided that the absence of this transporter whilst not ideal would not 
greatly affect the cytotoxicity studies. This is supported by the fact that the level of 
accumulation of TFV was the same in both cell lines. These results showed there was no 
significant difference between the transporter expression in the WT cells compared to the 
expression in the fully modified galactose-grown cells. This shows that at the point that the 
galactose cells will be used for subsequent experiments their transporter expression is not 
affected by galactose culturing. Interestingly, it was observed that the accumulation of TFV 
initially decreased following galactose culturing; this was unexpected and would require 
further investigation to find a reason for this reduction in accumulation (Figure 2.7 A and B). 
During the modification of the WT cells into galactose-grown cells, transporter expression 
increased after the initial culturing with galactose. This could be due to an increase in the 
expression of cellular transporters in response to cell stress. This has previously been reported 
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in vitro and in vivo using kidney cells treated with gentamicin in which the expression of 
MRP2 increased due to cellular stress [20]. There was variation in the HepG2 WT transporter 
expression over time; this could be due to cellular aging which could result in difference in 
transporter expression. However, none of the variations were significant. 
Recent studies have highlighted how the human equilibrative nucleoside transporter 1 (hENT-
1), which is located on mitochondrial membranes, is essential for mitochondrial accumulation 
of antivirals [21]. Studies have shown that an increased expression of this transporter can lead 
to enhanced mitochondrial toxicity of NRTI’s [21]. Therefore future studies could determine 
the expression of hENT-1 within the different cell lines and see if its expression is influenced 
by cells adapted in galactose-containing media. 
Future work could involve using seahorse technology to measure the glycolytic vs. 
mitochondrial OXPHOS rates within the cells when culturing the cells within galactose media 
vs. glucose media. 
Using immortalised cells is not the ideal method for studying mechanistic pathways; however 
they are currently the best option available as TFV toxicity is delayed clinically, making it 
difficult to use primary cells. Overall the data presented within this chapter show that 
culturing cells in galactose media made them more susceptible to mitochondrial toxins, 
without compromising or changing the physiological characteristics of the cells. Thus these 
modified cells are good tools for studying the mechanistic pathway of TFV induced 
cytotoxicity. It was decided that HepG2 cells would be used for the majority of the 
subsequent studies as they were more reliable during culturing than the HEK293 KIM-1 cells. 
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Chapter Three 
 
INVESTIGATION OF THE MECHANISM OF 
CYTOTOXICITY INDUCED BY TENOFOVIR IN HUMAN 
RENAL AND HEPATIC CELL LINES 
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3.1 Introduction 
Current evidence links HARRT and its adverse effects to impaired mitochondrial replication 
[1]. Many in vitro and in vivo studies support the hypothesis that NRTI exposure leads to 
mitochondrial impairment [2-5]. The clinical evidence of mitochondrial impairment due to 
NRTI treatment is demonstrated by the development of lactic acidosis within patients [6-8]. 
The hallmark of mitochondrial dysfunction is the onset of hyperlactatemia, which can be 
symptomatic or asymptomatic and is caused by an increase in the cellular lactate / pyruvate 
ratio. Lactic acidosis arises due to the reduced ability of the mitochondria to oxidise lactate 
and by an increased glycolytic flux which compensates for a reduction in mitochondrial 
OXPHOS [6-8]. 
 The pathogenesis of NRTI-induced mitochondrial dysfunction can be split into three distinct 
steps. The first step is the competition of the NRTI triphosphates with the naturally occurring 
nucleotide triphosphates within the cell [9]. Upon successful competition the second step 
takes place. NRTI’s are incorporated into the mitochondrial DNA (mtDNA) strands, leading 
to chain termination as the NRTI’s lack a second hydroxyl group required for the addition of 
new DNA bases. Finally the result of chain termination is impaired mitochondrial polymerase 
γ (mtDNA pol γ), leading to mtDNA depletion and a reduction in mtDNA copy number [9]. 
 The mitochondrial effect of NRTI's arises from the DNA polymerase γ hypothesis of Lewis 
[10]. This hypothesis states that as NRTI's act to inhibit HIV-1 reverse transcriptase, they can 
also inhibit mtDNA pol γ in a non-selective manner [2-3, 11].  MtDNA pol γ is essential for 
the replication of the mitochondria and depletion will lead to impaired cellular ATP 
production [10].  This decrease in the cellular physiological scope dramatically impacts on 
cellular function and structure, and is considered the perpetrator responsible for the long term 
side effects associated with NRTI use [10].  
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The extent of NRTI mtDNA pol γ inhibition is dependent upon the type of NRTI and the 
tissue being affected [2, 10-12]. The type of NRTI can influence the extent of pol γ inhibition 
as they all have different affinities for pol γ. Previous studies have shown the order of NRTI 
pol γ affinity to be the following (highest to lowest): zalcitabine (ddC) > dianosine (ddI) > 
stavudine (d4T) > lamivudine (3TC) > abacavir (ABC) >  tenofovir disproxil fumarate (TDF) 
> emtricitabine (FTC) [2-5]. 
In vitro studies have been carried out to look at mtDNA depletion caused by NRTIs in 
peripheral blood mononuclear cells (PBMCs) and in HepG2 cells (these cells have a high 
mtDNA copy number making the study of mtDNA easier) [2-5]. The depletion of mtDNA 
was detected using PCR methods in the above mentioned cells treated with different NRTI's 
[2-5]. The depletion of mtDNA was detected with the following rank; ddC >, ddI >, d4T >, 
zidovudine (AZT) >, ABC= 3TC = TDF [2-5] 
The tissue type can influence susceptibility to mitochondrial toxicity induced by NRTI’s via a 
number of factors such as the size of the nucleotide pools, the kinase activity of the cells and 
the bio-energetic demand of specific tissues [2, 10-12]. Previous research showed there to be 
precursor nucleotide pools within cells that are specific for mtDNA [13]. Studies have also 
showed that these pools selectively resist depletion until a threshold point; if a cell has a 
smaller nucleotide pool, it will be more susceptible to mitochondrial toxicity induced by 
NRTI’s [14-16]. The kinase enzymes within a cell are responsible for the activation of 
NRTI’s via phosphorylation [14-16]. Research has shown a direct correlation between NRTI 
phosphorylation and mitochondrial toxicity induced by NRTI use [14-16]. The bio-energetic 
energy demands of the tissue may be high, for example proximal tubule cells require higher 
cellular ATP levels due to the large amount of active transport carried out within the cell. For 
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this reason, proximal tubules are highly abundant in mitochondria, making them more 
susceptible to mitochondrial toxicity induced by NRTI’s [16].  
Studies have shown that specific genotypes make an individual more susceptible to the 
NRTI-induced toxicity [17-18]. For example one study showed that individuals with 
variations in the tumour necrosis factor (TNF) α promoter have increased associations with 
the onset of lipoatrophy [17-18]. Other genetic studies have shown that variations in mtDNA 
pol y itself can increase an individual’s susceptibility to NRTI induced mitochondrial toxicity 
[19]. 
3.1.1 Mitochondrial DNA and its importance to cell survival 
The mitochondria has its own DNA, making it unique compared to other organelles; this 
feature was first described in the 1960's [20]. MtDNA is a double-stranded circular DNA 
molecule that is around 16,000 bases. It codes for 13 polypeptides (such as membranes), 2 
ribosomal RNAs and 22 transfer RNAs [21]. 
Mitochondrial diseases result from both mtDNA and nuclear DNA mutations or 
rearrangements, which mostly affect post-mitotic tissues [22]. Mitochondrial diseases can 
affect the following organs: bone marrow, skeletal / cardiac muscles, the kidneys, the central 
nervous system (CNS), the peripheral nervous system (PNS), the pancreas, the 
gastrointestinal tract and the liver [22]. 
Those diseases resulting from mtDNA mutations are inherited maternally and lead to diseases 
such as Pearson syndrome, which is a disease affecting the pancreas and bone marrow [23]. 
The diseases that arise due to mutations within the nuclear DNA are acquired and include 
diseases such as Alzheimer’s which leads to impaired memory function [24]. 
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There are currently 9 known polymerases that play a key role in the maintenance and 
replication of the cellular DNA; however, polymerase γ (pol γ) is the only polymerase 
responsible for mtDNA replication [25]. The genome for human pol γ was first studied, 
characterised and eventually cloned by Ropp and Copeland in the year 1996 [25]. In vitro 
studies have shown that when cells have depleted mtDNA, pol γ becomes expressed and 
translated as a protective mechanism within the cell [26]. Pol γ mediates both replication and 
repair of mtDNA, although until recently, it was believed that mtDNA had no capacity to 
repair itself [27].  
In vitro studies have shown that toxicity affecting mtDNA pol γ will only present itself in 
patients after a threshold of mutated mitochondria is reached (Figure 3.1) [23]. In a normal 
healthy cell, the mitochondria are said to be in a homoplastic state. When the cellular mtDNA 
pol γ becomes inhibited due to toxicity (e.g. from exposure to NRTIs), some of the 
mitochondria become mutated and dysfunctional [23]. In vitro studies have shown that these 
dysfunctional mitochondrial populations can co-exist with normal mitochondria within cells 
in a state called heteroplasmy [23]. During cellular replication the segregation of the 
mitochondria is completely random; this leads to the production of daughter cells that contain 
different ratios of dysfunctional mitochondria. When the ratio of dysfunctional mitochondria 
is above the threshold for the specific tissue (which could be from 70 - 95 %) mitochondrial 
dysfunction will result [28].  
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Figure 3.1: A schematic diagram showing the threshold effect within the mitochondria 
(modified from White et al., 2010) 
 
3.1.2 Aims of Chapter 
In this chapter the investigation of cytotoxicity induced by the antiretroviral drugs, tenofovir 
(TFV), Adefovir (ADEF) and Lamivudine (3TC) were assessed.  
ADEF was manufactured by Gilead Sciences under the trade name of Preveon for the 
treatment of HIV. However, in 1999 its use as for HIV treatment was not granted by the Food 
and Drug Administration (FDA) and the development of this drug was discontinued [29]. The 
FDA did not approve its use at the doses needed for HIV treatment (60 - 120 mg) as at these 
doses of ADEF caused severe renal toxicity [29]. Gilead Sciences developed this drug for use 
as hepatitis B (HBV) treatment using a much lower dose of 10 mg under the trade name 
Hepsera [29]. The FDA approved this drug for HBV treatment on the 20
th
 September 2002 
and it was later approved for HBV treatment in the European Union (EU) in March 2003 
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[29].  Further studies into ADEF renal toxicity found that its primary cause was due to 
mitochondrial toxicity via the inhibition of mitochondrial pol γ [30]. As ADEF and TFV have 
similar structures (as seen in Figure 3.2 below) with only the addition of a methyl group on 
TFV compared to ADEF, the adverse effects of ADEF may be mechanistically shared by 
TFV. Therefore, ADEF will be used as a positive control for mtDNA depletion and 
mitochondrial dysfunction. 3TC will be used as a negative control as previous studies have 
shown it to have no effect on the mitochondria [2]. The negative and positive controls were 
selected to keep the study focused around NRTI’s as this is the drug class that TFV belongs 
to. 
 
Figure 3.2: Structure of TFV and ADEF showing the extra methyl group on TFV   
The first aim of this chapter was to establish a novel in vitro cell model in order to study 
NRTI cytotoxicity using aerobically modification in vitro cell models.  
The cytotoxicity of ADEF, TFV and 3TC was assessed and compared using MTT, NR and 
ATP assays. The effects of ADEF and TFV on cellular ATP levels were determined as any 
change in ATP can give an indication of the effects of drugs on energy production 
specifically in the galactose-grown cells that are reliant on mitochondrial OXPHOS. The 
accumulation of TFV and ADEF was assessed using titrated ([
3
H]) forms of the drugs. 
The second aim of this study was to utilise this in vitro model to examine the effects of the 
antiretroviral TFV and ADEF upon mtDNA, using similar PCR methods as used in [31]. 
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3.2 Materials and Methods 
3.2.1 Materials 
The cell culture media (DMEM high glucose and DMEM no glucose) were ordered from life 
technologies, Invitrogen (Paisley, UK) Hanks balanced salt solution (HBSS), 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltrazolium bromide (MTT), Sodium dodecyl sulphate 
(SDS), N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), sodium pyruvate, 
trypan blue (0.4%)solution, dimethylsulphoxide (DMSO), ethanol, acetic acid,   Neutral Red, 
Adefovir, Lamivudine , n-dimethylformamide (DMF),Foetal bovine serum (FBS) andD-(+)-
Galactose were all purchased from Sigma (Poole, UK). Tenofovir was ordered from Toronto 
Research Chemicals (Toronto, Canada). The probes were ordered from Applied Biosystems, 
(Warrington, UK) and the ATP bioluminescence kit was purchased from Roche 
(Hertfordshire, UK) 
3.2.2 Cell culture and experimental preparation 
As in section 2.2.2, Chapter 2. For > 5 day incubations the media + treatment (e.g. drug / 
vehicle) was removed and fresh media + treatment was added every 72 hours. 
3.2.3 The assessment of cytotoxicity using MTT assays 
As in section 2.2.3, Chapter 2. For > 5 day incubations the media + treatment (e.g. drug / 
vehicle) was removed and fresh media + treatment was added every 72 hours. 
3.2.4 The assessment of cytotoxicity using Neutral Red assays  
As in section 2.2.4, Chapter 2. For > 5 day incubations the media + treatment (e.g. drug / 
vehicle) was removed and fresh media + treatment was added every 72 hours. 
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3.2.5 The determination of cellular Tenofovir and Adefovir 
accumulation 
As in section 2.2.5, Chapter 2, with a few modifications. The accumulation of both TFV 
([
3
H]-TFV) and ADEF ([
3
H]-ADEF) will be determined. Accumulation studies will be 
carried out at both 37
0
C and 4
0
C. At 4
0
C studies have shown that cellular transporters are not 
active therefore any passive transport of the antiretroviral drugs TFV and ADEF will be 
determined.   
 
3.2.6 The luminescent analysis of cellular ATP.  
A kit that is commercially available (Roche, Hertfordshire, UK) was used for the detection of 
cellular ATP. This ATP kit quantifies the phosphorylation of glycerol to generate a product 
that is detected by luminescent methods. The Kit was used according to manufactures 
instructions. The plate was read using a plate reader (MRX, Dynatech Laboratories). 
 
3.2.7 The determination of cellular mtDNA and nuclear DNA levels 
using PCR methods 
3.2.7.1 Identification of unique regions of the mitochondrial 
genome for use as primers / probes 
 
The method found within [31] was followed, which utilised unique regions of the 
mitochondrial genome (Table 3.1) that are not replicated within the nuclear genome for 
quantification. This study used BLAST in order to find the regions of the mitochondrial 
genome that were duplicated within the nuclear genome and ENSEMBL was used to find 
those unique mitochondrial regions that were not duplicated within the nuclear genome [31]. 
The mitochondrial specific primer was synthesised at Sigma-Genosys UK, the predesigned 
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RNaseP taqman probe was used (Applied Biosystems) to determine nuclear DNA and the 
RLPO probe was used as a housekeeping gene (AppliedBiosystems) 
        Table 3.1: Primers and probes sequences used. 
 
3.2.7.2 Genomic DNA preparation 
Cellular genomic DNA was obtained using the QIAMP MINI DNA kit (Qiagen), following 
the manufacturer’s instructions. The concentration of the DNA was adjusted to 10 ng / µl. 
Shearing was carried out, at least 100 ng / µl of DNA was passed repeatedly through a 1 mm 
needle for 25 seconds. DNA in a total volume of 100 ng / µl was subjected to sonication for 
2–10 minutes using a Bath Sonicator (Kerry, Pulsa-tron 55). To avoid errors arising due to 
repeated freeze thaw cycles, the cellular DNA samples were kept at 4
O
C for the duration of 
this study [31] 
 
3.2.7.3 Real time qPCR 
 
MtDNA and nuclear DNA were determined using probes specific to both regions. The RLPO 
probe was used as a house keeping gene in order to normalise both the mtDNA and nuclear 
DNA content. A 62-bp fragment of mtDNA was amplified using the following primers: 
hmito-319F5 and hmito-383R5, and hmitoP5 used as the hybridisation probe, containing the 
FAM (6-carboxy fluorescein) as a fluorescent reporter dye and NFQ as a quencher dye at the 
30 end [31]. Nuclear content was quantified by targeting a unique region of the RNaseP gene, 
using the FAM™ dye–labelled probe (Applied Biosystems). The RLPO gene was determined 
using the VIC /TAMRA™ probe (Applied Biosystems). The PCR machine used was the Bio-
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Rad / MJ Research Opticon 2 Real-Time PCR. Relative gene expression was calculated using 
the comparative CT method also referred to as the 2
_ΔΔCT
 method [32]. After CT values were 
calculated, the mtDNA vs. nuclear DNA ratio was determined.  
 
3.2.8 Statistical analysis 
Statistical analysis was carried out on all data. Values are expressed as a mean + standard 
deviation of the mean (SD), this is represented as error bars on all graphs. A Shapiro-Wilk 
test was first carried out on the data to see if it was considered normal.  A Student’s t-test was 
used for all normally distributed data and a Mann-Whitney U test was carried out on non-
normally distributed data. All calculations were carried out using the StatsDirect software. 
Significance is indicated as follows * P < 0.05, ** P < 0.01, *** P <  0.001. 
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3.3 Results 
3.3.1 The assessment of Tenofovir, Adefovir and Lamivudine-
induced cytotoxicity using MTT assays. 
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Figure 3.3 Dose-response curves of HepG2 and HEK 293 KIM-1 cells with TFV/ 
ADEF/3TC for 5 days A = HepG2 galactose /WT treated with TFV. B = HEK293 KIM-1 
galactose / WT treated with TFV. C = HepG2 galactose /WT treated with ADEF. D = 
HEK293 KIM-1 galactose /WT treated with ADEF. E = HepG2 galactose/ WT treated with 
3TC. F = HEK293 KIM-1 galactose / WT treated with 3TC. Results are the mean ± S.D of 
three or more independent experiments.  
  
F 
E 
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Table 3.2 Table showing EC50 values for MTT 
incubations of HepG2 / HEK293 KIM-1 galactose and 
HepG2 / HEK293 KIM-1 WT in the presence 
Table 3.3 Table showing average control values for MTT 
MTT incubations (5 -20 day) for HepG2/ HEK293 KIM-1 
galactose and  
HepG2 / HEK293 KIM-1 WT . 
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Table 3.4 A, B, C, D, E and F. Show the statistical analysis performed on the MTT data (5, 
10, 15 and 20 days)  for the HepG2 WT /HepG2 galactose-cultured cells[ in the  presence of 
TFV (3.4A), ADEF (3.4 B) and 3TC (3.4C) ] and  for the HEK 293 KIM-1 WT / HEK293 
KIM-1 galactose-cultured cells[ in the  presence of TFV (3.4D), ADEF (3.4 E) and 3TC 
(3.4F) ] Significance is indicated as follows * P < 0.05, ** P < 0.01, *** P < 0.001. 
           
 
                  
A 
D 
C B 
F E 
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The dose response  data  showing the determination of TFV induced cytotoxicity via MTT 
analysis (Figures 3.3 A- 3.3F / Tables 3.2, 3.4A-3.4F) show that TFV induces cytotoxicity 
in a time and dose dependent manner within the galactose grown HepG2 and HEK293 KIM-
1 cells. TFV cytotoxicity is only seen after 5 days as shown in   Figures 3.3 A and B where 
the EC50 for the HepG2 galactose cells is 25.1µM and for the HEK293 KIM-1 galactose cells 
the EC50 was  38.4 µM (for the WT cells of both cell lines the EC50 was >100 µM). The EC50 
value reduces for both cells lines grown in galactose media as the incubation time increases, 
for the HepG2 galactose cells the EC50 at 20 days is 9.5 µM and for the HEK293 KIM-1 
galactose cells the EC50 at 20 days the EC50 is 9.8 µM. The EC50 for the WT of both cell 
lines remains at > 100 µM for all incubation periods. This demonstrated that the galactose 
cultured cells have become more susceptible to toxicity. 
The dose response data showing the determination of ADEF induced cytotoxicity measured 
by MTT analysis (Figures 3.3 C and D) demonstrate that ADEF induces time and dose 
dependent cytotoxicity in both HepG2 / HEK293 KIM-1 cells grown in glucose and galactose 
media. This is demonstrated after 5 days when the maximal EC50 is reached for the galactose 
cultured for the HepG2 galactose cells the EC50 is 9.3, and for the HEK293 KIM-1 galactose 
cells the EC50 9.1 µM. However for the HepG2 / HEK293 KIM-1 WT the maximal EC50 
value is not observed until 10 days when the EC50 for the HepG2 WT cells is 27.9 µM, and 
for the HEK293 KIM-1 WT the EC50 is 29.3 µM (Table 3.2).  
The dose response data showing the determination of 3TC induced cytotoxicity measured by 
MTT analysis (Figures 3.2 E and F) shows that 3TC did not cause any cytotoxicity at all 
incubation periods in these cell lines, this can be seen by the EC50 values (Table 3.2) which 
remain at > 100 µM  for all cell lines at all incubation periods. 
  
92 
 
3.3.2 The assessment of cytotoxicity using Neutral red assays in the 
presence of Tenofovir, Adefovir and Lamivudine 
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Figure 3.4 Dose-response curves of HepG2 and HEK 293 KIM-1 cells with TFV/ 
ADEF/3TC for 5 days A = HepG2 galactose / WT treated with TFV. B = HEK293 KIM-1 
galactose / WT treated with TFV. C = HepG2 galactose / WT treated with ADEF. D = 
HEK293 KIM-1 galactose WT treated with ADEF. E = HepG2 galactose / WT treated with 
3TC. F = HEK293 KIM-1 galactose / WT treated with 3TC. Results are the mean ± S.D of 
three or more independent experiments.  
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Table 3.5 Table showing EC50 values for NR 
incubations of HepG2 / HEK293 KIM-1 galactose and 
HepG2 / HEK293 KIM-1 WT in the presence 
Table 3.6 Table showing average control values for MTT 
NR incubations (5 -20 day) for HepG2/ HEK293 KIM-1 galactose 
and  
HepG2 / HEK293 KIM-1 WT . 
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Table 3.7 A, B, C, D, E and F. Show the statistical analysis performed on the NR data for 
the HepG2 WT /HepG2 galactose-cultured cells[ in the  presence of TFV (3.4A), ADEF (3.4 
B) and 3TC (3.4C) ] and  for the HEK 293 KIM-1 WT / HEK293 KIM-1 galactose-cultured 
cells[ in the  presence of TFV (3.4D), ADEF (3.4 E) and 3TC (3.4F) ] Significance is 
indicated as follows * P < 0.05, ** P < 0.01, *** P < 0.001. 
               
 
                 
A 
F E D 
C B 
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The dose response data showing the determination of TFV induced cytotoxicity via NR 
analysis (Figures 3.4 A and B  and Table 3.5) show that TFV causes cytotoxicity in a time 
and dose dependent manner within the galactose grown HepG2 and HEK293 KIM-1 cells. 
TFV cytotoxicity is seen after 5 days as shown in  Figures 3.4 A and B where the EC50 for the 
HepG2 galactose cells is 54.9 µM and for the HEK293 KIM-1 galactose cells the EC50 was  
53.0 µM (for the WT cells of both cell lines the EC50 was > 100 µM). The EC50 value reduces 
for both cells lines grown in galactose media as the incubation time increases, thus 
demonstrating their increased susceptibility. For the HepG2 galactose cells the EC50 at 20 
days is 13.9 µM and in the HEK293 KIM-1 galactose cells the EC50 at 20 days is 12.2 µM. 
The EC50 for the WT of both cell lines remains at > 100 µM for all incubation periods. 
The dose response data showing the determination of ADEF induced cytotoxicity measured 
by NR analysis (Figures 3.4 C and D / Table 3.5) demonstrated that ADEF causes time and 
dose dependent cytotoxicity in both HepG2 / HEK293 KIM-1 cells grown in glucose and 
galactose media. For the galactose grown cells the maximal EC50 (Table 3.5) was reached 
after 5 days. For the HepG2 galactose cells the EC50 at 5 days is 12.6 µM and for the 
HEK293 KIM-1 galactose cells the EC50 at 5 days is 11.3 µM. However for the HepG2 WT 
cells the maximal EC50 is not reached until 10 days when the EC50 is 36.8 µM. For the 
HEK293 KIM-1 WT the maximal EC50 was reached at 15 days when EC50 was 25.9 µM. 
The dose response data showing the determination of 3TC induced cytotoxicity measured by 
MTT analysis (Figures 3.4 E and F / Table 3.5 ) shows that 3TC did not cause any 
cytotoxicity at all incubation periods in these cell lines, this can be seen by the EC50 values 
(Table 3.3), which remain at > 100 µM  for all cell lines at all incubation periods. 
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3.3.3 The determination of cellular TFV and ADEF accumulation 
3.3.3.1 Tenofovir and Adefovir accumulation at 37 
o
C 
 
 
 
Figure 3.5 A and B. The assessment of TFV and ADEF accumulation within HepG2 
WT and HepG2 galactose-cultures cells at 37
o
C. A = accumulation of TFV and ADEF 
in HepG2 WT and HepG2 galactose cells for 1 hour. B = accumulation of TFV and ADEF 
in HEK293 KIM-1 WT and HEK293 KIM-1 galactose cells for 1 hour. Results are the 
mean + S.D of three or more independent experiments.   
The accumulation at 37
o
C graphs show that there is almost 6 times more ADEF getting 
into the HepG2 WT cells compared to the HepG2 WT TFV accumulation. Also there is no 
significant difference between the accumulation of TFV or ADEF in the WT cells 
compared to the cells grown in galactose (Figure 3.5A and B). 
A 
B 
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3.3.3.2 Tenofovir and Adefovir accumulation at 4 
o
C 
 
 
 
Figure 3.6 A and 3.6 B. The assessment of TFV and ADEF accumulation within 
HepG2 WT and HepG2 galactose-cultures cells at 4
o
C.  A= accumulation of TFV and 
ADEF in HepG2 WT and HepG2 galactose cells.  B= accumulation of TFV and ADEF in 
HEK293 KIM-1 WT and HEK293 KIM-1 galactose cells. Results are the mean + S.D of 
three or more independent experiments.  
 
The accumulation at 4
o
C graphs show that there no significant difference between ADEF 
and TFV accumulation in both cell lines. Also there is no significant difference between 
the accumulation of TFV or ADEF in the WT cells compared to the cells grown in 
galactose (Figure 3.6 A and B). 
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B 
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3.3.4 The luminescent analysis of cellular ATP in the presence of 
tenofovir and adefovir. 
 
 
Figure 3.7 - ATP analysis of HepG2 cells treated with TFV. A = HepG2 galactose and 
Hepg2 WT treated with ADEF for 5 days. B = HepG2 galactose and HepG2 WT treated with 
TFV for 5 days. Results are the mean ± S.D of three or more independent experiments  
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ATP analysis demonstrated that ADEF causes significant reduction in the ATP levels in both 
the HepG2 WT (reduces to 65.4 %, a 1.5 fold reduction) and the HepG2 galactose (reduces to 
37.9 %, a 2.64 fold decreased) cells at 50 µM (Figure 3.7 A). HepG2 cells treated with TFV 
caused a significant decrease in the cellular ATP levels in the HepG2 galactose cells 
(decreases to 65.4 %, a 1.5 fold decrease). At 100 µM TFV, however the HepG2 WT ATP 
levels were only decreased to 82.7 % which is not significant (Figure 3.7 B).  
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3.3.5 Effects of Tenofovir and Adefovir on cellular mtDNA and 
nuclear DNA levels using real-time PCR. 
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Figure 3.8: The effect of  varying concentrations of TFV and ADEF on the mtDNA / nuclear 
DNA ratio and the effect of incubation length on mtDNA/ nuclear DNA ration upon 
treatment. A = HepG2 WT / galactose dosed with TFV for 15 days. B = HepG2 WT / 
galactose dosed with ADEF for 15 days C = HepG2 WT/ galactose dosed with TFV (10 µM) 
for 10, 15 and 20 days. D = HepG2 WT/ galactose dosed with ADEF (10 µM) for 10, 15 and 
20 days. 
MtDNA / nuclear DNA ratio in HepG2 cells in the presence of TFV were estimated (Figure 
3.8 A and C). Results demonstrated that after an initial increase (> 1 ) TFV  decreased this 
ratio in HepG2 galactose cells in a time dependant manner. This can be observed in Figure 
3.8 C which shows a time course with a TFV (10 µM), at 10 days TFV dosing induced an 
increase in the mtDNA / nuclear DNA to 1.7, however at 15 and 20 days the mtDNA / 
C 
D 
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nuclear DNA ratio in the HepG2 galactose cells is lower in those cells dose with higher 
concentrations of TFV concentration increases (for the 20 day the ratio is 0.3). Interestingly 
the mtDNA / nuclear DNA ratio in HepG2 WT cells is higher after 10 days TFV (10 µM) 
dosing (Figure 3.8C, ratio > 1 ) , the ratio then reduces at the 15 day incubation (0.9) but for 
the 20 day incubation the mtDNA/ nuclear DNA ratio again increased to 1.6.  
The determined mtDNA / nuclear DNA ratio in HepG2 cells dosed with ADEF (Figure 3.8 
Band D), shows that after an initial increase in the ratio (> 1) ADEF reduces this ratio in a 
time dependant way for both the galactose and WT cells this is shown by the decrease in the 
ratio at each time point (Figure 3.8D). For example in the HepG2 galactose cells at 10 days 
the ratio was 0.6 (100 µM ADEF), at 15 days it decreases to 0.2 (100 µM ADEF) and finally 
at 20 days the mtDNA / nuclear DNA ratio decreases to 0.1 (100 µM ADEF). This effect was 
also seen within the HepG2 WT cells at 10 days the ratio was 0.7 (100 µM ADEF), the ratio 
then decreased to 0.3 at 15 days (100 µM ADEF), and finally at 20 days the mtDNA / nuclear 
DNA ratio decreases to 0.01(100 µM ADEF). 
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3.4 Discussion 
In this chapter the cytotoxic effects and mechanisms of action of the antiretroviral drug TFV 
was investigated in human hepatic and renal cell lines. ADEF and 3TC were included as 
positive and negative controls, respectively [2-3].This is important as previous in vitro studies 
have not adequately demonstrated TFV cytotoxicity [33].  
The cytotoxicity of these drugs was assessed using MTT and NR assays. The cytotoxicity 
data contained in this chapter demonstrated that ADEF causes cytotoxicity after 5 days 
incubation  in  both HepG2 / HEK293 KIM-1 galactose and WT cells. This cytotoxicity was 
dose and time dependent and increased as the incubation period increased. TFV caused slight 
cytotoxicity after 5 days in HepG2 /HEK293 KIM-1 galactose cells. This cytotoxicity 
increased at 10, 15 and 20 days.  
3TC did not cause any cytotoxicity in HepG2 / HEK293 KIM-1 galactose or WT cells at the 
highest concentration tested (100 µM), which can be seen by the EC50 values for both MTT 
(Table 3.2) and NR (Table 3.5) as the EC50 remains at > 100 for all incubation periods and 
all concentrations of 3TC. 
Previously, in vitro studies have not been able to reproduce that TFV does not cause any 
cytotoxicity [33]. Work within this chapter has shown that upon metabolic modification of 
the cell lines in order to make them more susceptible to mitotoxins TFV cytotoxicity can be 
seen from 5 days. This supports the original hypothesis that culturing the cells in galactose 
media would make them more susceptible to mitotoxins and therefore TFV induced 
mitochondrial dysfunction would become apparent. The cytotoxicity of TFV seems to have a 
delayed occurrence when compared to the cytotoxicity of ADEF, however at 15 and 20 days 
the EC50 values of TFV are similar to those of ADEF (Tables 3.2 and 3.5) showing that TFV 
caused time delayed mitochondrial dysfunction. Previous in vitro studies of TFV cytotoxicity 
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used immortalised cell lines that derive their energy from the glycolytic pathway. This makes 
the study of mitotoxins non-existent, as they have no impact on cellular growth or viability 
[34]. The models used within this chapter are novel and have not previously been used to 
study NRTI cytotoxicity. Therefore, these novel cell models, used within this chapter will be 
useful for future both within academia and in industry, to study NRTI-induced toxicity. 
The accumulation of the antiretroviral drugs TFV and ADEF was studied in order to 
demonstrate that both drugs were entering the cells and to determine if any differential uptake 
may account for the differences in cytotoxicity. No previous studies regarding TFV / ADEF 
uptake into HepG2 or HEK293 KIM-1 cells have been reported. It was found that both drugs 
did accumulate appreciably within both cell lines (Figures 3.5 A/B and 3.6A/ B). The 
accumulation study carried out at 4
o
C showed that ADEF and TFV may enter the cell lines 
through the transporters not via passive diffusion, at this temperature when the transporters 
are not active the accumulation of both drugs decreased. The most interesting thing found in 
this study was that the accumulation of ADEF was 7 times higher than TFV accumulation 
(Figure 3.5 B) which may explain why TFV cytotoxicity is reduced and delayed when 
compared to ADEF cytotoxicity, as shown in the cytotoxicity assays within this chapter. As 
previously discussed, ADEF and TFV are analogues of each other with only an extra methyl 
group added to TFV when compared to ADEF (Figure 3.2). It could be that this extra methyl 
group reduces transport of TFV when compared to ADEF (Figures 3.3 A and C). The 
addition of the methyl group to TFV’s structure does not affect physiochemical properties 
such as its viral inhibition, when compared to ADEF. It is a possibility that this extra methyl 
group decreases the affinity of TFV to the transporter in comparison to ADEF leading to a 
lower accumulation rate; however this will need to be investigated. 
The effects of the antiretroviral drugs TFV and ADEF on cellular ATP levels were assessed 
as any change in cellular ATP could create a clearer picture of the type of cytotoxicity being 
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induced by these drugs. In the galactose cells ATP is only being synthesised via 
mitochondrial OXPHOS, therefore any determined effect on the ATP levels is reflective of 
the electron transport chain activity. A decrease in cellular ATP due to cytotoxicity is a 
hallmark of cell death via necrosis as apoptosis requires energy in order to proceed [35]. The 
decrease in ATP levels for the HepG2 galactose cells dosed with TFV for 5 days were not as 
prominent as expected when comparing the EC50 values determined via cytotoxicity assays at 
these time points, but is significant (Figure 3.7B and Table 3.2). This was unexpected and 
could be due to a protective effect taking place within the cells, and therefore preventing the 
reduction in cellular ATP. This protective effect could possibly be due to the up-regulation of 
pol γ [36].  
The final step in this chapter was to determine whether the antiretroviral drugs TFV and 
ADEF induced a detrimental effect on mtDNA levels. This was done by estimating the 
mtDNA / nuclear DNA ratio. A decreased ratio indicates loss of mtDNA relative to nuclear 
DNA.  Loss of mtDNA could be due to decreased mtDNA synthesis or due to a decrease in 
the quality of DNA; both are direct results of the inhibitation of pol γ [2-4]. ADEF is known 
as being an inhibitor of mitochondrial pol γ and therefore decreases cellular mtDNA levels 
[2-4]. As it has been hypothesised that TFV is also acting in a similar way to ADEF by 
inhibiting mitochondrial pol y the mtDNA / nuclear DNA ratios were determined using the 
comparative CT method [32].  The results showed that ADEF caused a decrease in the 
mtDNA/ nuclear DNA ratios in HepG2 galactose and HepG2 WT from 10 days. The quotient 
point from this study was that TFV caused a significant decrease in the mtDNA / nuclear 
DNA ratio from 15 days in the HepG2 galactose cells. This data show that TFV is causing a 
decrease in this ratio which is similar but not as significant as ADEF’s effects and this 
difference could be due to more ADEF being transported into the cell as shown in (Figure 
3.5A). The result showed that upon initial ADEF / TFV dosing, the mtDNA/ nuclear DNA 
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ratio increased. This increase could be due to the up-regulation of pol γ, which previous 
studies have shown to take place as a protective response when cellular mtDNA levels begin 
to decline [36]. The difference in response to TFV dosing between the HepG2 WT and 
HepG2 galactose could be due to a potential increase in mtDNA synthesis to support the 
continued dependence on the electron transport chain (ETC), as components from the ETC 
are encoded for by mtDNA. This could lead to an increased rate of accumulation of 
dysfunctional mitochondrial induced via TFV or ADEF. Previous studies have reported that 
TFV did not cause a decrease in cellular mtDNA levels in vitro [3]. The results determined 
within in this study are different to the results previously reported possibly because the cell 
model used here has been modified to better represent the aerobic conditions within human 
cells, thus making the cells more susceptible to TFV-induced mitochondrial dysfunction. 
Whilst the comparative CT method used within this study to calculate the mtDNA / nuclear 
ratio is a widely used and valid method, another method that establishes the mtDNA/ nuclear 
DNA ratio via calculating the mitochondrial copy number vs. nuclear copy number has been 
recently cited as a more reliable method [31]. This method takes into account the structural 
variation that has been described recently as copy number variation. The variable copy 
numbers within a sample are determined and compared to a standard reference genome which 
has been reported as being more accurate method [31].  Recently the study of the mtDNA/ 
nuclear DNA ratio has been used clinically, within patient PBMC’s as a biomarker for the 
early detection of mitochondrial dysfunction [31]. Future studies should look into this as a 
possible bio-marker for TFV induced mitochondrial dysfunction. 
Overall the work presented within this chapter shows that TFV is inducing cytotoxicity that is 
causing cellular mitochondrial DNA depletion, this leads to a decrease in the cellular ATP 
levels, as mitochondria become dysfunctional and this could ultimately lead to cell death via 
necrosis. The cytotoxicity caused by TFV is similar to that induced by ADEF but is time 
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delayed and reduced in comparison; this difference could be due to differences in cellular 
accumulation as it was shown that ADEF has a higher accumulation rate. 
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Chapter Four 
 
INVESTIGATION OF THE MECHANISM OF TENOFOVIR -
INDUCED CELL DEATH IN HUMAN RENAL AND HEPATIC 
CELL LINES 
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4.1 Introduction 
Cell death can proceed via three pathways, apoptosis (programmed cell death), necrosis and 
autophagy and all then contribute to the balance of cell cycle progression. Cell death can be 
caused by external or internal toxins that disrupt cellular physiology, leading to the death of 
the cell. Previous studies into the mechanism of TFV-induced cell death have had mixed 
results, therefore in this chapter, the study of TFV-induced cell death and its effects on cell 
cycle progression will be elucidated in vitro using the validated aerobically modified cell 
models used in previous chapters. 
4.1.1 Apoptosis 
Apoptosis or programmed cell death is essential for maintaining cellular homeostasis in 
multicellular organisms [1]. Apoptosis is key to maintaining cell numbers and to ensure that 
cells are positioned for optimal function within their specific tissues [1]. The process of 
apoptosis was first noted in 1972, when it was observed and described after scientists 
repeatedly found the same morphological features of cell death across many different cell 
types  [2]. 
Apoptosis is highly conserved as it is such an important process [1]. Apoptosis is essential 
during development, as many more cells are produced than are needed. These excess cells are 
broken down via programmed cell death, which contributes to the sculpting of tissues and 
organs [1]. It is a tightly regulated and balanced physiological process, with disruption to the 
balance resulting in pathological conditions such as neurodegeneration, developmental 
defects, cancer or autoimmune diseases [3]. 
The characteristic features of apoptosis include blebbing of the cell membrane, condensation 
of chromatin, fragmentation of the DNA, cell shrinkage and the final step is cellular 
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engulfment via macrophages or neighbouring cells. The final step of apoptosis ensures that 
inflammatory responses in nearby tissues are avoided, hence the reason why apoptosis is 
defined as the 'clean' form of cell death [1]. 
There are two types of apoptosis in mammalian cells: the intrinsic pathway and the extrinsic 
pathway (Figure 4.1). 
4.1.1.2 The extrinsic pathway. 
The extrinsic pathway is mediated via the death receptor pathway. Death receptors are 
located on the cell surface and involve Fas, tumour necrosis factor (TNF) and TRAIL 
receptors [4]. Death receptors become activated by the extrinsic binding of death-inducing 
ligands (Figure 4.1). Once the death ligand binds to the death receptor, oligomerisation is 
induced and subsequent Fas-associated death domain (FADD) and caspase 8 are recruited to 
form a death-inducing signal complex (DISC) (Figure 4.1). The activation of caspase 8 leads 
to subsequent activation of effector caspases (caspase -3, -6 and -7). These effector caspases 
act down stream in the cell death programme, ultimately leading to the activation of cell 
death via apoptosis [4] (Figure 4.1). 
4.1.1.4 The intrinsic apoptotic pathway. 
The mitochondria act as the key regulators of the intrinsic apoptotic pathway. These 
pathways are activated inside the cell and evidence shows that the mitochondria act as the 
central regulators [5]. The essential mitochondrial change involved in the apoptotic pathway 
is the permeabilisation of the mitochondrial outer membrane (PMOM). PMOM is activated 
by family members of the Bcl-2 protein and leads to loss of essential functions [5]. Activation 
of PMOM leads to cell death via one of two mechanisms. The first mechanism is based upon 
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the release of pro-apoptotic molecules, most of which lead to the induction of caspases [5] 
(Figure 4.1). 
Figure 4.1 A schematic diagram of the apoptotic pathways (modified from a picture in the 
thesis of Amy Mercer). The red crosses show the point that the pathway can become inhibited 
 
The main molecule released in this way is cytochrome c (Figure 4.1), which normally 
functions as an electron shuttle within the electron transport chain (ETC) [6]. Upon release it 
has been shown that cytochrome c binds to Apoptotic protease activating factor 1 (Apaf-1), 
forming an apoptosome once recruited along with caspase-9 (Figure 4.1). Caspase-9 
Mitochondrion 
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becomes activated and subsequently leads to the activation of the executioner caspases-3, -6 
and -7(Figure 4.1) [6]. 
The second mechanism is the disruption of the essential mitochondrial functions leading to 
cell death [1]. A Study has shown that drug induced tubular cell death (shown to be induced 
via TFV clinically), can proceed via the apoptotic and necrotic cell death pathways, 
determined via histological sections from the kidneys of patients who experienced drug 
induced proximal tubule dysfunction [7]. 
4.1.1.3 The caspase family 
Caspases are essential initiators and executioners of the apoptosis pathway. Caspases make 
up a family of proteins; their activation is the main predecessor of apoptosis [8]. There are 
currently 14 mammalian caspases that have been identified, all share common features. These 
caspases can be separated into three main categories [8]. The first is made up of inflammatory 
caspases (caspase -1, -4, -5, -11, -12, -13 and -14) which are not associated with apoptosis. 
The second caspase group consists of apoptotic initiator caspases [8]. The initiator caspases 
have extended pro-domains that consist of either a death effector domain (DED) (caspase -8 
and -10), or a caspase activation and recruitment domain (CARD) (caspase -2 and -9) 
(Figure 4.1). The CARD caspases interact with the adaptor molecules that are upstream in 
the extrinsic pathway. The final caspase group are known as the effector caspases (caspase -3, 
-6, and -7) (Figure 4.1).  These characteristically contain a short pro-domain. The effector 
caspases become activated by upstream caspases in a cascade. Their activation leads to the 
start of the apoptotic execution process, which is found downstream and causes cleavage of 
the many cell substrates ultimately leading to cell death [8]. 
It has previously been shown that the pro-caspase-3 and pro-caspase-7 can become activated 
via the upstream initiator caspases (caspase -6, - 8, -9 and -10) (Figure 4.1) [9]. It was also 
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shown that effector caspases are found in greater abundance than the initiator caspases [9]. 
The importance of the executioner caspases has been demonstrated by genetic studies.  
Results demonstrated that the loss of caspase-3 leads to malfunction of the brain and 
premature death [10]. In vivo, animal studies showed that caspase-3 knock out (KO) mice 
could not activate apoptosis, when stimulated by the intrinsic and extrinsic apoptotic 
pathways; this leads to the survival of defective cells which could lead to pathological 
conditions such as cancer [10]. 
4.1.2 Necrosis 
Necrosis differs form apoptosis as it is unregulated and is energy-independent [11]. Necrosis 
takes place when the physiological pathway needed for normal cellular homeostasis is 
disrupted. For example, energy production (ATP generation), ion transport and PH balance, 
disturbance to these processes leads to necrosis [11]. The key morphological characteristics 
of necrosis are the vacuolation of cellular cytoplasm, the plasma membrane breakdown and 
induced inflammatory response in the area around the dying cell, due to leakage of cellular 
contents and the pro-inflammatory molecules (e.g.TNF-α) [11]. The classical example of 
necrosis is ischemia, when oxygen levels are drastically depleted along with depletion of 
glucose and other key tropic factors. This dramatic depletion of essential cellular molecules 
leads to dramatically large levels of necrosis in the endothelial and non-proliferating cells that 
surround the ischemic tissue [12]. 
Studies have shown that necrosis not only occurs due to pathological events as mentioned 
above, but can also occur as a component of some physiological pathways [13]. It was shown 
that both apoptosis and necrosis play a key role in the renewal of enterocytes in the small 
intestine. Necrosis may take place instead of apoptosis when ATP levels become depleted as 
necrosis is shown to be ATP-independent [14]. 
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Clinical studies on renal biopsies from patients receiving ADEF who developed acute renal 
failure showed ADEF-induced cell death via the necrotic pathway [15]. As ADEF and TFV 
have similar structures it is reasonable to assume that TFV may trigger the same cell death 
response.  
4.1.3 Autophagy 
A recent study reported that the antiretroviral drug Efavirenz (EFV), induced autophagy at 
clinically relevant concentrations [16]. EFV is a non-nucleoside reverse transcriptase 
inhibitor (NNRTI), which has previously been linked to the onset of mitochondrial 
dysfunction within hepatic cells [16-17]. The induction of autophagy via EFZ was shown 
within both Hep3B (primary hepatocytes) and HeLa cells [16].  
It has been shown that autophagy is an intracellular catabolic mechanism that is mediated via 
the lysosomes [18]. Autophagy becomes stimulated due to cellular stresses, including 
oxidative stress, cell volume changes, starvation of the cell, disrupted hormonal signalling, 
increased concentrations of misfolded proteins, irradiation and xenobiotic treatments [19]. 
Autophagy is also induced in situations when apoptosis becomes inhibited which has been 
shown during in vitro studies using etoposide in Bax/ Bak double knockout mice [30]. 
Autophagy switches cells to a catabolic state that leads to degeneration of cellular 
components to produce energy for cellular survival during periods of depleted nutrients [14].  
Upon activation of autophagy, the endoplasmic reticulum’s membrane-bound double layered 
structures begins to undergo assembly and expansion. This leads to the formation of 
autophagosomes [20]. The function of autophagosome is to engulf materials in the cytosol; 
the autophagosome then binds and fuses to lysosomes [20]. The fusion with the lysosomes 
leads to the autophagosomal contents being degraded [20]. Evidence has shown that the 
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signalling pathway linked to the induction of autophagy includes phosphyatidylinositol-3-
kinase (PI3K) and the kinase target of rampicin [20].  
EFV-induced autophagy was determined via the detection of autophagic vacuoles and the 
presence of the specific autophagic marker proteins, microtubule-associated protein 1A/1B 
light chain 3 (LC-3) and Beclin-1 [16]. Using an autophagy inhibitor, showed that autophagy 
was acting as an adaptive mechanism of cell survival [16]. This study highlighted the 
importance of autophagy for cellular survival, the study of TFV and its possible induction of 
autophagy will be determined within this chapter. 
 
A previous study has linked diseases such as neurodegenerative diseases, cancer and 
myopathies to alterations in the autophagic pathway [21]. Autophagy was first noticed in 
Saccharomyces Cerevisae yeast, which allowed better understanding of the autophagic 
pathway [22-23]. Studies have shown that upon caspase- 8 inhibition, autophagy is activated. 
This evidence shows that caspases are involved in the regulation of apoptotic and non-
apoptotic cell death [23]. 
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4.1.4 Aims of Chapter 
Current evidence is conflicting with regards to TFV-induced cell death. Some in vitro studies 
using human primary renal proximal tubule cells, have shown that TFV does not cause 
apoptosis [24], however, an in vitro study that used the breast cancer cell line MCF-7 
reported that TFV did not induce cytotoxicity, but induced morphological features that shows 
cell death was being induced via apoptosis [25]. Therefore the aim of this chapter is to 
elucidate the mechanism of cell death induced by TFV in the novel susceptible cell models. 
The effects of TFV on cell cycle progression were studied using propidium iodide (PI) 
staining. The effects of TFV on the status of the cell (viable, apoptotic or necrotic) was 
studied using a double staining method (annexin V / PI). The activation of cellular caspase-3 / 
-7 and reactive oxygen species (ROS) was determined in the presence of TFV. Mitochondrial 
depolarisation was studied in the presence of TFV using tetramethylrhodamine, ethyl ester 
(TMRE) staining. The potential role of autophagy due to TFV was studied using the 
autophagy inhibitor 3-methyladenine (3MA) and assessed by MTT assays. 
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4.2 Materials and Methods 
4.2.1 Materials 
The cell culture media (DMEM high glucose and DMEM no glucose) were ordered from life 
technologies, Invitrogen (Paisley, UK). All other reagents were purchased from Sigma-
Aldrich (Poole, UK). Tenofovir was ordered from Toronto Research Chemicals (Toronto, 
Canada).  The caspase -3/7 glo assay was purchased from Promega life sciences 
(Southampton, UK) 
4.2.2 Cell culture and experimental preparation 
As in section 2.2.2, Chapter 3. HepG2 cells were used for all cell death assays as they are 
well characterised for use as mechanistic tools to study cell death. 
4.2.3 Analysis by flow cytometry. 
Flow cytometry (FACs) was carried out using an Epics XL and XL MCL - Beckman Coulter, 
flow cytometry machine. The parameters were set using control cells, these were used to 
adjust the forward scatter (FS) and side scatter (SS), to obtain a population of viable cells, 
with a voltage threshold set to exclude cell debris (Figure 4.2). The FS is used to determine 
cell size and the SS is used to determine granularity. For all FACs experiments at least 5000 
cells were analysed from each sample. The fluorescence channel FL-1 or FL-3 was used to 
measure fluorescence. 
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Figure 4.2: representation of cell gating to exclude cell debris 
 
4.2.3.1 The determination of cellular DNA content using Propidium 
Iodide upon Tenofovir treatment. 
Propidium iodide (PI) can be used to measure cellular DNA content, as it is a major groove 
binder of DNA. When it intercalates with DNA it produces a red fluorescence shift which can 
be detected [26]. 
 The cells (4 x 10
5
) that had been incubated (24 hours to 15 days) with the drugs (0 to 100 
µM) were centrifuged (1400 rpm, 5 minutes). After centrifuging the supernatant was 
removed and the cells were washed twice in HBSS (1ml), by centrifugation (1400 rpm, 5 
minutes). The supernatant was discarded and the cell pellet was resuspended in 70 % ice-cold 
ethanol (1 ml) and then frozen at – 4 0C (2 hours) to fix the cells. After 2 hrs the ethanol was 
removed and the cell pellet was resuspended in 1 ml of PI stock solution (1 % RNAse (50 
µM), 1 % citric acid (380 µM)). The cells were then incubated for 30 minutes before being 
analysed using flow cytometry (Epics XL and XL MCL - Beckman Coulter, flow cytometry 
machine). The intensity of PI fluorescence was measured using the fluorescence channel, FL-
3. The quantification of cells in each stage of the cell cycle was calculated from the DNA 
content of the cell using WinMDI, version 2.8. Etoposide (10 µM) was used as a positive 
control as it is a known inducer of apoptosis [27]. 
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4.2.3.2 The determination of cell death using Annexin v / Propiduim 
Iodide upon Tenofovir treatment. 
The annexin V and PI (annexinV/ PI kit from Sigma-Aldrich, Poole, UK) stains are used in 
conjunction in order to determine the cytotoxic status of the cells, apoptotic, necrotic, viable 
or in the state of secondary necrosis. The stains are able to do this through the differences in 
plasma membrane permeability and integrity upon exposure to damaging affects [26]. PI does 
not stain viable cells; its accumulation within the cell is dependent upon membrane 
permeability, and for this reason PI stains necrotic or secondary necrotic cells due to their 
loss of plasma / nuclear membranes. The loss of membranes allows PI to intercalate with 
cellular nucleic acids which releases a red shift in fluorescence [26]. During apoptosis, major 
changes take place to the cell surface. One of these changes involves the externalisation of 
phosphatidylserine (PS) [28]. Annexin V binds to phospholipids in a calcium-dependent 
manner, therefore annexin V stains for apoptotic and secondary necrotic cells [28]. 
The cells (4 x 10
5
) that had been incubated (24 hours to 15 days) with the drugs (0 to 100µM) 
were centrifuged (1400 rpm, 5 minutes). After centrifuging the supernatant was removed and 
the cells were washed twice in HBSS (1ml) by centrifugation (1400 rpm, 5 minutes). The 
supernatant was discarded and the cell pellet was resuspended in 195 µl binding buffer and 5 
µl annexin. The cells were then incubated in the dark (room temperature, 10 minutes). The 
samples were centrifuged (4000 rpm, 5 minutes); after centrifuging the supernatant was 
removed and the cells were washed twice in HBSS (1ml) by centrifugation (1400 rpm, 5 
minutes).  The supernatant was removed and the cells were re-suspended in 190 µl binding 
buffer and 10 µl PI. Then 600µl HBSS was added to the cells before being analysed on the 
flow cytometer (Epics XL and XL MCL - Beckman Coulter, flow cytometry machine). The 
FL1 channel was used and at least 5000 cells where counted. The proportion of cells in the 
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different cellular states (viable, apoptotic, necrotic and secondary necrotic) were quantified 
and data were analysed using WinMDI, version 2.8. Etoposide (10 µM) was used as a 
positive control as it is a known inducer of apoptosis [27] 
 
4.2.3.3 The determination of cellular mitochondrial depolarisation 
using tetramethylrhodamine ethyl ester upon Tenofovir treatment. 
Tetramethylrhodamine ethyl ester (TMRE) was used to determine mitochondrial 
depolarisation of cells. TMRE is a positively charged, red dye that is cell membrane-
permeable; it labels active mitochondria due to their negative charge. Accumulation of 
TMRE causes a red shift in TMRE’s absorption and fluorescence spectra. Mitochondria that 
have become depolarised due to cytotoxicity, experience a decrease in membrane potential, 
therefore the accumulation of TMRE decreases and a decrease in fluorescence can be 
detected [29].  
 The cells (4 x 10
5
) that had been incubated (24 hours to 15 days) with the drugs (0 to 100µM 
were centrifuged (1400 rpm, 5 minutes). The supernatant was removed and the cells were 
washed twice in 1ml HBSS by centrifugation (1400 rpm, 5 minutes). The supernatant was 
discarded and the cell pellet was resuspended in TMRE solution (50 µM, 500µl). The 
samples were then incubated (37 
0
C for 10 mins) before being analysed on the FACs 
machine. The intensity of TMRE fluorescence was measured using the fluorescence channel, 
FL-3. The quantification of cellular mitochondrial depolarisation was calculated from the 
TMRE content of the cell using WinMDI, version 2.8. Etoposide (10 µM) was used as a 
positive control as it is a known inducer of apoptosis [27] 
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4.2.3.4 The determination of cellular superoxide reactive oxygen 
species content using dihydroethidium upon Tenofovir treatment. 
Dihydroethidium (DHE) was used to determine cellular superoxide ROS content. DHE is cell 
permeable; when it comes into contact with superoxide anions within the cell it forms the red 
fluorescent product 2-hydroxyethidium. The production of 2-hydroxyethidium can be 
detected via a red shift in the fluorescence spectra [31].  
The cells (4 x 10
5
) that had been incubated (24 hours to 15 days) with the drugs (0 to 100µM 
were centrifuged (1400 rpm, 5 minutes). The supernatant was removed and the cells were 
washed twice in 1ml HBSS by centrifugation (1400 rpm, 5 minutes) and the supernatant 
discarded after eash wash. The cell pellet was resuspended in DHE (10 µM, 500µl) and 
incubated (37 
0
C, 10 minutes) before being analysed on the FACs machine. The intensity of 
DHE fluorescence was measured using the fluorescence channel, FL-3. The quantification of 
cellular ROS production was calculated from the DHE content of the cell using WinMDI, 
version 2.8. [32]. Menadione (10µM) was used as a positive control as it is a known inducer 
of apoptosis [32]. 
 
4.2.4 The luminescent analysis of cellular Caspase-3 and Caspase-7 
upon Tenofovir treatment. 
A kit (caspase-glo 3/7, from Promega life sciences (Southampton, UK)) that is commercially 
available for the detection of caspases -3 and 7 was used to measure the DEVD-ase activity 
of these caspases. Within the assay is a caspase-3/7 proluminescent substrate; this contains 
the tetrapeptide sequence DEVD. DEVD is cleaved by caspases which produces a 
luminescent signal that can be detected.  
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The manufactures instructions were followed. Cells were plated out on a white plate and 
incubated (24 hours to 5 days) as in section 3.2.2 (Chapter 3). After the required incubation 
time with the drugs, caspase 3/7 glo reagent (100 µl) was added to all wells and the plate was 
shaken on a plate shaker (30 seconds, 400 rpm). The cells were incubated at room 
temperature (30 minutes) and then the luminescence was read using a plate reader (BioTek 
FL600). Etoposide (10 µM) was used as a positive control as it is a known inducer of 
apoptosis [27] 
4.2.5 The study of the potential role of autophagy induced by 
Tenofovir, via the use of the autophagy inhibitor 3-methyladenine 
MTT cytotoxicity assays were carried out as in sections 2.2.3 in Chapter 2. These were 
carried out in the presence of the autophagy inhibitor 3MA (3-methyladenine). 3MA is an 
inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway, which has been shown to play 
a key role in the induction of autophagy [16]. All cells were pre-dosed with 3MA (25µM, 
2hours, 37
0
C).  
 
2.2.6 Statistical Analysis 
Statistical analysis was carried out on all data. Values are expressed as a mean + standard 
deviation (SD) of the mean. This is represented as error bars on all graphs. A Shapiro-Wilk 
test was first carried out on the data to see if they were was considered normal.  A Student’s 
t-test was used for all normally distributed data and a Mann-Whitney U test was carried out 
on non-normally distributed data. All calculations were carried out using the StatsDirect 
software. Significance is indicated as follows * P < 0.05, ** P < 0.01, *** P < 0.001 
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4.3 Results 
4.3.1 Effects of Tenofovir on cellular DNA content by Propidium 
Iodide staining. 
PI intercalates with nuclear DNA within the cells, this leads to the formation of an adduct that 
is highly fluorescent. This fluorescence is measured by flow cytometry and is proportional to 
cellular DNA content. Each stage of the cell cycle (Figure 4.3 A), relates to a distinct region 
of the histogram (Figure 4.3 B). An increase in the G1/ G0 (also called G1 phase) phases is 
indicative of apoptosis [33]. 
               
                
 
 
Figure4.3: A– The Cell Cycle B– Representative histogram of PI stained HepG2 galactose 
cells, vehicle only control cells (15 day incubation), where viability > 95 %. C- 
Representative histogram of PI stained HepG2 galactose cells, TFV treated (10 µM for 15 
days) D- Representative histogram of PI stained HepG2 cells treated with etoposide (10µM 
for 15 days) 
A 
C 
B 
D 
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Figure 4.4 – Graphs of PI analysis of HepG2 cells treated with TFV for 15 days. A = 
HepG2 galactose. B = HepG2 WT days Results are the mean +S.D of three or more 
independent experiments.  
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Figure 4.5 – Graphs of time course of PI analysis of HepG2 cells treated with TFV 
(10µM). A = HepG2 galactose B = HepG2 WT. Results are the mean ±S.D of three or more 
independent experiments. KEY: Red = Sub G1, Blue = G1, Yellow = S and Green = G2. * p < 
0.05, ** p < 0.01 and *** p  < 0.001. 
 
 
 
A 
B 
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Figure 4.4 A and Figure 4.5 A demonstrate that TFV acts in a time dependant and dose 
dependent  manner against the HepG2 galactose cells, causing a G2 / M cell cycle arrest 
which leads to an accumulation of cells in the S phase. This can be seen clearly by the 
significant increase in cells within the S phase at 10 and 15 days (10 µM TFV, S phase is 
4.9 %   at 5 days and increases to 18.8% at 15 days) (Figure 4.5 A). The amount of cells in 
the G1 (G1 / G0) phase also significantly increased (10 µM TFV, G1 phase is 20.1 %   at 5 
days and increases to 31.2 % at 15 days) (Figure 4.5 A). There is  significant reduction of 
cells in the G2 / M phase at 5 , 10 and 15 days (10 µM TFV,G2/M is 19.9% at 5 days and 
reduces to 5.7 % at 15 days) (Figure 4.5 A). Cells within Sub G1 also significantly 
increase at 15 days within the HepG2 galactose cells (10 µM TFV )  (Figure 4.5 A).Within 
Figure 4.5 B, the time course data (at 10 µM TFV), demonstrates that at 15 days the same 
effects seen within the HepG2 galactose cells are beginning to take place within the HepG2 
WT cells. This can be seen by the significant increase in the S phase and the significant 
reduction in the G2 / M phase (Figure 4.5 B at 10 µM TFV).  
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4.3.2 Determination of Tenofovir-induced cell death using Annexin 
v / Propiduim Iodide dual staining. 
Annexin V and PI can be used in conjunction as a dual stain to determine cell status, viable 
(annexin V - / PI -), apoptotic (annexin V + / PI -), necrotic (annexin V - / PI +) and 
secondary necrotic (annexin V + / PI +) (Figure 4.6). 
 
Figure 4.6 representative dot plot of HepG2 galactose cells incubation for 15 days with A –vehicle control B – 
TFV (100 µM) 
 
 
 
 
 
B A 
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Figure 4.7 – Graphs of annexin V/ PI analysis of HepG2 cells treated with TFV for 15 
days. A = HepG2 galactose. B = HepG2 WT days Results are the mean +S.D of three or 
more independent experiments.  
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Figure 4.8 – Graphs of time course of annexin V/ PI analysis of HepG2 cells treated with 
TFV (10µM). A = HepG2 galactose B = HepG2 WT. Results are the mean ±S.D of three or 
more independent data sets of experiments. KEY: Red = necrosis, Blue = secondary necrosis, 
Yellow = viable and Green = apoptosis. * p < 0.05, ** p < 0.01 and *** p  < 0.001. 
 
The graphs for the annexin v / PI FACs demonstrate that the HepG2 galactose cells are more 
susceptible to TFV induced cytotoxicity than the HepG2 WT cells. This can be seen clearly 
when comparing Figure 4.7 A to Figure 4.7 B. In Figure 4.7A (the HepG2 galactose cells) 
the amount of viable cells at 15 days was significantly (p < 0.01) reduced from 95.0 % 
A 
B 
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(control) to 48.3 % (at 10 µM TFV), however in Figure 4.7 B (the HepG2 WT cells) it can be 
seen that the percentage of viable cells doesn’t significantly change (95.0 % to 96.1 %), when 
dosed with TFV (10 µM).The data presented in Figures 4.7 A and 4.8 A, demonstrate that 
TFV acts in a dose-dependent and time-dependent manner to cause cytotoxicity, ultimately 
leading to cell death via apoptosis or necrosis. This can be seen by the significant (p < 0.05) 
increase in apoptosis and necrosis at 15 days in Figure 4.8 A (apoptosis increased from 4.2% 
to 19.8%; necrosis increased from 5.3% to 14.3 %. The amount of secondary necrosis also 
increases, however it was not significant (Figure 4.8 A). 
 
4.3.3 Effects of Tenofovir on mitochondrial membrane potential by 
tetramethylrhodamine ethyl ester staining. 
 
As discussed in section 4.2.3.3 TMRE staining is used to determine mitochondrial 
depolarisation. Mitochondrial depolarisation is demonstrated when there is a decrease in 
quantity of TMRE florescence detected (Figure 4.9 ) 
 
Figure 4.9: A representative histogram of TMRE staining within HepG2 galactose cells 
(after a 10 day incubation). A – Vehicle control B – TFV treated (100 µM). R1: cells with 
low TMRE fluorescence R2: cells with high TMRE fluorescence 
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Figure 4.10 – Graphs of TMRE analysis within HepG2 cells treated with varing 
concentrations of TFV. Etoposide (10µM) was used as a positive control . A = HepG2 
galactose/ WT cells treated with TFV for 15 days. B = Time course of HepG2 galactose/ WT 
cells treated with TFV (10µM). Results are the mean ± S.D of three or more independent 
experiments. 
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TFV causes dose-dependent (Figure 4.10 A) and time-dependent (Figure 4.10 B) 
depolarisation of the mitochondria specifically in the HepG2 cells grown in galactose 
media. This can be seen in Figure 4.10 B (at 10 µM TFV) when comparing the percentage 
of TMRE in each cell type over the different time points, For the HepG2 WT the 
percentage of TMRE fluorescence does not significantly reduce any time point, whereas in 
the HepG2 galactose there is a significant (p < 0.05) reduction in TMRE fluorescence at 15 
days (reduction from 81.2 % at 5 day to 69.8 % at 15 day). 
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4.3.4 Effects of Tenofovir on cellular Caspase-3 and Caspase-7 
levels by luminescent staining. 
 
 
Figure 4.11 -– Graphs of caspase 3/7 glo analysis of HepG2 cells treated with TFV. A = 
HepG2 galactose/ WT cells treated for 5 days. B = HepG2 galactose/ WT cells treated for 10 
days. Results are the mean ± S.D of three or more independent experiments.  
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TFV induces caspase 3/ 7 glo activity of HepG2 cells cultured in galactose media after 5 days 
(Figure 4.11B). The results demonstrate that TFV acts in a time dependent and dose 
dependent manner and causes a significantly (p < 0.05) higher percentage of caspase 
luminescence  within the HepG2 galactose cells at 10 day incubations  when compared to 
vehicle control cells (170.4 %  at 100 µM TFV ) (Figure 4.11 B). However, TFV did not 
cause and increase in caspase activity within the HepG2 WT cells (the percentage of caspase 
activity was 109% at 10 days upon treatment with TFV 100µM) (Figure 4.11 A), thus 
showing that the HepG2 + gal cells were more susceptible to TFV cytotoxicity as caspases 
are released as part of the apoptotic pathway. 
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4.3.5 Effects of Tenofovir on cellular superoxide reactive oxygen 
species levels using dihydroethidium staining. 
 
 
 
Figure 4.12 – Graphs of DHE analysis of HepG2 cells treated with TFV. A = HepG2 
galactose/ WT cells treated with TFV for 15 days. B = Time course of HepG2 galactose/ WT 
cells treated with TFV (10µM). Results are the mean ± S.D of three or more independent 
experiments.  
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There was DHE in all samples tested, but the levels in the HepG2 + galactose cells were 
not significantly different to those in the HepG2 WT cells (Figure 2.12). The detection of 
DHE (Figures 4.12 A and B) unexpectedly demonstrates that TFV is not inducing any 
superoxide ROS generation. This can be clearly seen in Figure 4.12 B as there is no 
significant change in the amount of superoxide ROS detected. The positive control 
(Menadione, 10) induced a significant increase in production of superoxide ROS within 
both the HepG2 WT and HepG2 galactose cells, with levels being higher in the HepG2 + 
galactose cells (Figure 4.12 A), thus confirming that the assay was working correctly. 
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4.3.6 Determination of Tenofovir-induced autophagy, via the use of 
the autophagy inhibitor 3-methyladenine 
 
 
Figure 4.13 – Dose-response curve of HepG2 galactose cells treated with TFV for 5 days, 
with and without 3MA (25 µM) Results are the mean ± S.D of three or more independent 
experiments.  
 
 
 
Figure 4.14 – Graph of time course MTT analysis within HepG2 galactose cells treated 
with TFV (10µM) without or with 3MA (25 µM). Results are the mean ±S.D of three or 
more independent experiments.  
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induced by TFV within HepG2 galactose cells at 5 days (Figures 4.13), when cultured in the 
presence of the autophagy inhibitor 3MA, indicate that the autophagy inhibitor acted to 
exacerbate the cytotoxic effects of TFV, this is indicative that autophagy is acting as an 
adaptive mechanism of cellular survival induced by TFV dosing. However, this protective 
effect is only apparent and significant ( p < 0.05) at the earlier time point of 5 days (Figure 
4.14), shown by the reduction in the EC50 (the EC 50 for HepG2 galactose cells dosed with 
TFV (0.1µM – 100 µM) at 5 days is 25.0 µM, when dosed with TFV (0.1µM – 100 µM) in 
the presence of a fixed dose concentration of  3MA (25µM) the EC50 decreases significantly( 
p < 0.05) to 11.7 µM (Figure 4.14 A). At all other time points (10, 15 and 20 days), results 
demonstrate there was no significant difference in the cytotoxicity induced by TFV in both 
HepG2 galactose / WT, with and without the presence of the autophagy inhibitor 3MA. 
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4.4 Discussion 
The studies presented within this chapter have investigated the mechanistic pathways of TFV 
induced cell death via the study of biochemical and structural events involved at different 
points of the various cell death pathways. Previous studies have showed that other NRTI’s 
induce cell death via both apoptotic and necrotic pathways [15], however the mechanistic 
pathway of TFV induced cell death still remains unknown, due to lack of appropriate in vitro 
models. 
These finding can be combined in order to establish a molecular pathway of TFV-induced 
cell death, Figure 4.15. 
 
Figure 4.15 A schematic diagram of the determined mechanistic pathway of TFV induced 
cell death 
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Due to a recent paper showing that EFZ-induced autophagy acted as an adaptive mechanism 
of cell survival, the study of the possible role of autophagy induced by TFV was carried out 
using the autophagy inhibitor 3MA [16]. The results demonstrated that at only the 5 day 
incubation period, in the presence of 3MA the cytotoxicity of TFV was significantly 
increased, within both the HepG2 galactose and the HepG2 WT cells (Figure 4.14). This is 
indicative that autophagy is induced by TFV and plays a protective role within the cells at the 
early time points. This may underline the long time periods required to see TFV-induced 
cytotoxicity. In future more work needs to be carried out, in order to establish the relationship 
between TFV dosing, autophagy and cell death. Further studies within in vitro and in vivo 
models should be carried out, using western blott analysis to look for the presence of the 
specific autophagy protein LC-3 induced by TFV [16]. Future intervention studies should be 
carried out to see if the induction of autophagy may be a possible protective mechanism that 
could be used in the future. This treatment could benefit those patients that have been 
identified as predisposed to TFV-induced toxicity. 
The determination of cellular DNA content and its position within the cell cycle can be 
indicative of any DNA damage leading to cell cycle arrest [34]. The cell cycle has two main 
checkpoints that determine if progression through the cycle continues. The cell cycle has 
check points within the G1 (before the S phase), and in G2 (after the S phase) [34]. Any 
cellular DNA damage detected by these checkpoints results in cell cycle arrest at the point of 
detection, ultimately leading to apoptosis (Willis et at., 2011). Therefore, the cellular DNA 
content in the presence of TFV was determined. The results demonstrated that TFV caused a 
time dependent and dose dependent G2 /M cell cycle arrest within HepG2 galactose cells at 5 
days, which lead to an accumulation of cells in the S phase of the cell cycle. The data 
presented within this chapter indicate that the G2 checkpoint was triggered. This may be a 
result of the DNA damage observed in Chapter 3, resulting in accumulation of cells in the S 
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phase. Previous in vitro work has shown that an accumulation of cells within the S phase is 
linked to mtDNA damage [35]. These results support evidence that TFV may be inducing 
mitochondrial DNA damage. It was demonstrated that the G1 (G1/ G0) population also 
significantly increased within HepG2 galactose cells dosed with TFV after 10 days, this is 
indicative that TFV is inducing cell death via apoptosis [33]. 
Disruption in cellular superoxide ROS levels has been cited as an early indicator of apoptosis 
as a result of ETC disruption, therefore cellular superoxide ROS levels were determined via 
DHE staining in the presence of TFV [36]. Earlier time points were investigated for the 
detection of early apoptosis (24 hour / 48 hour), when there was no detection of superoxide 
ROS at these time points (data not shown), later time points were carried out (5 days and 10 
days). Results demonstrated that TFV did not induce ROS production at the early or later 
time points, which was unexpected, as data within this chapter shows that TFV induces 
mitochondrial cytotoxicity leading to apoptosis within the HepG2 galactose cells after 5 days 
(Figure 4.13). This could be indicative that whilst TFV is causing mitochondrial damage, it 
may only reduce the quantity of mitochondria rather than the quality, therefore superoxide 
ROS production may proceed as usual. But data presented here agrees with   previous 
observations that TFV does not induce cellular ROS production in vitro [25]. 
The depolarisation of the mitochondrial membrane has been cited as an early apoptotic event 
as it may lead to cytochrome c release, this could mediate the induction of a caspase cascade 
that leads to cell death via apoptosis [8]. The mitochondrial membrane potential (MMP) was 
therefore assessed following TFV treatment using TMRE staining [37]. Results demonstrated 
that after 10 days TFV induced a significant reduction in MMP within the HepG2 galactose 
cells in a time dependent and dose dependent manner (Figures 4.10 A and B). These results 
do not determine if the reduction in MMP occurs after the initial chemical stress induced by 
TFV, as part of the apoptotic pathway or whether TFV is targeting the mitochondria 
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specifically. However, as the PI staining Figure 4.5A shows a G2/M arrest at 5 days, this is 
indicative that a reduction in MMP has been induced via a cell cycle arrest and the induction 
of apoptosis. 
The caspases 3 and 7 are essential for the execution of apoptosis therefore the activities of 
these caspases were determined following treatment of the cells with TFV [5]. The results 
demonstrated that TFV induced caspase 3 /7 activation slightly at 5 days and significantly at 
10 days (Figure 4.11 A and B). At 10 days cytotoxicity of TFV has been shown within these 
modified cell lines (Chapter 3, Table 3.2 and 3.5), this cytotoxicity may be induced via the 
apoptotic caspase pathway. This could be the intrinsic pathway, although many cell death 
pathways can lead to the upstream caspase activation and subsequent cascade of caspase 
activation [5]. Future work could be to look for the release of cytochrome C induced by TFV 
dosing as this is specific to the intrinsic pathway. Work could also be carried out using 
caspase inhibitors such as the Caspase 2/3 Inhibitor (Ac-LDESD-CHO can be purchased 
from sigma-Aldrich, Poole, UK) to see if this is protective to the cell when dosed with TFV. 
The induction of apoptosis or necrosis via TFV was determined using annexin V /PI dual 
staining. Results demonstrated that TFV caused time-dependent and dose-dependent 
induction of necrosis and apoptosis. Although an increase in both apoptosis and necrosis was 
detected, the data suggest that cell death is predominantly apoptosis for the 5, and 10 day 
incubations shown by an increase in apoptosis and secondary necrosis (secondary necrosis is 
the resultant end point of apoptosis, so cells detected in this state were also apoptotic cells 
[38]). Results for the 15 day incubation period demonstrated that necrosis was the 
predominant form of cell death in the HepG2 galactose cells dosed with TFV at this time 
point; this could be due to a decrease in cellular ATP as seen in Chapter 3 (Figure 3.7B).  
Apoptosis is an active process that is ATP dependent; when cellular ATP levels fall below a 
certain threshold, cell death proceeds via the necrotic pathway [11]. Previous in vitro work 
  
146 
 
reported that TFV does not cause cell death [24-27, 30-40]. This could be due to the length of 
incubation times used for these studies which were 24 – 48 hours, as the data presented 
within this thesis (Chapter 3, Table 3.2 and 3.5) has demonstrated that TFV cytotoxicity is 
time-delayed requiring at least a 5 day incubation period. Previous studies into ADEF 
induced cell death showed that it caused cell death via the necrotic pathway [13], which is 
similar to data shown within this chapter (Figure 4.7 A). 
When taking into account all the cell death data generated, it has been demonstrated that TFV 
induces a G2 /M cell cycle arrest. This causes an accumulation of cells in the S phase which 
eventually leads to the activation of apoptosis, which may be via the intrinsic pathway, 
leading to depolarisation of the mitochondrial membrane. This could lead to cytochrome c 
release that causes subsequent activation of caspases 3 / 7, ultimately leading to cell death via 
apoptosis. When cellular ATP levels decrease cell death proceeds via the necrotic pathway. 
Results also demonstrated that autophagy may act as an adaptive mechanism of cellular 
survival induced by TFV; however this protective effect is only significant at the earlier 5 day 
time point. Further studies are needed in vitro before studying these theories further in a 
clinical setting. 
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Chapter Five 
 
ASSESSMENT OF KIM-1 IN HIV PATIENT 
URINE SAMPLES: POTENTIAL UTILITY AS A 
BIOMARKER OF TENOFOVIR MEDIATED 
KIDNEY DAMAGE 
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 5.1 Introduction 
Many drugs induce renal toxicities and TFV has been linked in particular to proximal tubule 
dysfunction [1-3]. If TFV is not withdrawn in patients experiencing renal injury the onset of 
CKD could result, leading to irreversible kidney damage [4].  Drug monitoring of kidney 
function in patients receiving a HAART regimen containing TFV is therefore vital [5].  
A number of markers of renal insufficiency are currently used clinically, including  blood 
urea nitrogen (BUN) and serum creatinine (SCr), used for the determination of glomerular 
filtration rate (GFR). These markers involve the use of histopathology and function tests 
(such as blood tests). However, in vitro and in vivo studies of renal dysfunction have shown 
that these markers have many limitations [6]. The main limitation is they are not region-
specific so the area of the kidney undergoing toxicity remains unclear [7]. Another 
disadvantage of these traditional markers is they will not detect renal insult until 30- 50% 
renal damage has occurred. This highlights the importance of developing biomarkers that can 
detect damage at earlier time points in specific regions of the kidney. 
Currently the importance of TFV as a front line treatment against HIV-1 outweighs the risks 
of developing renal dysfunction. Therefore, novel biomarkers must be developed in order to 
monitor patients and minimise the risk of developing irreversible renal damage as previous 
studies showed the onset of proximal tubule damage to be 20% in patients receiving TFV [8-
10].  
Due to the limitations of current markers a working group of scientists in the pharmaceutical 
industry was set up; named the Predictive Safety Testing group. This group is led by the 
Critical path Institute (C-path) which is a non-profit organisation. Recently, data for possible 
urinary proteins that could be used as biomarkers (Figure 5.1) for renal dysfunction was 
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presented by the PSTC to the regulatory bodies, the Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) [7]. Amongst these urinary proteins was kidney 
injury molecule -1 (KIM-1), which emerged as a good possible biomarker for proximal 
tubule damage due to its specificity to this region of the kidney [11]. 
Previous prospective studies have evaluated GFR as a predictor of TFV-induced toxicity, as a 
decline in GFR is an indicator of the onset of kidney dysfunction. All studies reported that 
TFV did not cause any decline in GFR when comparing patients on TFV treatments against 
other antiretroviral drugs [12-14]. However, these studies have all focused on the glomerular 
function when many animal studies have shown TFV to cause proximal tubule dysfunction 
specifically, therefore they may miss the onset of kidney damage [15-17]. The early clinical 
indicator of induced proximal tubule damage is hypophosphateamia, which is closely 
followed by a decline in reabsorbtion of phosphates, causing excessive phosphate loss within 
the urine [5]. A previous study showed that evaluation of hypophosphateamia revealed that 
the incidence rate of hypophosphatemia was higher in patients taking TFV compared to 
patients on other antiretroviral drugs [18]. This demonstrates that hypophosphateamia could 
be a better biomarker than GFR for predicting TFV-induced proximal tubule damage. In 
another study,  a cohort of 284 HIV-1 patients were evaluated for SCr levels and β2-
microglobulin, proximal tubule damage was defined as the presence of two or more well 
defined urine abnormalities. It was shown that SCr levels remained normal in all patients 
including those on TFV, whilst those patients taking TFV had the highest levels of β2-
microglobulin levels within their urine. β2-microglobulin is thought of as one of the most 
specific markers of tubular damage [9]. These studies highlight the importance of finding a 
biomarker that is specific to proximal tubules damage. However, this study shows that 
although β2-microglobulin maybe a good biomarker for monitoring TFV induced kidney 
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damage, other studies have shown that β2-microglobulin is not specific to just the proximal 
tubule and is also shed from the glomerulus (Figure 5.1) [11]. 
 
Figure 5.1: A schematic diagram of the kidney showing the localization of the novel 
biomarkers (modified from a picture in [19]) 
 
As TFV is such an important drug for the use in most HAART regimens due to its good 
pharmacodynamic and pharmacokinetic properties, and has recently been approved for pre-
exposure prophylaxis, determination of urinary KIM-1 may become an advantageous tool for 
monitoring proximal tubule dysfunction TFV patients. 
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5.1.1 Kidney Injury Molecule -1 
When damage occurs to the proximal tubule epithelial cells the morphological changes that 
occur include loss of polarity, dedifferentiation, apoptosis and loss of the brush border [20]. 
When advanced damage occurs to these cells it leads to the detachment from the basement 
membrane of both necrotic and viable tubular epithelial cells, which leads to obstruction of 
the renal lumen [20], the surviving cells that are dedifferentiated proceed to spread over the 
broken down basement membrane. They undergo mitogenesis to ultimately re-differentiate 
and restore normal epithelial polarity / function [21]. These processes are well defined due to 
extensive studies in in vitro and in vivo platforms; however the molecular factors that regulate 
these events are not understood [21].  
One key molecule identified through in vivo studies involving post-ischaemic rats was KIM-
1. KIM-1 is also called T cell immunoglobulin mucin domains-1 (TIM-1) because it is 
expressed by sub populations of activated T-cells at low levels. KIM-1 is also called hepatitis 
A virus cellular receptor 1 (HAVCR-1) because it is expressed by hepatocytes. 
 
 
 Figure 5.2: A schematic image of KIM-1 modified from a picture in [22] 
 The KIM-1 gene encodes for a type 1 cellular membrane glycoprotein.  This glycoprotein 
has a unique immunoglobulin domain that contains 6 cysteine residues and an extracellular 
region that is mucin-rich (As seen in Figure 5.2). Studies have shown KIM-1 to be highly 
conserved in the following species:  dogs, rodents, zebra fish, primates and humans which 
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could be useful in order to bridge information from in vitro / in vivo investigations and relate 
them back into man [20].  
Studies have found that KIM-1 is undetectable in a normal human kidney and rodent kidney, 
but that expression increases post kidney injury [20, 23]. The localisation of the KIM-1 
expression post renal injury is specific to surviving epithelial cells of the proximal tubules 
[20]. The localisation of KIM-1 and other novel biomarkers can be seen in Figure 5.1. Other 
studies also showed that the expression of KIM-1 mRNA is increased more than any other 
gene post kidney injury [23] 
In vitro investigations using renal proximal tubular epithelial cells showed that upon kidney 
insult, the ectodomain of KIM-1 is shed into the urine [24]. This evidence was supported by 
further in vitro studies involving rodent urine [25] and human urine samples [26] which 
showed shedding of the KIM-1 ectodomain into urine after the initiation of renal insult. The 
selectivity and sensitivity of KIM-1 compared to the traditional markers BUN and SCr and 
the novel biomarker N-acetyl-β-D-glucosaminidase (NAG) was assessed in vivo using 
multiple rat models of kidney injury. The results showed that KIM-1 significantly 
outperformed the 'gold standard' biomarkers BUN and SCr [11]. This was demonstrated in 
this study by the differences in sensitivity between the gold standard biomarkers: BUN had a 
sensitivity of 0.48 and 0.29 for SCr whilst the sensitivity of urinary KIM-1 was 0.71 
following kidney injuries [11]. KIM-1 is currently the only injury biomarker specific to the 
kidney to be approved by the FDA and EMA; thus making it an acceptable biomarker for the 
prediction of TFV-induced proximal tubule dysfunction. 
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5.1.3 Aims of Chapter 
In this chapter KIM-1 analysis will be carried out in urine samples from a small cohort of 30 
HIV-1 patients. Of these patients 16 are on a TFV-containing regimen and 14 were not on 
TFV containing regimens. Urine samples were collected with the full consent of the patients 
who were asked in advance if they were taking any antiretroviral drugs. The urine samples 
were anonymised and collected from genitourinary medicine (GUM) clinics and tested for the 
presence of HIV-1, those found to be HIV-1 positive were then tested to determine presence 
of antiretroviral drugs.  The hypothesis being tested is that those patients on TFV containing 
regimens will have higher KIM-1 levels in urine in comparison to those patients not receiving 
TFV. 
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5.2 Materials and Methods 
5.2.1 Materials 
The cell culture media (DMEM high glucose and DMEM no glucose) were from life 
technologies, Invitrogen (Paisley, UK). All other reagents were purchased from Sigma-
Aldrich (Poole, UK). Tenofovir was from Toronto Research Chemicals (Toronto, Canada).  
The MSD Toxicology KIM-1 assay kit was ordered from MESO Scale Discovery 
(Gaithersburg, USA). 
5.2.2 Cell culture and experimental preparation 
As in section 3.2.2, Chapter 3. Only HEK293 KIM-1 cells were use in this chapter as they are 
transfected with human KIM-.1 
5.2.3 Clinical sample collection and preparation 
The clinical HIV-1 urinary patient samples were supplied from the University of Liverpool 
Bio-Analytical Facility (BAF) and full ethical approval had been previously granted for work 
from a previous cohort study that was carried out. 
The urine from healthy volunteers was obtained with the volunteer’s full consent. With these 
samples the heat / formalin inactivation methods were validated to find the best method to 
inactivate the HIV-1 within the clinical samples. For formalin treatment, urine samples were 
incubated with 10 % formalin (500 µl at room temperature) overnight. For the heat treatment 
urine samples were left in a water bath for 1 hour at 56 
o
C. 
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5.2.4 The determination of sample creatinine concentrations. 
Serum creatinine is currently used as a marker for kidney injury [27]. For these studies the 
urinary creatinine was measured in order to normalise the concentration of urinary KIM-1. 
This normalisation step minimises the influence of the volume of patient urine output and is 
the current method used when determining urinary KIM-1 values [27]. 
To calculate the unknown creatinine concentrations a calibration curve of 8 different 
concentrations was produced containing the following creatinine concentrations (mg / dL) 80, 
40, 20, 10, 5, 2.25, 1.25 and 0. 
Sample urine was diluted 1 in 10 (with d H2O), and then 25 µl of each sample was added to 
wells of a 96 well flat bottomed plate. 125 µl of reagent A (5 ml of 0.5 M NaOH, 2.5 ml of 
0.1 M sodium phosphate dibasic, 2.95 ml of 0.56 M  borax, 2.5 ml SDS, 4.5 ml picric acid 
and 0.5 ml DMSO), was added to each well. After the addition of reagent A the plate was left 
for 2 minutes at room temperature, then 5 µl of reagent B (0.5 ml acetic acid, 0.1 ml H2SO4 
and 4.4 ml d H2O) was added to each well. The plate was then incubated at room temperature 
for 5 minutes on a plate shaker (300 rpm). The plate was then read at an absorbance of 490 
nm using a plate reader (MRX Dynatech laboratories, London, UK) 
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5.2.5 The determination of sample Kidney Injury Molecule -1 
concentrations using Meso Scale Discovery methods. 
The Meso Scale Discovery (MSD) platform was selected for urinary KIM-1 analysis  for 
several reasons. Firstly, previous work has demonstrated that MSD has 10 times increased 
sensitivity and a 2 fold increase in dynamic range compared to Enzyme-Linked Immuno-
Sorbant Assay (ELISA) kits, which can also be used to detect urinary KIM-1. The MSD 
platform is also more time and cost effective compared to ELISA kits (MSD handout, 2012, 
personal correspondence University of Liverpool) 
KIM-1 was chosen as the best bio-marker to look for TFV induced dysfunction as it is 
specific to damage caused in the proximal tubule (Ichimura et al., 2008).The MSD plates are 
based upon a sandwich principle (Figure 5.3 A), they have electrodes on the bottom of each 
pre-coated well that can conduct a voltage. The MSD plates used were pre-coated with KIM-
1 capture antibodies. Once the sample and solution containing capture antibodies (which are 
conjugated to electrochemiluminescence labels, the unique MSD SULFO-TAG) are added to 
the plate, the analytes in the sample bind to the capture antibodies.  The bound analytes then 
recruit the binding of the capture antibodies which completes the sandwich. When the MSD 
read buffer is added to the plate, it creates a chemical balance that is optimum for 
electrochemiluminescence. When the plate is added to the SECTOR imager (see Figure 5.3 
B) a voltage is applied to the electrodes at the bottom of each well and causes the captured 
SULFO-TAG labels to emit light. The SECTOR imager measures the intensity of the emitted 
light to give a quantitative measurement of sample analyte concentration.  
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Figure 5.3 A- A schematic image of the MSD sandwich (modified from an image in the 
MSD handbook) and 5.3 B – the set up of the SECTOR imager well 
A KIM-1 calibration curve was produced in order to establish the unknown KIM-1 
concentrations within the samples. The following concentrations of KIM-1 (pg/ml) were 
used; 5000, 1250, 313, 178, 20, 4.9 and a blank (diluent 37). 
To the MSD plate 150 µl of Blocker A (1.25 g Blocker A and 20 ml de-ionised water) was 
added to each well. The plate was then sealed and shaken (30 minutes, 500 rpm, room 
temperature). The plate was washed 4 times in 150 µl / well of PBS-T. Urine samples were 
diluted 1 in 10 with diluent 37, then 50 µl of either calibrator or sample was added per well. 
The plate was sealed and shaken (2 hours, room temperature, 500 rpm). The plate was then 
washed with 150 µl / well of PBS-T (repeated 4 times). After washing, 25 µl of 1 x detection 
antibody solution (60 µl of 50 x SULFO-TAG anti-hu KIM-1 antibody and 2.94 ml diluent 
37) was added to each well. The plate was sealed and incubated as before. After 2 hours the 
plate was washed in 150 µl / well of PBS-T, then 150 µl of read buffer (10 ml read buffer 4 x 
and 10 ml de-ionised water) was added to each well. The plate was read using a sector 
imager. Results were analysed using the MSD discovery workbench software.  
 
 
A 
B 
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5.2.6 The analysis of cellular KIM-1 in HEK293 KIM-1cells 
HEK293 KIM-1 cells were incubated with TFV (10 µM and 100 µM) for a period of 5, 10, 
15 and 20 days. After incubation cell supernatant was diluted 1 in 10, 1 in 100 or 1 in 1000 
and were analysed using the MSD protocol. Neat concentrations were not used following the 
advice in the MSD manual 
5.2.6 Statistical analysis 
Statistical analysis was carried out on all data. Values are expressed as a mean + standard 
deviation of the mean (SD), this is represented as error bars on all graphs. A Shapiro-Wilk 
test was first carried out on the data to see if they were considered normal.  Univariate 
analysis was carried out on samples using a Spearman's rank correlation (calculated using the 
StatsDirect software). Multivariate analysis was carried out on data using a backwards linear 
model calculated with the SPSS version 20 software. Significance is indicated as follows * P 
< 0.05, ** P < 0.01, *** P < 0.001 
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5.3 Results 
5.3.1 The analysis of cellular KIM-1 in HEK293 KIM-1 cells 
 
Figure 5.4: Calibration curve for detection of KIM-1 within HEK293 KIM-1 cells 
treated with varying concentrations of TFV, this was produced by the MSD SECTOR 
imager and shows that KIM-1 levels in the HEK293 KIM-1 cells (red dots)  
The MSD SECTOR imager machine measures the amount of KIM-1 detected within the cells 
and then constructs a standard curve (TFV concentrations that cells were treated with are 
manually input into the MSD SECTOR imager ) that the cells were dosed with. The 
calibration curve for the detection of KIM-1 within in vitro samples (Figure 5.4) shows that 
KIM-1 levels were undetectable. The samples (in red) were below the line of detection 
(dotted line). For all samples the value given from the MSD SECTOR imager was 0. 
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5.3.2 The validation of HIV-1 inactivation methods, using urine 
collected from healthy volunteers 
Urine from healthy volunteers was use to analyse KIM-1 within the samples and to see how 
inactivation methods would influence these values. Samples were split into three categories 
and received different treatments; untreated, heat treated or formalin treated. These categories 
were also split in two, half of which were spiked with a known concentration of KIM-1. Then 
all samples were analysed for their KIM-1 levels.  
 
 
 
Figure 5.5: Calibration curve for detection of KIM-1 in urine samples treated with formalin or 
heat treated, this was produced by the MSD SECTOR imager and shows that KIM-1 levels in the 
samples are detectable represented by the green dots.  
 
The calibration curve for the detection of KIM-1 in healthy volunteers urine (when untreated, 
heat treated and formalin treated) was produced by the MSD SECTOR imager (Figure 5.5) 
and shows that the KIM-1 can be detected in these samples. 
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Figure 5.6: Graph showing KIM-1 values in healthy volunteer’s urine, comparing 
untreated to formalin treated and heat treated (F = female and M = male). KEY * P <0.05, 
**P < 0.01, *** P < 0.001 for formalin treatment vs. untreated.  # P< 0.05 for heat 
treatment vs. untreated. 
 
 
 
Table 5.1: Shows the values for urinary KIM-1 when formalin or heat treated expressed as 
a percentage of the UNTREATED KIM-1 values.   
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Measuring KIM-1 levels in healthy volunteer’s urine (when untreated, heat treated and 
formalin treated – Figure 5.6), demonstrates that the levels of KIM-1 were reduced by both 
heat and formalin treatment, however heat treatment caused less of a reduction. This can be 
seen clearly when looking at the % of KIM-1 signal in the heat / formalin treatments in 
comparison to the untreated samples (Table 5.1). When heat treated the average % of KIM-1 
recovery was 97.5 % (in un-spiked samples) in comparison to the average % of KIM-1 
recovery for the formalin treatment which was 43.69%. The mean KIM-1 concentration for 
the untreated male samples was1773.6 and for the untreated females it was 503.6 pg/ ml 
A second set of volunteer samples was used for the validation of the heat treatment. 
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Figure 5.7: Graph showing KIM-1 values in healthy volunteer’s urine when heat treated 
vs. untreated. (F = female and M = male).  KEY * P < 0.05 for untreated vs. heat treated  
 
The graph showing the KIM-1 detected within the urine of healthy volunteers in untreated 
and heat treated samples (Figure 5.7), shows that the heat treatment of the samples on 
average has not significantly reduced the value of KIM-1 detected within the urine. The 
maximum reduction in KIM-1 concentration due to the heat treatment was seen in sample 7 
were KIM-1 reduced from 867.1 pg/ml to 617.6 pg/ml. The minimal reduction in KIM-1 
concentration due to heat treatment was seen in sample 1 KIM-1 reduced from 735.3 pg/ml to 
728.8 pg / ml. Unexpectedly for sample 2 and 4 there was an increase in KIM-1 when the 
sample was heat treated (In sample 2 KIM-1 increased from 834.2 pg /ml to 988.9 pg / ml 
and for sample 4 KIM-1 increased from 651.3 pg / ml to 671.4 pg / ml). The overall average 
% recovery of KIM-1 signal when the samples were heat treated was 97 % including sample 
2 and 4 and 91.2 % when discounting sample 2 and 4. The mean KIM-1 concentration for the 
males was 850.7 pg /ml and for the females it was 607.6 pg/ ml. 
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A third set of volunteer urine samples was used to validate how heat treatment affects KIM-
1, urinary creatinine and the widely used KIM-1 /creatinine ratio. 
 
 
 
Figure 5.8: Graph showing KIM-1 values in healthy volunteer’s urine when heat treated vs. 
untreated (F = female and M = male). KEY * P <0.05 for heat treatment vs. untreated. 
The graph showing the determined KIM-1 concentrations (pg / ml) of urine from healthy 
volunteers when untreated and heat treated (Figure 5.8), showed that heat treatment on 
average did not significantly decrease the KIM-1 within the urine samples. The maximum 
reduction in KIM-1caused by the heat treatment can be seen in 7, the KIM-1 reduced from 
306.7 pg / ml to 254.5 pg / ml. The minimal reduction in KIM-1 caused by the heat treatment 
was observed in sample 2 KIM-1 reduced from 388.4 pg /ml to 374.3 pg / ml. The overall 
KIM-1 % recovery when the samples were heat treated was 90.2%. The mean KIM-1 
concentration for the males 472 pg /ml was and for the females it was 278.9 pg /ml. 
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Figure 5.9: Graph showing creatinine values in healthy volunteer’s urine when heat 
treated vs. untreated (F = female and M = male). KEY * P <0.05, ** P < 0.01 for heat 
treatment vs. untreated. 
 
 
 
The graph showing the determined creatinine concentrations (mg/dL) of urine from healthy 
volunteers when untreated and heat treated (Figure 5.9), showed that the heat treatment on 
average did not significantly decrease the creatinine concentrations within the urine samples. 
The maximal creatinine reduction induced by the heat treatment can be seen in sample 1, 
creatinine reduced from 36.37 mg/dL to 29.44 mg/dL. The minimal reduction in creatinine 
was observed in sample 2, creatinine reduced from 22.63 mg/dL to 22.47 mg/dL. The overall 
% of creatinine recovery when the samples were heat treated was 90.1%. The mean creatinine 
concentration for the males 29.5 mg / dL was and for the females it was 27 mg / dL. 
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Figure 5.10: Graph showing KIM-1 / creatinine ratio in healthy volunteer’s urine when heat 
treated vs. untreated (F = female and M = male).  
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Figure 5.11: Strip Graph showing KIM-1/ Creatinine ratio (ng / mg) in healthy volunteer’s 
urine when heat treated vs. untreated. The median values are shown on the graph represented by a 
line.   
 
 
The graph showing the determined urine samples KIM-1/ creatinine ratios (Figure 5.10), 
shows that the KIM-1 / creatinine (ng / mg) ratio was not significantly reduced by heat 
treatment. The mean KIM-1 / creatinine ratio in untreated urine samples was 1.10 ng / mg, 
this was reduced to 1.02 ng / mg in heat treated samples. The overall % recovery of the KIM-
1 / creatinine ratio within the heat treated samples when compared to untreated samples was 
99.69 %. The spread of this validation data and the averages of each data set (untreated and 
heat treated) can be seen in Figure 5.11. The mean KIM-1 concentration for the males was 
1.64 ng / mg and for the females it was 1.04 ng / mg .  
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5.5.4 The determination of the urinary KIM-1 in patient samples 
using MSD methods. 
 
Figure 5.12: Graph showing determined KIM-1 (pg/ml) values in patient urine  
 
 
When KIM-1 levels were determined within patient samples (Figure 5.12), results 
demonstrated that there was a wide range of KIM-1 levels within the patients (from 
32.2pg/ml to 9342.2 pg /ml). It can be seen that several patients not taking TFV have similar 
levels of KIM-1 as patients taking TFV, for example patient 6 (on TFV treatment) has a 
KIM-1 value of 39.54 pg / ml and patient 7 (not on TFV treatment) has a KIM-1 value of 
38.93 pg / ml. Patient 14 (not on TFV treatment) has the highest KIM-1 concentration of 
9342.23 pg / ml and patient 26 (on TFV treatment) had the lowest KIM-1 value of 32.15 pg / 
ml. The mean KIM-1 value for all the data is 736.8 pg / ml, the mean KIM-1 for those 
patients on TFV was 433.1 pg / ml and the mean KIM-1 value for the patients not on TFV 
was 1084 pg / ml ( when patient 14 is removed this value reduces to 448.7 pg / ml). The 
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median KIM-1 value for all the data was 352 pg / ml , the median KIM-1 for those patients 
on TFV was 344.8 pg / ml and the median  KIM-1 for the patients not on TFV was 384.3 pg / 
ml ( when patient 14 is removed this value reduces to 335.5 pg / ml).   
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Figure 5.13: Graph showing determined creatinine (mg /dL) values in patient urine  
 
The determined creatinine (mg / dL) levels within patient samples (Figure 5.13), 
demonstrates that there was a wide range of creatinine levels within the cohort patients. 
Patient 14 (not on TFV treatment) has the highest creatinine concentration of 149.32 mg/ dL 
and patient 26 (on TFV treatment) had the lowest creatinine value of 19.12 mg/ dL. The mean 
values for all the data was 54.8 mg/ dL , the mean creatinine concentration  for those patients 
on TFV was 47.7 mg/ dL and the mean creatinine value for the patients not on TFV was 63.0 
mg/ dL ( when patient 14 is removed this value reduces to 50.3 mg/ dL).   
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Figure 5.14: Graph showing determined KIM-1 / creatinine ratio in patient urine   
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patient 
Number 
creatinine 
(mg/Dl) 
KIM-1 
(pg/ml) 
KIM-1 ng/ 
creatinine 
(mg/ml) 
TFV 
treatment 
TDF 
detected in 
urine 
FTC 
detected 
in urine 
3TC 
detected 
in urine 
1 39.55 265.31 0.67 NO BLQ BLQ BLQ 
2 69.90 288.64 0.41 NO BLQ BLQ BLQ 
3 36.08 403.58 1.12 YES 12576.04 9123.364 BLQ 
4 40.66 38.78 0.10 YES 25522.91 10807.4 BLQ 
5 73.44 443.73 0.60 NO BLQ BLQ BLQ 
6 24.91 39.54 0.16 YES 19232.71 7852.589 BLQ 
7 25.39 38.93 0.15 NO BLQ BLQ BLQ 
8 35.74 432.93 1.21 NO BLQ BLQ BLQ 
9 58.10 1032.28 1.78 YES BLQ BLQ 170209 
10 35.51 321.36 0.91 YES 90237.97 22487.09 BLQ 
11 31.60 67.53 0.21 YES 17232.51 7258.936 BLQ 
12 27.07 368.52 1.36 YES 47666.3 8286.948 BLQ 
13 110.70 662.67 0.60 YES 289423.1 54920.59 BLQ 
14 149.32 9342.23 6.26 NO BLQ BLQ BLQ 
15 35.74 721.94 2.02 YES 2750.006 757.818 BLQ 
16 42.93 585.87 1.36 YES 66286.26 20725.63 BLQ 
17 41.71 434.82 1.04 NO BLQ BLQ BLQ 
18 25.78 41.33 0.16 NO BLQ BLQ BLQ 
19 61.18 164.05 0.27 NO BLQ BLQ BLQ 
20 24.61 174.11 0.71 YES 33438.03 6091.926 BLQ 
21 123.89 1006.57 0.81 YES 101156.3 45046.38 BLQ 
22 30.63 286.21 0.93 YES 63316.8 8034.422 BLQ 
23 80.75 933.24 1.16 NO BLQ BLQ BLQ 
24 59.69 458.14 0.77 NO BLQ BLQ BLQ 
25 80.15 335.52 0.42 NO BLQ BLQ BLQ 
26 19.12 32.15 0.17 YES BLQ BLQ 52806.84 
27 57.85 220.93 0.38 NO BLQ BLQ BLQ 
28 67.99 947.03 1.39 YES 979466.1 120362.7 737.807 
29 80.96 1776.29 2.19 NO BLQ BLQ BLQ 
30 53.16 240.93 0.45 YES 389121.5 38927.3 BLQ 
 
Table 5.2: Table showing the determined KIM-1 (pg / ml) levels, creatinine (mg/dL) 
levels and KIM-1 /Creatinine ratios (ng / mg) within the patient urine samples. Also 
shown is the data obtained from The University of Liverpool BAF, showing the levels of 
TDF, FTC and 3TC found within these urine samples. BLQ is below limit of 
quantification 
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Figure 5.15: Strip Graph showing KIM-1/ Creatinine ratio (ng / mg) in clinical urine 
samples. The median values are shown on the graphs represented by a line.  
 
The ratios of KIM-1 / creatinine (ng / mg) levels were determined within the patient samples 
(Figure 5.14), and the results demonstrated that there was a wide range of ratio levels within 
the patients. Patient 14 (not on TFV treatment) has the highest ratio of 6.25 ng /mg and 
patient 4 (on TFV treatment) had the lowest ratio value of 0.10 ng /mg. The mean ratio for all 
the data was 0.99 ng /mg, the mean ratio for those patients on TFV was 0.88  ng/mg  and the 
mean creatinine value for the patients not on TFV was 1.22 ng/mg (when patient 14 is 
removed this value reduces to 0.64). The median  ratio value for all the data was 0.74 ng/mg  
, the median ratio for those patients on TFV was 0.86 ng/mg  and the median  creatinine value 
for the patients not on TFV was 0.64 ng/mg  (when patient 14 is removed this value reduces 
to 0.60 ng /mg).  The spread of this clinical data and the averages of each data set (not taking 
TFV and on TFV treatment) can be seen in Figure 5.15. 
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When uni-variant analysis was carried out between TFV concentrations found within the 
patient’s urine (Table 5.2 all patients on TFV) and KIM-1 values the positive correlation p 
value was 0.09. When univariate analysis was carried out between TFV concentrations and 
creatinine values the positive correlation p values was 0.014. When univariate analysis was 
carried out between TFV concentrations and the KIM-1 /creatinine (ng/mg) ratio the positive 
correlation p values was 0.42. When univariate analysis was carried out between the KIM-1 
values and the creatinine values the positive correlation p value was 0.01. 
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5.6 Discussion 
This chapter has focused on using KIM-1 as a potential bio-marker to predict TFV-induced 
renal dysfunction. Within this chapter the association between TFV and KIM-1 levels in vitro 
using the supernatant from HEK293 KIM-1 cells was examined. The calibration curve for the 
detection of KIM-1 within the in vitro samples (Figure 5.4) demonstrated that the KIM-1 
levels were undetectable in these samples irrespective of concentration of TFV and 
incubation length. Previous work within the department suggested that this could be due to 
the FBS interfering with this platform (Personal correspondence, The University of 
Liverpool). As the incubation periods required to see TFV-induced cytotoxicity are long (10 
– 20 days as determined in Chapter 3 and 4), the cells could not be grown in a serum-free 
media without the cells phenotype becoming compromised. In conclusion in order to assess 
the influence of TFV on KIM-1 concentrations, the MSD platform will perform better with 
urine samples instead of in vitro samples due to this interference issue. 
Following on from the in vitro analysis, KIM-1/creatinine (ng / mg) ratios were determined in 
urine samples from healthy volunteers. The MSD assay used for the determination of KIM-1 
within urine samples was previously validated within this department using spiked urine; the 
lower limit of detection and lower limit of quantification were determined. Work was carried 
out to validate different inactivation methods that would be needed in order to analyse urine 
samples from HIV-1-infected patients. It can be seen in Figure 5.6 that the formalin 
treatment of the urine samples has significantly reduced the KIM-1 signal within the urine 
samples, resulting in a lowered capacity to detect KIM-1. The heat treatment also caused a 
slight decrease in KIM-1 concentrations; however there was an average percentage loss of 
only 2.4% which is within the current accepted guidelines for recovery. The current 
guidelines for recovery state that an accepted percentage loss should be < 10 % [27] 
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Further validation of heat treatment of urine samples from healthy volunteers was carried out. 
Firstly a further study of the effects of heat treatment on the urinary KIM-1 concentration was 
carried out in urine samples from 8 healthy volunteers. As seen in Figure 5.7 this validation 
step again showed that the heat treatment caused an acceptable average percentage loss of 
8.2%. Another set of urine samples from 7 healthy volunteers was obtained, and the effects of 
heat treatment on KIM-1, urinary creatinine levels and the KIM-1 / creatinine ratio was 
determined within these samples. In Figure 5.8 it can be seen that the heat treatment has 
caused an accepted percentage loss of 9.8 % to the KIM-1 concentrations (comparing the 
untreated samples to heat treated samples). The creatinine concentrations determined within 
these samples can be seen in Figure 5.9. When comparing the untreated samples to the heat 
treated samples the average percentage loss was 9.9%, which is within the accepted 10 % 
guidelines. The KIM-1 concentrations were normalized to the creatinine concentration found 
within these urine samples, in order to obtain the KIM-1 / creatinine ratio (ng / mg).  This is 
the currently used method to determine KIM-1 within urine samples [27]. When looking at 
Figure 5.10 and 5.11 results show that the KIM-1 / creatinine ratio was not affected by the 
heat treatment and the average percentage loss was only 0.31% 
After the validation work had been carried out the urinary KIM-1 / creatinine (ng/mg) ratios 
were determined in a cohort of 30 HIV-1 patients. This cohort was readily available from the 
Liverpool BAF and relevant to this work as it was possible to compare patients with and 
without TFV present in urine the patients were not well characterised and not much was 
known about them. Clinical urine samples were first inactivated via heat treatment, in order 
to be removed from a BL2 laboratory, and the influence of TFV on this ratio was determined.  
Results demonstrated that there was a large degree of variability observed in these samples 
with respect to KIM-1 levels (Figure 5.12). Interestingly for both KIM-1 and creatinine 
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values within these patients samples; the group with the highest average is the patients not 
taking TFV, although this number does not reach significance. This trend was also seen in 
Figure 5.14 when calculating the urinary KIM-1 / creatinine ratios within the patient 
samples. However, when the median values for each data set was calculated, as the median is 
not influenced by the spread of the group ( patient 14 in those patients not taking TFV would 
cause the mean values to be higher), the median values were slightly higher but not 
significant  for those patients on TFV compared to those not on TFV treatment. An increased 
KIM-1 for those patients on TFV can also be seen when patient 14 is left out of the mean 
calculations. These mean and median values could become significant if a bigger cohort of 
patients was used. 
 An interesting fact to note is that the average baseline urinary KIM-1 within healthy 
volunteers was 1.1 ng/mg.  This was higher than the average baseline within the HIV-1 
patients, which was 0.99 ng/ mg, although the difference is not significant.  It could be a 
possibility that baseline KIM-1 levels within HIV-1 patients may be slightly lowered, due to 
the HIV-1 virus compromising kidney function and decreasing urinary output [28]. 
Patient 14 has the highest KIM-1(pg / ml) and creatinine (mg/Dl) concentrations and in 
Figure 5.14 it can be seen that patient 14 also has the highest KIM-1 / creatinine (ng / mg) 
ratio. When looking at Table 5.2 it is clear that this patient is not on any TFV containing 
regimens, as the current kidney function of this patient is  not known the possibility that this 
patient has kidney dysfunction cannot be determined. It is a possibility that this patient is 
experiencing kidney dysfunction as a direct result of being HIV-1 positive.  Studies have 
linked HIV-1 patients to development of kidney dysfunction due to the virus [28]. 
The univariate analysis of those patients on TFV, demonstrated that the urinary creatinine 
concentrations had a significant P value (P < **) compared to those patients not on TFV 
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treatment. However, KIM-1 did not show as significant within those patients on TFV. This 
shows that creatinine may not be as specific as KIM-1 when it comes to determining the 
onset of proximal tubule kidney dysfunction. As urinary creatinine is affected by factors that 
influence kidney function, such as chemical stress, using creatinine as a marker for proximal 
tubule toxicity may result in false positives. A false positive would lead to patient withdrawal 
from an effective treatment and for HIV-1 patients this could increase their risk factor for 
developing resistance.   
The univariate analysis of all patients KIM-1 concentrations against creatinine concentrations 
showed KIM-1 and creatinine had a highly significant correlation ( P < **); this was to be 
expected as urinary creatinine is linked to GFR, and therefore any increase in GFR will also 
increase urinary creatinine output. As GFR increases it is assumed that KIM-1 output will 
also increase as previous studies have shown that KIM-1 is shed through the urine [27]. 
There are conflicting reports in the literature with respect to the detection of KIM-1 in 
samples from healthy volunteers. Previous studies stated that urinary KIM-1 was 
undetectable within healthy populations [23]. However, others have shown this to not be the 
case [27], also work within the department using the MSD platform has found that there is an 
average KIM-1 / creatinine ratio of 1 ng / ml in neonates (Personal correspondence, The 
University of Liverpool). In Figure 5.11 it can be seen that the average baseline ratio of 
KIM-1/ creatinine in urine of   healthy volunteers was 1.1 ng/ml. The range of the healthy 
volunteer’s baseline urinary KIM-1 / creatinine ratio was 1.72 ng/ml to 0.83 ng/ml. In a 
previous study, it was shown that the urinary KIM-1/ creatinine ratio was detectable in 
healthy volunteers and they had a range of 0.07 ng / ml to 0.988 ng / ml [27]. This range is 
slightly lower than the range that has been shown within this Chapter. It could be that the 
MSD platform used in this chapter was more sensitive and had a lower limit of quantification 
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than the ELISA kits that were used in previous studies. Therefore, these results could show a 
better of representation baseline urinary KIM-1 levels within a healthy population. Together, 
these findings suggest that there is always a higher than previously thought baseline level of 
KIM-1 within a seemingly healthy person. This background KIM-1 may be due to daily renal 
cellular shedding. More work needs to be carried out to find a true representation of this 
baseline urinary KIM-1 level within healthy populations, as well as within HIV-1 infected 
patients , before KIM-1 can be used as an effective bio-marker.  
The validation work using the urine form healthy volunteers carried out within this study 
showed that males have a higher baseline KIM-1 level when compared to females. This 
difference could be due to the known fact that males have a higher metabolic rate than 
females, therefore males produce more waste produces than females leading to a higher 
concentration of KIM-1(KIM-1 is shed in urine). This leads to the questions of other factors 
that may influence an individual’s baseline KIM-1 levels that are as yet unanswered.  
Demographic factors such as height, weight, genetics, race and age may affect their baseline 
urinary KIM-1 levels. Also certain over the counter medications such as ibuprofen (which 
affects kidney function [29] may affect a person’s baseline KIM-1 level. These factors need 
to be studied further in order to establish a threshold that would give a positive result for 
proximal tubule dysfunction within patients.  
For HIV-1 patients, their baseline urinary KIM-1 / creatinine ratio before treatment could be 
determined and monitored, in order to see any significant increase that would suggest onset 
of proximal tubule dysfunction. 
A larger cohort of HIV-1 patients would provide a higher powered study to establish how 
TFV influences a HIV-1 patients urinary KIM-1 / creatinine. More information about the 
patients should be collected (age, race, height, weight, gender, period of time they have had 
  
181 
 
HIV-1, previous HARRT regimens taken, current HAART regimen being taken and 
concentrations  and length on these treatments) as well as bloods (in order to establish GFR , 
protein urea and serum creatinine). These extra measurements would allow a clearer 
understanding of the variability in urinary KIM-1 / creatinine ratios and show the limitations 
of the current study.  
Other biomarkers should also be considered in the future for use as TFV-specific biomarkers. 
Recent reports have highlighted the effectiveness of using mitochondrial DNA (mtDNA) 
levels within patient PBMC’s as a good biomarker for the detection of mitochondrial 
dysfunction [30]. As work within this thesis has shown TFV to induce mitochondrial 
dysfunction, the use of mtDNA could be a potential marker for TFV-induced toxicity.  
Overall, the work presented within this chapter highlights the feasibility of KIM-1 as a 
biomarker for TFV associated renal toxicity, additional information is needed to understand 
the effects of drug treatment on KIM-1 levels. Work has shown that heat inactivation would 
not influence the KIM-1 / creatinine ratios within clinical urine samples, and showed that 
future work needs to be carried out in order to establish healthy population’s baseline urinary 
KIM-1 / creatinine levels. The possible use of KIM-1 as a biomarker for TFV-induced 
proximal tubule dysfunction could be used within a clinical setting once more confirmatory 
work has been carried out. Further study, in a larger cohort, is now warranted. 
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Chapter Six 
 
GENERAL DISCUSSION 
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In this thesis, research has focused on the antiretroviral drug TFV in order to elucidate the 
mechanistic pathways of its toxicity. This work was essential for understanding the 
underlying mechanisms of proximal tubule toxicity that has been linked to TFV use clinically 
[1]. 
It is important to understand how TFV-induced proximal tubule dysfunction takes place as 
TFV is currently a front line antiretroviral drug that makes up the backbone of most HAART 
regimens due to its favourable pharmacokinetic and pharmacodynamic properties, which 
allows for a single daily dose [2]. If the toxicological mechanisms of TFV were elucidated 
patients that are at higher risk of developing proximal tubule toxicity could be identified and 
closely monitored [3]. 
The original aim of this thesis was to elucidate the mechanistic pathway of TFV-induced 
toxicity in order to develop safer HIV treatments in future, either via the identification of 
potential biomarkers to monitor TFV-induced renal dysfunction, or by identifying those 
patients who are more susceptible to TFV-induced renal dysfunction. Upon reflection, work 
presented within this thesis has fulfilled this aim as the research has led to the construction of 
a picture that demonstrates the mechanistic pathway of TFV-induced cytotoxicity (Figure 
6.1). However, more work needs to be done in the future in order to support these findings 
and to expand on them especially with regards to the use of KIM-1 as a potential biomarker. 
A key area that has changed since this thesis started is the use of TFV as an HIV 
preventative. A novel indication for TFV treatment has recently been approved in which TFV 
is used as chemoprophylaxis for the prevention of HIV infection in HIV negative patients [4-
5]. This treatment is known as pre-exposure prophylaxis (PrEP). An idealistic tool for HIV 
prevention would be the use of a protective vaccine, however this still remains unfeasible due 
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issues surrounding the effectiveness [6]. PrEP uses antiretroviral drugs to prevent HIV 
contraction should HIV exposure occur (promiscuous sex / the sharing of needles/ contact 
with infected bodily fluids) [7-8].  Antiretroviral drugs are already currently used for the 
prevention of HIV in other high risk situations such as high risk sexual exposures, rape and 
prevention of mother to baby transmission [7-8]. The difference with PrEP treatment,  
compared to the other prevention strategies listed above, is that the target population will 
most likely be young adults in prime health that have no immediate risk of HIV exposure [9].   
For this reason PrEP must have proven benefit in order to have a good risk benefit ratio;  
PrEP must be cost effective for patients and studies must show that it has a low toxic profile 
[10].  
Recently TFV was approved to be used for PrEP treatment; it is the only drug that has been 
approved for this treatment type. A typical pre-exposure prophylaxis regimen is either oral 
tablets containing TFV alone (Viread) or as vaginal gel (1% tenofovir) [11]. The introduction 
of TFV as a PrEP reinforces the importance of understanding the mechanism of TFV-induced 
toxicity as a wider population of people will be exposed to TFV in the future and people who 
are at risk could be monitored via the use of biomarkers or offered an alternative treatment 
[3]. Based upon the findings within this thesis, people who take TFV for PrEP treatment 
should be monitored closely for signs of proximal tubule specific kidney damage; hopefully 
in the future this can be done by screening the patient’s urine for changes in KIM-1 
expression.  
The research carried out within this thesis is of key importance for understanding the 
mechanistic pathway of TFV-induced toxicity. This work was required as previous in vitro 
studies have reported that TFV does not cause any cytotoxicity in vitro which could be due to 
them using immortalised cell lines grown in high glucose media [12]. These results conflict 
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with clinical data that has shown that as many as 20% of patients have presented with TFV-
induced proximal tubule dysfunction clinically [3], this could be due to the patients having 
underlining renal dysfunction caused by the HIV-1 virus itself [3, 15-16] 
The cell lines used for the research carried out within this thesis were modified via growing 
them in galactose media which forces cellular ATP production to proceed via mitochondrial 
OXPHOS [13]. This modification produces an in vitro model which better represents the 
physiological characteristics of the proximal tubule cell.   These modifications were carried 
out as studies have shown that animal cells produce 95% of ATP via mitochondrial OXPHOS 
[13], whilst the cells used in previous TFV cytotoxicity studies have been immortalised cell 
lines grown in high glucose media that generate their energy mainly via glycolysis [14]. 
Therefore the data presented within this thesis better represent the mechanistic pathway of 
TFV (Chapter 2).  
Although every effort was made to find an in vitro model that closely represented the 
phenotypical characteristics of human proximal tubule cells, the model still has flaws. These 
arise from the fact that they are immortalised, therefore have an altered cell cycle and 
proliferation and are grown in culture (so are not a part of an organ system). The 
development of an in vitro model that is phenotypically matched to a human proximal tubule 
cell is very difficult. The impact of the immortalisation of cells can be seen within this thesis. 
The HEK293 cells that were derived from human kidney cells did not contain the transporter 
OAT1 (Figure 2.10C); this was unexpected and shows that the phenotypical characteristics 
of the cells are altered by immortalisation process. However the in vitro models set up within 
this thesis was aerobically matched to proximal tubule cells and contained all the other major 
transporters required for TFV accumulation.  
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Recent advances within the in vitro field have led to the development of models that are more 
representative of the in vivo cells of interest, such as 3D spheroids [17]. Recently Human 
kidney epithelial cell spheroids became available, within this cell culture type 3D aggregates 
also called spheroids are formed. Recent data demonstrated that the kidney spheroids 
promoted an appropriate microenvironment, which generated the renal progenitor function 
[18]. These cells could be better representative models in order to study TFV-induced 
toxicity. Future work that could be carried out within different cell models involves the 
following: looking at the cytotoxicity of TFV in primary proximal tubule cells that have 
recently become available within our department. The study of TFV-induced cytotoxicity on 
cultured cells that have been isolated from the urine and have been shown to be a close 
phenotypical match to the proximal tubule cells (this work has recently become available 
within our department).  
The work carried out within this thesis has built up a picture of the mechanistic pathway of 
TFV-induced cytotoxicity (Figure 6.1). Results showed that TFV-induces cell death via 
apoptosis and /or necrosis, dependent upon cellular ATP levels. Further work is required in 
order to determine the apoptotic mediators involved in TFV-induced cell death; the further 
work required is described in detail throughout the following discussion. 
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Figure 6.1: A Schematic image of the mechanistic pathway of TFV-induced cytotoxicity as 
determined by work carried out within this thesis 
 
The preliminary work using both glucose-grown and galactose-grown cells and the classical 
mitochondrial toxin rotenone, demonstrated that rotenone-induced mitochondrial toxicity 
could only be determined within the galactose grown cells. This showed that the galactose 
cultured cells were more susceptible to mito-toxins. This work was carried forward and 
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repeated using TFV.  It was demonstrated that TFV induces mitochondrial damage within the 
galactose cultured cells after 5 days (Table 3.2, Figure 3.3A). 
 
Investigations were carried out into the possible protective role of autophagy induced by 
TFV. This study was performed as it has been reported that the antiretroviral drug efavirenz 
(EFV), induced autophagy at clinically relevant concentrations [19]. This previous study 
highlighted the importance of autophagy for cellular survival, TFV may induce autophagy 
masking the true extent of its cytotoxicity; therefore, the study of TFV and its possible 
induction of autophagy were determined within this thesis. It was found that autophagy plays 
a protective role at only the 5 day time point in HepG2 galactose and HepG2 WT cells 
(Chapter 4). These results were  indicative that autophagy is induced by TFV and plays a 
protective role within the cells at the early time points. This may underline the long time 
periods required to see TFV-induced cytotoxicity.  A further study looking into the role of 
autophagy could be carried out looking for other essential autophagy proteins such as LC-3 
determined using western blot methods and using genetic and molecular modifications 
(siRNA ect) to determine the functional role of this pathway. 
Cytotoxicity studies via MTT / NR assays have shown that TFV induces cellular death as cell 
viability was shown to decrease in HepG2 galactose cells after 5 days (Chapter 3). TFV 
dosing leads to the induction of mitochondrial membrane depolarisation which is the 
hallmark of early apoptosis [20]. This was shown by TMRE determination which increased 
with both time and dose in galactose grown HepG2 cells from 5 days (Chapter 4). The next 
hypothesised step involves the release of cytochrome C, which is widely reported to closely 
follow mitochondria membrane depolarisation [21-24]. Future studies could stain for 
cytochrome C release via western blot methods. Studies have shown that upon cellular 
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cytochrome C release the formation of an apoptosome is mediated [21]. The apoptosome is 
made up of cytochrome C and APAF-1 and its formation is dependent upon cellular ATP 
levels. The apoptosome recruits pro-caspase 9 which leads to its activation [21-24]. Caspase 
9 is an initiator caspase that activates the effector caspases 3/7 [21-24]. Caspase 3/7 levels 
where shown to increase in HepG2 galactose cells after 5 days when determining caspase 3 / 
7 levels using a luminescent kit (Chapter 4). Once activated , caspase 3/ 7 mediate cell death 
via apoptosis [25]. The involvement of the caspases could be studied further via the use of 
caspase inhibitors an example is X-linked IAP (XIAP) an inhibitor of caspase 3, 7 and 9 [26]. 
This would inhibit apoptotic cell death and show they are essential to the TFV-induced 
apoptotic pathway. This work supports the clinical case studies that have shown TFV to 
induce fanconi syndrome within patients [27-35]. Fanconi syndrome is a disease of the renal 
proximal tubule and one of its defining factors is cell death via apoptosis [36]. 
Following TFV dosing, TFV accumulates within the cell (shown by accumulation studies in 
Chapter 2 and Chapter 3), possibly leading to its accumulation within the mitochondria 
possibly via the hENT1 transporter [37]. hENT1 is a member of a nucleoside transporter 
family;  the gene encodes for a transmembrane glycoprotein that locates to either the plasma 
or mitochondrial membrane. hENT1 is responsible for the uptake of cellular nucleosides and 
nucleotides. TFV is an analogue of a nucleotide; therefore, hENT1 could play an important 
role in TFV uptake into the mitochondria [37]. Future studies could determine if TFV 
accumulates within the mitochondria and if hENT 1 is essential for this accumulation. The 
accumulation within the mitochondria could lead to inhibition of mitochondrial pol γ in a 
similar mechanism to how TFV inhibits HIV-1 reverse transcriptase. A decline in 
mitochondrial pol γ activity would result in a decline in mitochondrial DNA; such a decrease 
was shown to be induced post TFV dosing and was determined by a decrease in the 
mitochondrial DNA / nuclear DNA ratio in HepG2 galactose cells after 15 days (PCR 
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analysis Chapter 3). Previous studies have shown that TFV has low affinity to pol γ within 
immortalised cell lines [38-40]. The cell models used within this thesis have been modified to 
be dependent upon the mitochondria for ATP production, which may cause a higher rate of 
mitochondrial proliferation to support these energy requirements. Therefore, any damage 
inflicted by TFV would have a faster accumulation rate of dysfunctional mitochondria, thus 
making these cells more susceptible to TFV-induced mitochondrial damage and providing a 
better representation to proximal tubule cells. This decrease in mitochondrial DNA results in 
dysfunctional mitochondria within the cell; the levels of dysfunctional mitochondria 
gradually build up and eventually trigger the G2 checkpoint (this checkpoint detects any DNA 
damage), within the cell cycle progression. After the G2 checkpoint has been triggered, it 
mediates cell cycle arrest and results in cellular accumulation in the S phase. This was shown 
by the determination of cell cycle progression via PI staining within HepG2 galactose cells 
from 5 days (Chapter 4). A future study could determine quantitative mitochondrial DNA 
copy number against nuclear DNA copy number as this has been shown [41] to be a more 
reliable method of determining mitochondrial DNA damage to confidently show that TFV 
has reduced mitochondrial DNA. This method takes into account the structural variation that 
has been described recently as copy number variation [41]. The variable copy numbers within 
a sample are determined and compared to a standard reference genome this has been reported 
as a more reliable/accurate method [41].  This method was not used as the software required 
to carry it out was not available. Once the threshold point of dysfunctional mitochondria 
within the cell has been reached cellular ATP levels begin to decline [42]. Studies within this 
thesis showed that TFV (100µM) caused a significant decline in cellular ATP levels at 5 days 
in HepG2 galactose cells (Chapter 3).  
Both the necrotic and apoptotic pathways were shown to be induced by TFV dosing after 5 
days in HepG2 galactose cells. However, the necrotic pathway is time-delayed as it requires 
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the buildup of dysfunctional mitochondria and results show it is induced after 15 days in 
HepG2 galactose cells (Table 3.2 and 3.5). Once the threshold level of cellular dysfunctional 
mitochondria has been reached, the apoptotic pathway is inhibited as cellular ATP levels 
become too low to sustain apoptosis, which is an active process, leading to cell death via 
necrosis [43]. This balance of apoptotic against necrotic death which is dependent upon 
cellular ATP levels is depicted in Figure 6.1. These results match the clinical effects reported 
[43]. Apoptosis is induced as an early response to toxicity mainly as a protective role to 
prevent further damage (apoptosis is a clean and controlled event) [25]. When cellular 
damage becomes too overt, cell death proceeds predominantly via necrosis leading to 
irreversible damage [43]. 
The results presented within this thesis show that TFV-induced mitochondrial-specific 
cytotoxicity when cell lines were modified to better represent the physiological conditions of 
the human cells where toxicity has been reported.  Throughout many of the studies presented 
in this thesis, the cytotoxicity of the antiretroviral   ADEF was also assessed. The cytotoxic 
effects induced by ADEF were always more prominent and occurred faster than the 
cytotoxicity of TFV (Figures 3.3 A, B, C and D). ADEF also affected the HepG2 WT cells at 
the longer incubation periods. The difference between the toxicity induced by ADEF to that 
induced by TFV could be due to the difference in cellular accumulation between the two 
drugs (Chapter 3) as it was shown that ADEF had a higher rate of accumulation than TFV 
(Figure 3.5 A and B). This work also highlights how transporters could impact on TFV-
induced toxicity. It has been hypothesised that a person with an increased OAT 1 / 3 activity 
or decreased MRP 2/ 4 activity may be at an increased risk of developing TFV-induced renal 
dysfunction [44]. If the increased cytotoxicity of ADEF compared to TFV is a direct result of 
the increased accumulation of ADEF, then any increase in TFV accumulation or decrease in 
elimination will lead to increased TFV cytotoxicity. 
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Within this thesis work was presented to look for a possible biomarker of TFV proximal 
tubule dysfunction. Kidney injury molecule -1 was selected as there is evidence that it is 
specific to proximal tubule cells [45]. Results demonstrated that TFV did not significantly 
alter the KIM-1 / creatinine ratio within patient urine samples. However, the data from this 
pilot study are novel (work looking at KIM-1 as a possible biomarker for TFV-induced 
toxicity has not been carried out) and can be used for future research into the possible use of 
KIM-1 as a biomarker for TFV-induced proximal tubule dysfunction. The data collected 
should be carried forward to power a future study using a larger patient cohort. This would 
benefit the patients and clinicians in future;  patients on TFV could be easily monitored via a 
urine test that is non-invasive, which allows early detection of TFV-induced proximal tubule 
dysfunction and prevents the onset of irreversible renal damage. Future work could also 
determine if mtDNA levels within patients isolated PBMCs could be used as a predictive 
biomarker of TFV-induced mitochondrial dysfunction as previously reported data 
demonstrated that PBMCs can be used to detect mitochondrial damage within a patient [41].   
The research carried out within this thesis has provided more detailed mechanistic 
information on the molecular pathways initiated by TFV.  Overall, the research presented 
here has elucidated the molecular mechanism of TFV-induced cell death. Specifically, TFV 
causes delayed mitochondrial cytotoxicity, leading to cell cycle arrest, which is likely due to 
the inhibition of mitochondrial pol γ, leading to decreased mitochondrial DNA and increased 
cell death firstly via apoptosis (caused by the release of caspase 3/ 7), and then necrosis when 
cellular ATP levels become too low to sustain apoptosis. Work presented also showed that 
autophagy induced by TFV, could play a protective role within cells at lower time periods. 
Within this thesis in vitro cell models were modified in order to be more aerobically matched 
to human proximal tubule cells and allow the study of mitotoxins. This work showed TFV-
induced cytotoxicity for the first time in vitro; proving the original hypothesis that growing 
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the cells in galactose media would make them more susceptible to mitochondrial toxicity and 
therefore TFV-induced cytotoxicity could be studied. This cell model could be useful for the 
industry to probe possible drug candidates for mitochondrial toxicity. This work has now 
opened doors for further study into the cytotoxicity of other antiretrovirals within these 
modified cell lines.  
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